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3Abstract
The word ‘pain’ is described by the International Association for the Study of Pain
(IASP) as an unpleasant sensory and emotional experience associated with actual or
potential tissue damage, or described in terms of such damage. Shifts in pain
thresholds and responsiveness are an expression of neural plasticity, a process
whereby changes in the nervous system modulate the response to a given stimulus.
It is widely believed that this process may contribute to chronic pain. Forms of
long-term plasticity specifically require protein synthesis and such mechanisms are
widely believed to be cellular counterparts of long-term memory. Relevant to
mammalian pain nociceptors is the realisation that messenger ribonucleic acid
(mRNA) in dendrites, axons, axon terminals as well as cell bodies, is essential for
long-term synaptic plasticity and may therefore be important in pain processing.
The protein kinase mammalian target of rapamycin (mTOR) is a key regulator of
protein translation and can be specifically inhibited by the drug rapamycin and the
rapamycin analogue cell cycle inhibitor (CCI)-779 (CCI-779). This was investigated
in rats under physiological conditions and also pathophysiological conditions
relevant to clinical pain syndromes i.e. persistent pain-like states. A variety of
techniques were utilised: in vivo electrophysiology was used to obtain extracellular
single unit recordings of spinal cord lamina V wide dynamic range (WDR) neurones
that respond to innocuous and noxious stimuli to peripheral sites i.e. the rat hind
paw; behavioural studies were used to assess the progression of pain-like states
and assess the effects of rapamycin/CCI-779 on this behaviour and
immunohistochemistry was used to visualise active components of rapamycin-
sensitive protein translation pathways at the spinal level. In addition, the
dependence of these spinal mechanisms on descending serotonergic pathways from
higher brain centres was investigated pharmacologically by selectively activating or
blocking serotonergic spinal 5-HT3 receptors. These pathways have already been
proven to be pivotal in the maintenance of persistent pain-like states. The results
suggest that mTOR has a continuous role in maintaining persistent pain-like states
via rapid local protein translation, which can be influenced by descending
facilitatory controls from higher centres in the brain.
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Chapter 1
1 Understanding pain
The word ‘pain’ is described by the International Association for the Study of Pain
(IASP) as an unpleasant sensory and emotional experience associated with actual or
potential tissue damage, or described in terms of such damage (IASP, 1994).
Nociceptive pain, which is activated by noxious stimuli acting via high threshold
sensory pathways, is essential for the survival of organisms in a potentially
damaging environment (Millan, 1999). However, although pain is essential, in a
chronic form (which outlasts healing, tissue or nerve damage, or continues due to a
failure of the injury to heal), it can and often does cause a substantial amount of
distress, impacting largely on the patients’ quality of life.
Patients in pain are likely to become depressed, anxious and fearful, suffer from
disturbed sleep patterns and generally have a poor quality of life, suggesting
complex correlations in neuronal signalling within the circuits that underlie pain
and its comorbidities.  Furthermore, untreated pain has major social and economic
impact in terms of lost employment and medical cost. A European survey of chronic
pain and its impact on daily life and treatment has revealed just how devastating
and widespread chronic pain is. In fact, chronic pain, affects approximately one in
five adults in Europe (Breivik et al., 2006). According to the European Pain Network
(see http://www.europeanpainnetwork.com), Europeans with chronic pain suffer
on average for seven years. The costs to society are huge, with an estimated 500
million lost working days costing € 34 billion a year in Europe. The major clinical
chronic pains arise from surgery, trauma and disease and can be grouped as pain
from inflammation (rheumatism and arthritis), nerve injury (diabetic neuropathy,
AIDS and post-herpetic neuralgia) and cancer. Furthermore, in depth analysis of
these chronic pain patients has revealed that 46 % have pain all or most of the time
and 34 % of those with chronic pain rate it as severe (Breivik et al., 2006).
The survey by Breivik et al. also revealed that 45 % of chronic pain sufferers had
inadequate management of their pain. Only 2 % were treated by a pain specialist
and a third of chronic pain sufferers weren’t being treated at all. Yet current
treatments for chronic pain do exist and include non-medication treatments such
as massage, physical therapy and acupuncture; non-prescription analgesics such as
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non-steroidal anti-inflammatory drugs (NSAIDs), paracetamol and weak opioids and
prescription analgesics such as cyclooxygenase-2 (COX2) inhibitors, strong opioids,
antidepressants and anticonvulsants. However, despite recent advances in
understanding how pain is processed in the body as well as the wide range of
treatments that are currently available, there is still a large unmet clinical need
regarding chronic pain syndromes. Furthermore, for many of the drugs listed
above, the rationale for prescribing these drugs for chronic pain syndromes is often
based on trial and error. However, innovative and integrated studies particularly
over the past decade have been pivotal in furthering our understanding of
nociception, chronic pain syndromes and appropriate treatments
1.1 Development of nociceptors
Nociceptors (or pain receptors) comprise the large majority of small diameter
thinly myelinated Aδ-fibres and unmyelinated C-fibres. Unlike Aδ-fibres, C-fibres
are nociceptive specific and have been successfully categorised depending on their
physiological properties as well as their anatomical differences. During rodent
development, a large proportion of neurones (70 – 80 %) in the cell bodies of the
nerve fibres i.e. dorsal root ganglia (DRG) express the nerve growth factor (NGF)
receptor tyrosine kinase TrkA during development and require NGF for survival
during embryonic life. Most of these neurones also express the Runx1 runt domain
transcription factor, calcitonin gene-related peptide (CGRP) and substance P (SP)
and project to superficial regions of the spinal cord i.e. lamina I and II (Silos-
Santiago et al., 1995; Chen et al., 2006).
During maturation of rodents, the sensitivity of sensory neurones to trophic factors
changes such that in the first 3 postnatal weeks of the animal, approximately 50 %
of cells lose TrkA meaning that at adulthood, the receptor is only present in about
40 – 50 % of DRG neurones. These cells also express CGRP and SP. The cells that
lose TrkA bind isolectin B4 (IB4) and the enzymes fluoride-resistant acid
phosphatase (FRAP) and thymidine monophosphate (TMP) and project to the inner
layer of lamina II in the dorsal horn. The TrkA-negative neurones also express the
receptor tyrosine kinase Ret in the later embryonic stages and also over the first
postnatal week and become sensitive to glial cell-derived neurotrophic factor
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(GDNF) (Molliver et al., 1997). Other markers of sensory neurones include vanilloid
receptor 1 (VR1) which is now more commonly known as transient receptor
potential vanilloid 1 (TRPV1). This receptor responds to the chilli extract capsaicin
and thermal stimuli (>42 °C) and both IB4-binding and CGRP-expressing neurones
respond to capsaicin, indicating that both subsets of nociceptors express TRPV1. In
addition, the sensory neurone specific adenosine triphosphate (ATP) receptor P2X3
is highly expressed by IB4-binding, GDNF-sensitive nociceptors and a small minority
of peptide containing NGF-sensitive neurones (Snider and McMahon, 1998). To
date, there are many studies, which have utilised this information to further
categorise nociceptors. For example, transient Runx1 expression is not only
required for TRPV1, but also other thermal/chemical receptors including TRPM8
(activated by cold and cooling agents), TRPA1 (activated by chemicals including
formalin) and TRPV2 (activated by >52 °C) (Chen et al., 2006). Also, the sensory
neurone specific sodium channel Nav1.8 has been shown to be present in all IB4-
binding neurones and a small population of CGRP positive neurones (Abrahamsen et
al., 2008). Despite this, assigning specific roles for the individual subsets of
neurones has remained difficult.
1.2 Peripheral sensory fibre conduction
All sensory information is transmitted from a peripheral site where the stimulation
originates e.g. the skin, along primary afferent fibres including nociceptors to the
spinal cord where the signal is transferred via neurotransmitter release from the
central terminals to the spinal neurones in the cord. As would be expected, due to
the wide range of peripheral stimuli to which humans and animals are sensitive,
sensory information is transmitted via nerves, which are specific for particular
modalities. These nerve fibres are named Aβ, Aδ and C, each with their own
specific features that contribute to enabling sensation of innocuous and noxious
stimuli.
Aβ-fibres, or low threshold mechanoreceptors transmit innocuous mechanical
stimuli as well as tissue displacement, velocity of displacement and vibration
placement and are in close contact with tissue supporting structures such as
epidermal cells and connective tissue. These fibres are of large diameter and are
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heavily myelinated, allowing rapid conduction of action potentials to the spinal
cord. Aδ-fibres are smaller in diameter than Aβ-fibres and are lightly myelinated
therefore making them slower conducting than Aβ-fibres and these fibres respond
to mechanical and noxious thermal stimuli (Myers, 1997; Julius and Basbaum, 2001;
D'Mello and Dickenson, 2008). Although Aδ- and C-fibres are classified as
nociceptors, the light myelination of Aδ-fibres means that their conduction velocity
overlaps slightly with Aβ-fibres. Aβ-fibres conduct at a speed of 30 – 80 m/s; Aδ-
fibres conduct at a velocity of 6 – 30 m/s and C-fibres conduct at a velocity of 0.5 –
2 m/s (Schmidt and Willis, 2007). The slight overlap in conduction velocities of Aβ-
and Aδ- fibres explains why some Aδ-fibres display Aβ-fibre properties and vice
versa. C-fibres however are unmyelinated and of the smallest diameter and
therefore possess the slowest conduction velocities. C-fibres are generally thought
of as being nociceptive specific and many C-fibres are polymodal in their response
to noxious mechanical and thermal stimulation as well as chemical stimulation
(D'Mello and Dickenson, 2008).
1.3 Peripheral sensitisation
Peripheral sensitisation refers to a form of stimulus evoked functional plasticity of
nociceptors at peripheral sites (i.e. before the dorsal root entry zone) whereby due
to injury or tissue damage, inflammatory mediators sensitise the nociceptors to the
extent where the threshold is reduced and responsiveness to further stimuli is
enhanced. More specifically, injury or inflammation can result in the upregulation
of a large number of sensitising agents that cause peripheral sensitisation as a
result of cell disruption, mast cell degranulation and inflammatory cell secretion
(Woolf and Ma, 2007). This list includes NGF, bradykinin, serotonin, ATP, protons
(H+), histamine, prostaglandins and lipids (Julius and Basbaum, 2001) as well as
cytokines and nitric oxide (NO) (Marchand et al., 2005). More recently, other key
players have also been identified including the transforming growth factor β (TGFβ)
member activin, tumour necrosis factor α (TNFα), chemokine (C-C motif) ligand 3
(CCL3), GDNF and proteases such as thrombin and trypsin (Woolf and Ma, 2007).
These mediators will directly or indirectly modulate various receptors that are
located on peripheral terminals and/or axons of nociceptors, most of which are
summarised in tables 1.1 and 1.2.
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An example of a receptor that has received much attention in the past decade,
particularly in relation to peripheral sensitisation is TRPV1. This receptor is located
on nociceptors in the peripeheral nervous system as well as spinal neurones within
the central nervous system (CNS). Some pro-inflammatory mediators including
protons and lipid mediators e.g. anandamide can directly activate TRPV1. In
addition, TRPV1 can also be modulated by the action of protein kinases,
phosphatases and/or lipid messengers produced by receptor-coupled intracellular
signalling pathways. Some inflammatory mediators (e.g. bradykinin) bind to G-
protein-coupled receptors (GPCRs) which signal via PKA and PKC to sensitise
TRPV1. In addition, some inflammatory mediators including prostaglandins,
bradykinin and NGF may induce hyperalgesia by increasing the expression of TRPV1
at the cell surface (Huang et al., 2006).
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Receptor/channel Major subtypes Ligands Notes
Purine P2X2, P2X3
ATP, ADP,
adenosine
P2X2 is modulated by
protons; P2X3 is GDNF
regulated
Acid-sensing
proton-gated
DRASIC, ASIC
(α, β)
Protons
Amiloride-sensitive,
Mechanosensitive?
Vanilloid TRPV1
Heat,
capsaicin
Sensitised by heat; proton-
gated; NGF regulated
Sodium
tetrodotoxin
resistant
Nav1.8, Nav1.9 N/A
Protein kinase A/C
(PKA/C) substrate; NGF
regulated
Sodium
tetrodotoxin
sensitive
Nav1.6, Nav1.7 N/A NGF regulated
Voltage-
dependent
calcium channels
(VDCCs)
T- (low
threshold), L-
and N-type
(high threshold)
N/A
Secondary calcium
currents mediated by
GPCRs
Serotonin 5-HT3 Serotonin
NMDA
NR1/2
heterotetramers
Glutamate/
aspartate
Controls SP release
AMPA iGluR 1-3 Glutamate
Kainate iGluR5 Glutamate
Controls neurotransmitter
release
Table 1.1 Common Ionotropic receptors and ligand gated ion channels
expressed by nociceptive primary afferent neurones that are implicated in
persistent and chronic pain-like states (adapted from Woolf and Costigan, 1999).
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Receptor/Channel Major subtypes Ligands Notes
Prostanoids
Prostaglandins
EP1 - 4 PGE1 - 4
PGE2 sensitises some
normally unresponsive
cells to bradykinin;
PGE2-PKA/C mediated
modulation of Nav1.8
and 1.9; sensitises heat
stimuli
Prostacyclin IP PGI2
Histamine H1 Histamine Itch mediator
Serotonin
5-HT1A,
5-HT2A,
 5-HT3, 5-HT4
Serotonin
5-HT4 increases Nav1.8
and 1.9 currents via
PKA/C
Bradykinin
B1 (induced),
 B2
Bradykinin
B1 sensitises cells to
heat via PKA
B2 increases the number
of cells that respond to
capsaicin and protons
Cannabinoid CB1 - 2 Anandamide
Secondary calcium
currents mediated by
GPCRs
Tachykinin NK1 SP, neurokinin A
Opioid µ, δ, κ
Enkephalins,
dynorphins,
β-endorphins
Inflammatory cells
release endogenous
opioids. Inhibits
peripheral activation
Table 1.2 Common metabotropic receptors expressed by nociceptive primary
afferent neurones that are implicated in persistent and chronic pain-like states
(adapted from Woolf and Costigan, 1999).
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1.4 Organisation of the spinal cord
All sensory afferents terminate at specific locations in the spinal cord, a process
that is highly organised and dependent on not just the nature of the nerve fibre,
but also the environment into which they terminate. The point at which the nerve
fibres enter the region of the spinal cord is called the dorsal root entry zone. In the
early 1950’s Rexed reported on his organisation of the spinal cord into a series of
layers that shared the same features from the sacral to the cervical cord with
minor variations (Rexed, 1952). This organisation involved dividing the grey matter
into specific laminae numbered from I to X, whereby lamina I to VI form the dorsal
horn of the spinal cord and laminae VII to IX the ventral horn. Lamina X is the
substantia grisea centralis i.e. the grey matter surrounding the central canal (see
figure 1.1). Below, is more detail regarding lamina I, II and V, which are of most
relevance to this thesis.
1.4.1 Lamina I
Lamina I is the most superficial lamina of the dorsal horn of the spinal cord and
receives input from small diameter unmyelinated C-fibres and finely myelinated
Aδ-fibres. This is the termination region for CGRP/TrkA-expressing nociceptors as
well as SP/TrkA-expressing nociceptors (they also terminate in the outer region of
lamina II) (Snider and McMahon, 1998). Lamina I consists of small neurones that are
mainly nociceptive specific (NS) in nature and some are thermoreceptive or
sensitive to itch stimuli. Lamina I neurones project to the brain via long-distance
tracts such as the ascending spino-parabrachial tract and other neurones project
laterally to other neurones within the same lamina or dorsally to other neurones in
deeper laminae. Lamina I neurones are therefore able to modulate the excitability
of deeper laminae neurones directly from connecting pathways within the spinal
cord or via relay systems which feed back down to spinal cord via descending tracts
(Sorkin and Carlton, 1997; Suzuki et al., 2002; Dickenson and Bee, 2008).
29
Chapter 1
1.4.2 Lamina II
Lamina II or the substantia gelatinosa receives input from CGRP/TrkA-expressing
DRG nociceptors to the outer layer and IB4-binding and Ret-expressing DRG
nociceptors to the inner layer, which is also the termination zone for Aδ-fibres. The
neurones of lamina II form a layer of interneurones that, as well as forming lateral
connections with other interneurones in lamina II, also project to other neurones in
laminae above and below it, although they don’t appear to form connections with
supraspinal sites (Sorkin and Carlton, 1997; Snider and McMahon, 1998; Dickenson
and Bee, 2008). Of particular interest is the fact that the neuronal specific γ form
of protein kinase C (PKCγ) is specifically expressed throughout inner lamina II in the
target field of Ret-expressing neurones but not in primary sensory neurones
themselves. Studies involving a transgenic line of mice lacking PKCγ revealed that
although behavioural responses to thermal and mechanical stimuli were normal,
hypersensitivity induced by nerve injury was significantly reduced (Malmberg et
al., 1997; Snider and McMahon, 1998).  The majority of the PKCγ interneurones
have been found not to be γ-amino butyric acid (GABA)- immunoreactive or
immunoreactive for the µ-opioid receptor 1 (MOR-1) but instead immunoreactive
for neurotensin and somatostatin, indicating a restricted expression profile to
specific excitatory neurones (Polgar et al., 1999).
1.4.3 Lamina V
Lamina III and IV are known collectively as the nucleus proprius and contain cells
that respond to innocuous input such as that arriving along Aβ-fibres (Dickenson
and Bee, 2008). Deeper down in the spinal cord at lamina V resides a population of
neurones that are also important in pain perception and therefore chronic pain
states. These neurones are known as wide dynamic range (WDR) neurones (and are
also found in lamina VI), so called due to their ability to respond to both innocuous
and noxious stimuli. They also receive input directly or indirectly from all sensory
afferent subtypes (see figure 1.1.) WDR neurones typically respond to stimuli
applied to large receptive fields and can ‘wind up’, a term describing the temporal
summation of the responses of the neurone to repeated stimuli of the same
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intensity (Mendell and Wall, 1965) and this is mediated by C-fibre afferents
(Mendell, 1966).
1.4.4 Mechanism of wind up
Wind up is largely dependent on the excitatory neurotransmitter glutamate.
Glutamate exerts excitatory effects throughout the nervous system, so it is
therefore not surprising that it should have important roles in pain processing and
it has been shown to act at postsynaptic sites on spinal neurones containing the
glutamatergic α-amino-3-hydroxy-5-methyl-4-isoxazeloproprionic acid receptors
(AMPARs); N-methyl-D-aspartate receptors (NMDARs) and G-protein coupled
metabotropic glutamate receptors (mGluRs) as well as pre-synaptic kainite
receptors (D'Mello and Dickenson, 2008).
The amount and frequency of glutamate release is dependent on sensory afferent
stimulation such that the more noxious a stimulus is, the more glutamate that is
released. Fast acting AMPARs are thought to be the initial responders to glutamate
release. When there is an increase in C-fibre activity due to e.g. noxious stimuli,
prolonged glutamate release now results in wind up due to the recruitment of
initially silent NMDARs (Dickenson and Sullivan, 1987). This silence is due to a
physiological block of the receptor ion channel pore by magnesium ions (Mg2+).
Sustained depolarisation of the spinal neurones mediated at least in part by AMPA
receptors results in removal of the Mg2+ block thus allowing entry Ca2+ into spinal
neurones.  In accordance with this, AMPA receptor antagonists have been shown
not to be effective in altering wind up (Stanfa and Dickenson, 1999; Seagrove et
al., 2004). Furthermore, release of other transmitters from C-fibres such as SP and
CGRP are likely to contribute to the sustained depolarisation of spinal neurones
and thus removal of the Mg2+ block which would lead to wind up (Budai et al.,
1995; Khasabov et al., 2002; Suzuki et al., 2003).
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Figure 1.1 Sensory pathways from the periphery to the spinal cord. Primary
afferent fibres comprising Aβ  (blue)-, Aδ (green)- and C-fibres (red) transmit
signals from the periphery to the spinal cord. NS neurones are restricted to the
superficial laminae of the dorsal horn (laminae I and II) and receive input from
nociceptors i.e. Aδ- and C-fibres. WDR neurones are located deep in Lamina V (and
VI) and receive input directly or indirectly from all sensory neurone subtypes
(adapted from D'Mello and Dickenson, 2008).
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1.5 Ascending projections from the spinal cord to the brain
After signals are transmitted to the spinal cord, where they are sorted and
processed, they are then sent to the brain via spinal projection neurones where
they are analysed and transformed into ‘painful sensations’.
1.5.1 Lamina I projections
A major population of projection neurones reside in lamina I, of which most (80 %)
can be identified by immunoreactivity for the neurokinin 1 (NK1) receptor for SP
(Todd, 2002). In terms of pain processing, the main projection pathway is the
dense spinoparabrachial pathway. In this pathway, the parabrachial (PB) nuclei
collect and process signals from spinal neurones before they are transmitted to
higher brain centres (Blomqvist et al., 1989; Bester et al., 1997). These areas
include the amygdala, hypothalamus and the periaqueductal grey (PAG).  The
amygdala is involved in mediating aversion, anxiety and fear-induced avoidance
learning (Maren, 2007), the hypothalamus mediates homeostatic processes such as
blood pressure and heart rate (Vidal et al., 1984) and the PAG mediates opioid and
non-opioid endogenous analgesia (Lewis and Gebhart, 1977).  Another ascending
pathway that connects lamina I to the brain, albeit less dense than the
spinoparabrachial pathway, is the spinothalamic pathway, whereby projection
neurones project to caudal regions of thalamus. The thalamus then projects to the
insular and somatosensory cortices, thus enabling sensory discrimination (Bester et
al., 2000). It should be noted that there are also a number of projection neurones
that are found in lamina III and IV that project predominantly to the thalamus, thus
contributing to the spinothalamic tract (D'Mello and Dickenson, 2008).
1.5.2 Lamina V projections
Also contributing to the spinothalamic tract are projection pathways, which
connect spinal neurones in even deeper laminae with the thalamus (Lima et al.,
1991; Hunt and Mantyh, 2001). The thalamus sends projections onto the prefrontal
cortex, which has been shown to be involved in attention and the motivational
aspects of pain (Wiech et al., 2005).
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1.6 Descending projections from the brain to the spinal cord
The 1970s was a period that witnessed a flurry of research into descending systems
and their modulation of nociception. Pivotal to this was a study, which reported
that focal electrical stimulation in the rat midbrain PAG allowed abdominal surgery
(laparotomy) to be carried out on animals without general anaesthesia. This work
(Reynolds, 1969) acted as a catalyst not only in identifying the PAG and adjacent
areas as modulators of analgesia in awake animals, but also into the research which
has contributed to the discovery of the dynamic features relevant to descending
systems. The descending systems described below form part of the spino-bulbo-
spinal loop i.e. the circuitry that comprises ascending connections from the spinal
cord to the brain and descending connections from the brain back to the spinal
cord where incoming signals from the periphery as well as neuronal processing
within the cord are further modulated (see figure 1.2)
1.6.1 The PAG
Not long after the work of Reynolds, was the discovery by Hertz et al. who showed
that injecting morphine directly into the PAG area resulted in analgesia from a
nociceptive stimulus (Herz et al., 1970). This study, in addition to the
identification of specific opioid binding sites in the brain (Pert and Snyder, 1973)
and the isolation of endogenous opioid-like peptides in the brain (Hughes, 1975)
confirmed that not only was the PAG necessary for inhibition of spinal nociceptive
processing,  but that its inhibitory action was mediated by endogenous opioid-like
peptides such as enkephalins. Also of major importance during this era was the
finding that stimulus-induced analgesia of the PAG could be achieved if it was
administered for several minutes prior to the onset of a painful stimulus during
which, specific neurones are recruited or neurotransmitters released that act
either at the origin of the stimulus or at sites further away such as the spinal cord
(Melzack and Melinkoff, 1974).
Descending neurones from the PAG terminate in the dorsolateral pontine
tegmentum (DLPT), another site that is rostral to the RVM. Within this structure,
the locus coeruleus, the A5 and A7 noradrenergic cell groups are the main source
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of noradrenergic projections to the dorsal horn and are implicated in inhibiting
nociception (Proudfit and Clark, 1991; Millan, 2002; Rahman et al., 2008). At the
level of the spinal cord, noradrenaline acts predominantly at the α 2
adrenoreceptor (α2AR) subclass, thus inhibiting transmitter release from primary
afferent terminals, which suppresses firing of projection neurones in the dorsal
horn (Millan, 2002; Rahman et al., 2008).
1.6.2 The rostroventral medulla
Although the PAG is clearly of major importance, it is the rostroventral medulla
(RVM) that provides the common output for descending influences from rostral
sites such as the PAG (Gebhart, 2004).
The RVM contains the nucleus raphae magnus as well as the adjacent reticular
formation, including the nucleus reticularis magnocellularis (NRMC) (Mason, 2001).
Interestingly, stimulation of the RVM has been reported to both facilitate and
inhibit nociceptive responses (Suzuki et al., 2004a). In accordance with these
findings, cells within the RVM have been classified into three distinct groups based
on specific evoked responses to noxious heat stimulation. “Off” cells are indirectly
excited by opioids and inhibited by nociceptive input such that just before a
nociceptive reflex, they will display a transient interruption in their discharge.
“On” cells are inhibited by opioids and excited by nociceptive input such that just
before a nociceptive reflex, they will display a transient increase in their discharge
(Millan, 2002). “Neutral” cells maintain their discharge rate irrespective of a
nociceptive reflex, although their role in pain processing is still a source of debate
(Gao and Mason, 2000).
It is now widely accepted that the RVM can modulate neuronal activity at the
spinal level via descending influences that exert opposing effects. This is
attributable to the fact that descending pathways from the RVM modulate neuronal
activity by releasing a range of neurotransmitters including serotonin (5-
hydroxytryptamine or 5-HT), GABA, acetylcholine and enkephalins. These
transmitters can act at either multiple subtypes of receptors differentially coupled
to intracellular signalling mechanisms or a single receptor subtype localised on
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different classes of target spinal neurones (Millan, 2002). Of these
neurotransmitters, 5-HT has received a huge amount of interest. There are more
than 15 5-HT receptor (5-HTR) subtypes so it is therefore not surprising that this
neurotransmitter is implicated in both anti-nociceptive and pro-nociceptive effects
depending on the receptor subtype it acts on. Importantly, although descending
facilitation occurs along with descending inhibition, it is the shift in balance
towards facilitation that is proposed to be key in contributing to persistent pain
states. There are many studies that have focussed on the role of spinal 5-HT3Rs in
nociception and persistent pain-like states (Green et al., 2000; Suzuki et al., 2002;
Zeitz et al., 2002; Suzuki et al., 2004b; Suzuki et al., 2005; Donovan-Rodriguez et
al., 2006; Svensson et al., 2006). Like other spinal 5-HTRs, these receptors are
located on primary afferent terminals in the dorsal horn as well as inhibitory
interneurones containing enkephalins and GABA (Millan, 2002; Conte et al., 2005).
However, unlike all the other 5-HTRs, 5-HT3Rs are the only ligand gated ion
channel (Barnes and Sharp, 1999; Millan, 2002).
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Figure 1.2 Ascending and descending components of the spino-bulbo-spinal
loop. (Left) Ascending component shows projections from lamina I neurones in the
dorsal horn of the spinal cord (red) and lamina V (blue) to midbrain and higher
brain centres. (Right) Descending component shows projections from higher,
midbrain and brainstem regions to the dorsal horn of the spinal cord. AN, amygdala
nuclei; HN, hypothalamic nuclei; NCF, nucleus cuneiformis; PAG, periaqeductal
grey, PB, parabrachial nuclei; TN, thalamic nuclei; RVM, rostroventral medulla
(adapted from Hunt and Mantyh, 2001; Tracey and Mantyh, 2007).
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1.7 Central sensitisation
Clinically, peripheral sensitisation can result in allodynia whereby non-painful
stimuli become painful and hyperalgesia whereby painful stimuli become even
more painful. The afferent barrage into the spinal cord often results in central
sensitisation whereby neurones in the spinal cord and those in the brain centres
associated with pain now also become more responsive to incoming signals, thus
further potentiating signals that were originally too weak to initiate a response,
resulting in wide spread pain beyond the site of injury (Suzuki et al., 2004b; Suzuki
et al., 2005; Basbaum et al., 2008). This can be clearly demonstrated by inducing
wind up or short-term potentiation of spinal neurons, a method that can be
successfully employed as a read-out of central sensitisation (see section 1.4.4).
1.7.1 Central primary afferent terminals
From figure 1.1, it can be seen that the central terminals of primary afferent
sensory fibres terminate in the dorsal horn of the spinal cord. Although glutamate
is the main excitatory neurotransmitter in the CNS, nociceptors also transmit
signals via the release of neuropeptides such as CGRP and SP and proteins such as
brain-derived nerve growth factor (BDNF). Transmitter release has long been
known to be dependent upon Ca2+ influx after the arrival of action potentials along
the axon and to the terminals. The main voltage-dependent calcium channel
(VDCC) expressed by nociceptors is Cav2.2 (Castiglioni et al., 2006). Interestingly,
the α2δ accessory subunit of VDCCs has been identified as the binding site for the
drug gabapentin (GBP), which has efficacy in neuropathic pain (Field et al., 2006).
Furthermore, the α2δ accessory subunit has been shown to be upregulated in
central nociceptor afferent terminals after peripheral nerve injury, therefore
representing a specific target for the treatment of chronic pain syndromes (Luo et
al., 2001).
Transmitter release from central afferent terminals can either be inhibited or
potentiated via endogenous mechanisms, which act to modulate this process. For
example, transmitter release can be increased by prostaglandin E2 (PGE2), which is
produced by COX2 in dorsal horn neurones in response to inflammation.
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Transmitter release can also be increased by bradykinin, which increases Ca2+
influx through TRPA1 channels. As well as facilitating transmitter release, there are
also endogenous mechanisms that act to inhibit transmitter release from
nociceptive afferents. These include endogenous opioids acting on µ- and δ-opioid
receptors, GABA acting on GABAB receptors and endogenous cannabinoids acting on
CB1 receptors. These mechanisms also come into play during persistent pain states,
yet in persistent pain states, the facilitatory mechanisms outweigh the inhibitory
mechanisms (Woolf and Ma, 2007).
1.7.2 Dorsal horn neurones
The sustained afferent input to the spinal cord from the central terminals of the
primary afferents due to injury/inflammation results in an increased sensitivity of
the spinal neurones to incoming afferent input. Thus a state of spinal sensitisation
occurs resulting in an increase in excitability of dorsal horn units such that
responses to peripheral stimuli are enhanced (Chapman et al., 1998; Suzuki et al.,
2000).
At the cellular level, central sensitisation is mediated by changes that act to
increase spinal neuronal activity. As already discussed, wind up can be used as a
read-out of central sensitisation (i.e. wind up increases with central sensitisation)
and this means that NMDAR-dependent mechanisms are in part responsible for the
neuronal hyperexcitability that results from central sensitisation (Haley et al.,
1990; Chapman et al., 1994). Wind up and therefore central sensitisation are not
only dependent upon incoming signals from peripheral afferents. Central
sensitisation at the spinal level is also modulated by descending signals from higher
brain regions.
Innovative studies have revealed key features about the interactions between
descending facilitatory pathways from the brain to the spinal cord. Behavioural
studies have revealed that injections of the anaesthetic agent lidocaine into the
RVM can reverse behavioural hypersensitivity in nerve-injured rats (Burgess et al.,
2002). Following on from these studies, in vivo electrophysiology has been used to
study spinal neurones after RVM lidocaine treatment (Bee and Dickenson, 2007).
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This study showed that by injecting lidocaine into the RVM, dorsal horn WDR
neuronal responses to peripheral stimuli could be reduced. This effect was even
greater in nerve-injured rats that were hypersensitive to previously innocuous
stimuli, suggesting a mechanism for clinical allodynia.
At the root of descending modulation by the RVM are the group of projection
neurones in the dorsal horn that express NK1. It has been shown that by ablating
lamina I/III NK1-expressing neurones with SP conjugated to the toxin saporin (SP-
SAP), that the excitability of WDR neurones could be reduced. In addition,
spontaneous neuronal activity produced by injecting the inflammatory agent
formalin into the hind paw is reduced in SP-SAP rats, as is the persistent
behavioural hypersensitivity that occurs after the inflammatory agent complete
Freund’s adjuvant (CFA) is injected into the hind paw (Suzuki et al., 2002). These
descending modulatory actions were determined to be via the action of serotonin
on 5-HT3Rs due to the fact that spinally administering the selective 5-HT3R
antagonist ondansetron produced the same inhibitions of mechanically and
thermally evoked stimuli as those produced by SP-SAP (Suzuki et al., 2001). In
addition, ondansetron has been shown to be more effective in attenuating spinal
neuronal responses to peripheral mechanical and thermal stimuli in nerve-injured
rats compared to sham controls, suggesting that in persistent pain pain-like states,
there is an increase in the facilitatory serotonergic component of descending
pathways from the RVM (Suzuki et al., 2004b).
SP-SAP treatment has also been shown to attenuate behavioural hypersensitivity
and stimulus evoked neuronal responses in nerve-injured rats (Suzuki et al., 2005).
As well as reducing mechanical and thermal stimuli, SP-SAP treatment also blocks
wind up and a more sustained form of wind up, long-term potentiation (LTP). This
feature however is not mimicked by administration of spinal ondansetron (Rygh et
al., 2006). This indicates that some mechanisms of spinal sensitisation do not
require descending facilitatory pathways to be active, yet they can be modulated
by these pathways.
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Descending facilitatory pathways from the RVM are not only important for the
behavioural hypersensitivity observed in persistent pain-like states and the spinal
neuronal activity that is the basis for this behaviour, but they are also necessary
for state-dependent drugs to exert their effects. Such is the case with GBP. In vivo
electrophysiology studies have shown that spinal SP-SAP can actually block the
inhibitory effects of systemically administered GBP in nerve-injured rats (Suzuki et
al., 2005). In addition, selectively blocking the 5-HT3R with ondansetron also
prevents the inhibitory actions of GBP. Interestingly, selective activation of 5-
HT3Rs with the agonist 2-methyl 5-HT, a method employed to mimic persistent
pain-like states, renders GBP effective in naive rats.
Although descending facilitatory action at 5-HT3Rs would appear to be a feature of
all persistent pain-like states, this is not the case. The well-established
carrageenan-induced inflammation model, whereby the seaweed extract
carrageenan is injected into the hind paw is one such example of this. This model
presents with behavioural, mechanical and thermal hypersensitivity as well as
changes in neuronal plasticity (Kayser and Guilbaud, 1987; Stanfa et al., 1992). As
described above, ondansetron will attenuate spontaneous neuronal
hyperexcitability due to formalin-induced inflammation as well as mechanically
and thermally evoked neuronal responses to a greater degree in nerve-injured rats
compared to naive and sham rats. However, in the carrageenan-induced
inflammation model, ondanstetron will attenuate neuronal responses to the same
extent as naive rats (Rahman et al., 2004) meaning that descending pathways
acting at spinal 5-HT3Rs are unaltered. Figure 1.3 shows an overview of many of
the components involved in peripheral and central sensitisation.
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Figure 1.3 Overview of the spino-bulbo-spinal loop and components of
peripheral and central sensitisation. Nociceptive signals are transmitted from the
periphery to the spinal cord via nociceptive fibres. Peripheral sensitisation as a
result of inflammation due to inflammatory mediators or direct nerve injury
contributes to hypersensitivity (clinical allodynia and hyperalgesia) and can occur
via the upregulation of transcription factors for ion channels that contribute to
spontaneous activity. Sustained peripheral sensitisation often results in central
sensitisation whereby neurones of the spinal cord and brain regions act to further
enhance pain perception. Specifically, central sensitisation can be demonstrated
through an increased amount of wind up in spinal neurones. Wind up is an NMDAR-
dependent process mediated by C-fibres that involves increased neuronal output to
suprathreshold stimuli. Signals from spinal neurones are processed and transmitted
rostrally to the parabrachial area in the brainstem, which is associated with the
affective aspects of pain. These signals are then relayed back to the spinal cord via
the PAG and RVM. During many persistent pain-like states, there is an increase in
descending serotonergic modulation acting at 5-HT3Rs on primary afferent
terminals that overrides descending inhibitory modulation acting at e.g. α2ARs as
well as facilitation of inhibitory interneurones (adapted from Harvey and
Dickenson, 2008).
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1.8 Peripheral and central sensitisation: a role for non-neuronal
cells
The neuronal system is not the only cellular system that is involved in nociception
and the changes associated with persistent pain-like states. Recently, there has
been a surge in research that seeks to delineate the roles that inflammatory
mediators from immune cells play in persistent pain states. It is now clear that
these cells and their mediators have significant roles in inflammatory and
neuropathic pain-like states (Scholz and Woolf, 2007).  In the periphery, Schwann
cells, mast cells, macrophages and T-cells are recruited to the site of injury and
will release factors such as tumour necrosis factor α (TNFα), interleukin 1b, (IL1b),
IL6, CCL2, prostaglandins and NGF that contribute to the initiation and
maintenance of sensory abnormalities post-injury. Centrally, primary afferent
terminals are surrounded by microglia.  These cells are believed to be important in
maintaining the physiological conditions of the spinal cord. In persistent pain states
such as neuropathy, aberrant transmitter release from primary afferent terminals
activates microglia, resulting in a release of TNFα, IL1b, IL6, nitric oxide (NO), ATP
and prostaglandins which lead to neuronal hyperexcitability (Marchand et al.,
2005).
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1.9 Central sensitisation and intracellular signalling pathways
Despite the progress that has been achieved in determining the transmitters and
receptors involved in nociception and pain maintenance, our understanding of the
intracellular signalling mechanisms regulating nociceptor sensitisation downstream
of ligand binding to receptors is still at an early stage (Hucho and Levine, 2007).
However, individual signalling pathways are often activated by more than one
ligand/receptor combination. These pathways, especially in persistent pain-like
states act to promote mechanisms of spinal plasticity such as the more sustained
form of wind up, LTP.
1.9.1 LTP as a read-out of central sensitisation
LTP has been studied as a cellular model of synaptic plasticity for many years and
is generally defined as a long-lasting, but not necessarily irreversible increase in
synaptic plasticity (Sandkuhler, 2007). Early phase LTP is independent of de novo
protein synthesis and lasts for up to 3 hr whereas late phase LTP (LLTP) involves
protein synthesis and lasts longer than 3 hr, up to the lifespan of the animal and
involves structural changes at the synapse (Bailey et al., 2004). LTP was classically
demonstrated at synapses in the hippocampus (Bliss and Lomo, 1973) and is still
used as a model for learning and memory formation.
More than 100 molecules have been implicated as mediators of hippocampal LTP
and many of these are also involved in central sensitisation observed in persistent
pain-like states (Ji et al., 2003). This means that hippocampal LTP studies can
often be used to predict what transmitters/receptors/signalling cascades are
important in central sensitisation and therefore pain maintenance. One prime
example of this is the identification of the immediate early gene zif268 as an
important determinant of hippocampal LTP. As well as being important for
hippocampal LTP, this gene has also been shown to be important for the
behavioural outcome of hippocampal LTP i.e. learning and memory.  Interestingly,
it has been found that spinal LTP results in increased neuronal expression of Zif268
in the superficial lamina of the dorsal horn and that spinal Zif268 antisense
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treatment results in deficits of LTP in dorsal horn neurones following peripheral
injury (Rygh et al., 2006).
1.9.2 LTP and nociceptive circuits
LTP displayed by spinal neurones is mediated by the release of glutamate and SP
from central primary afferent terminals, which causes the opening of NMDAR
channels and T-type VDCCs as well as Ca2+ release from intracellular stores. This
activates Ca2+ dependent signal transduction pathways that involve protein kinases
and transcription factors. Synaptic strength is increased e.g. by phosphorylation of
synaptic proteins including AMPARs; altered trafficking of synaptic proteins and de
novo protein synthesis. These are changes that act to facilitate neurotransmitter
release and/or conduction (Bliss and Collingridge, 1993; Sandkuhler, 2007). These
changes result in an increased responsiveness of spinal neurones and are believed
to be pivotal in contributing to clinical hyperalgesia and allodynia (D'Mello and
Dickenson, 2008).
Bliss and Lomo were the first to describe the most frequently used form of
conditioning stimulation to induce hippocampal LTP, that consists of high
frequency electrical stimulation (HFS) of an input pathway (Bliss and Lomo, 1973).
Relevant to pain, Liu and Sandkuhler were the first to report that LTP of C-fibre
evoked field potentials in the superficial dorsal horn in vivo may last for more than
8 hr (Liu and Sandkuhler, 1995). This was achieved by stimulating the sciatic nerve
at a frequency of 100 Hz, given in 4 trains lasting 1 s at 10 s intervals i.e. high
frequency burst-like activity. Furthermore, the spinal LTP evoked was blocked
using the NMDA antagonist D-(-)-4-(3-phosphonopropyl)piperazine-2-carboxylic acid
(DCPP) confirming the necessity for NMDAR mediated Ca2+ influx. It has also been
found that repetitive HFS of primary afferents not only results in LTP of superficial
dorsal horn neurones that is C-fibre mediated, it also induces LTP mediated by Aδ-
fibres (Randic et al., 1993).
As well as inducing LTP with high frequency electrical stimuli, LTP mediated by
nociceptive C-fibres can also be induced by noxious stimuli that are directly
responsible for producing clinical allodynia and hyperalgesia including skin burns,
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contusions, inflammation and acute nerve injury (Sandkuhler and Liu, 1998). This
particular study by Sandkuhler and Liu as well as other LTP experiments carried out
by the same group were performed on spinalised rats whereby, after an injection
of the anaesthetic lidocaine into the third segment of the cervical region of the
spinal cord, the cord is then cut and the rats consequently mechanically
ventilated. However, LTP can also be induced in deep WDR neurones in intact rats
(Svendsen et al., 1997; Rygh et al., 1999), although LTP of C-fibre evoked
responses is larger and easier to obtain in spinalised rats (Rygh et al., 2002). The
fact that LTP can also be recorded from WDR neurones means that the effects of
LTP-induction are not being filtered out at other levels of the neuraxis. In addition,
the augmented LTP observed in spinalised rats confirms that LTP of WDR neurones
is mainly localised to the spinal neurones, yet can be modulated by descending
pathways under physiological conditions.
It is important to note that spinal LTP is different from the wind up discussed in
section 1.4.4. In the rat, LTP is induced by high frequency (100 Hz) electrical
stimulation of the sciatic nerve, resulting in enhanced responses of dorsal horn
WDR neurons to single Aδ- or C-fibre stimuli for up to 6 hr (Svendsen et al., 1997).
In contrast, wind up is induced by lower stimulation frequencies (0.3 – 2 Hz) and
the enhanced responsiveness may maximally last for a few minutes after the end of
a stimulation train. Whilst wind up has been used to explore putative mechanisms
underlying central sensitization, there is still some debate as to whether the study
of LTP is useful for examining mechanisms of centeral sensitization due to the
substantially high frequencies used to induce the state (Eide, 2000).
1.9.3 LTP and protein synthesis
The persistence of LTP and thus learning and memory has been shown to require
new protein synthesis.  Furthermore, it is believed that these newly synthesised
proteins are targeted by two main mechanisms that specifically target these
proteins to activated synapses. One mechanism, involves synthesis of proteins
within the cell body, which are then captured by active ‘tagged’ synapses
therefore facilitating responses to further stimuli at those synapses. The second
mechanism involves the synthesis of proteins locally in neuronal dendrites at the
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site of synaptic activation (Martin and Kosik, 2002; Bailey et al., 2004; Kelleher et
al., 2004).
In 1984, Krug et al. were the first to report a requirement for newly synthesised
proteins in long lasting hippocampal LTP (Krug et al., 1984). In their studies, freely
moving rats were chronically implanted with a stimulation electrode into the
medial entorhinal cortex and a recording electrode into the dentate gyrus of the
hippocampus in order to induce and record LTP with a tetanising stimulus. When
they administered an intraventricular dose of the global translation inhibitor
anisomycin (which inhibits ribosomal machinery and thus the decoding of
messenger ribonucleic acid (mRNA) in the cytoplasm of a cell), there was no effect
on the induction of LTP, yet long lasting LTP (3 hr - 7 d) was significantly
attenuated.
To date, there have been many detailed studies that have identified a variety of
signalling pathways and phosphorylation events that link synaptic activity to
changes in the activity of various regulatory transcriptional proteins i.e. proteins
that are involved in converting nuclear deoxyribonucleic acid (DNA) to mRNA during
protein synthesis.  One such transcriptional factor is cyclic adenosine
monophosphate (cAMP) response element binding protein (CREB). This transcription
factor is induced in many cell types in response to extracellular signals such as
neurotransmitters. These signals cause translocation of CREB to a short sequence of
DNA within the promoter of specific genes within the nucleus i.e. the CRE. In the
nervous system, targets for CREB include genes for BDNF and the NMDAR-coupled
signalling molecule neuronal nitric oxide synthase (nNOS) as well as others (West et
al., 2002).
Experiments on the Californian sea slug (Aplysia californica) have perhaps been the
most revealing in terms of mechanisms that mediate neuronal hyperexcitability
such as that seen with LTP. These animals are ideal for physiological research
because they have a relatively simple nervous system consisting of a few thousand
easily identifiable neurones. Key studies in Aplysia have demonstrated synaptic
tagging in a culture system where a single bifurcated Aplysia sensory neurone is in
contact with two spatially separated motor neurons (Casadio et al., 1999). In these
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studies, a single puff of 5-HT was delivered to one contact and five puffs were
delivered to the other contact. A single puff was found to produce only transient
facilitation whereas if five puffs were first applied to the other contact, then the
facilitation produced by the single puff was longer lasting. This increase in synaptic
potency persisted for more than 24 hr and was dependent upon transcription as
shown by inhibition with the transcriptional inhibitor actinomycin D. It was
confirmed that transcription was mediated by CREB due to the fact that injection
of anti-CREB antibodies into the neurone cell body blocked further facilitation at
the tagged synapse. Of particular interest, was the identification of two
components of the tagging system. Initiation of facilitation as well as facilitation
produced within the first 24 hr from a single puff of 5-HT was dependent upon
protein kinase A (PKA), which is upstream of CREB, yet this pathway was not
sufficient for the self-maintained stabilisation of the plastic changes that persisted
beyond 72 hr.  Instead, this was found to be dependent on specific protein
translation pathways that were sensitive to the drug rapamycin, the inhibitor of
the mammalian target of rapamycin (mTOR). In the past few years, there has been
much interest in the roles of these pathways and particularly, their roles in
neuronal plasticity.
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1.10 Rapamycin-sensitive pathways
The serine-threonine protein kinase mTOR was identified and cloned shortly after
the discovery of two yeast genes, TOR1 and TOR2, in the budding yeast
Saccharomyces cerevisiae during a screen for the resistance to the
immunosuppressant drug rapamycin (Hay and Sonenberg, 2004). mTOR can be
autophosphorylated via its intrinsic serine/threonine kinase activity and it
regulates protein synthesis through the phosphorylation and inactivation of the
repressor of mRNA translation, eukaryotic initiation factor 4E (eIF4E)-binding
protein (4EBP) and through the phosphorylation and activation of the 70 kDa
ribosomal protein S6 kinase (p70S6K) (Brown and Schreiber, 1996). Phosphorylation
of mTOR as well as p70S6K and 4EBP phosphorylation is commonly used as an
activity read-out of these pathways, which can be inhibited by the drug rapamycin.
Rapamycin is produced by the soil bacterium Streptomyces hygroscopicus and was
originally purified as an antifungal agent after its discovery from the soil of Easter
Island (Vezina et al., 1975). However, it was deemed unsuitable due to its
undesirable immunosuppressive side effects. After investigating further into these
side effects, rapamycin is now often the drug of choice to prevent rejection after
kidney transplantation due to its inhibitory effects on T-cell growth and IL2-
induced proliferation (Cohen, 2002). Furthermore, rapamycin was the first drug to
be approved for clinical use that selectively inhibits one protein kinase (Liu et al.,
1991). Rapamycin forms an inhibitory complex with its intracellular receptor, the
FK506-binding protein (FKBP12), which binds a region in the C terminus of mTOR
proteins, thereby inhibiting mTOR activity (Hay and Sonenberg, 2004).
mTOR regulates several intracellular processes in response to various extracellular
signals, nutrient availability, energy status of the cell and stress. Relevant to
nociceptors is the fact that rapamycin-sensitive pathways are known to regulate
survival, differentiation and development of neurones. It is therefore of no surprise
that mTOR activity is modified in a wide range of pathological states including
neurodegenerative disorders such as Alzheimer’s disease (Jaworski and Sheng,
2006; Swiech et al., 2008).
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The canonical pathway for mTOR activation begins with the activation of receptor
kinases by mitogens such as lipopolysaccharide, trophic factors such as BDNF or
hormones such as insulin. This leads to the activation of phosphoinositide-3 kinase
(PI3K) via the Ca2+-dependent recruitment of the protein Ras (as well as other
adaptor proteins) and increased production of phosphatidylinositol 3,4,5-
triphosphate (PIP3) via phosphorylation of phosphatidylinositol 4,5-biphosphate
(PIP2). PIP3 can be converted back to PIP2 via the action of phosphatase and tensin
homolog deleted on chromosome 10 (PTEN). The increase in PIP3 results in the
recruitment of 3-phosphoinositide-dependent protein kinsae 1 (PDK1) and the
serine-threonine kinase Akt to the membrane and the subsequent phosphorylation
of Akt by PDK1. Akt can then phosphorylate tuberin (TSC2) which, together with
hamartin (TSC1) forms the tuberous sclerosis complex TSC1/2. This acts as a
guanine triphosphate (GTP)-ase activating protein (GAP) for Rheb (Ras homolog
enriched in brain protein). Inactivation of TSC2, caused by Akt-mediated
phosphorylation, as well as activation of the guanine exchange factor for Rheb-
translationally controlled tumour protein (TCTP), results in increased Rheb-GTP
levels in the cell and this has a stimulatory effect on mTOR activity (Swiech et al.,
2008).  Together with its binding partner raptor, mTOR controls translation via the
phosphorylation of both 4EBP and p70S6K. This leads to the activation of a number
of targets involved in mRNA translation (Takei et al., 2004) (see figure 1.4). As well
as the canonical pathway, there are also other upstream regulators of mTOR at the
level of other signalling systems, receptors and neurotransmitters that have been
shown to engage rapamycin-sensitive pathways. Many of these components have
received much attention in the past few years and are summarised in tables 1.3
and 1.4.
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Figure 1.4 Schematic diagram of mTOR activity control. Stimulation of several
receptors at the plasma membrane by mitogens, trophic factors and
neurotransmitters leads to mTOR activation via Ras- and PI3K-dependent pathways.
The activity of mTOR can be specifically inhibited by the drug rapamycin. Arrows
indicate activation and bars indicate inhibition (adapted from Takei et al., 2004;
Swiech et al., 2008).
51
Chapter 1
Ligand/Receptor Evidence
Glutamate/NMDARs NMDARs modulate mTOR/p70S6K translation-related proteins
(Gong et al., 2006; Gonzalez-Mejia et al., 2006; Yoon et al.,
2008).
Cationic amino acid transporters mediate NMDAR activation-
dependent changes via the mTOR pathway (Huang et al.,
2007).
NMDARs engage mTOR pathways and are required for LTP
(Cammalleri et al., 2003).
Glutamate/mGluRs Protein translation via mTOR involves mGluR1/5 receptors
and contributes to behavioural hypersensitivity (Price et al.,
2007).
Long-term depression involves mGluR1/5-mTOR signaling
(Hou and Klann, 2004; Banko et al., 2006; Page et al., 2006).
5-HT/5-HTRs 5-HT-induced facilitation is mediated by mTOR signalling
(Casadio et al., 1999; Khan et al., 2001; Carroll et al., 2004;
Hu et al., 2006; Hu et al., 2007; Weragoda and Walters,
2007).
BDNF/TrkB BDNF-induced neuronal protein translation is mediated by
mTOR (Takei et al., 2001; Schratt et al., 2004; Takei et al.,
2004).
Neurotrophin 3
(NT3)/TrkC, TrkB,
low affinity nerve
growth factor
receptor (LNGFR)
NT3-mediated LTP requires mTOR signalling (Je et al.,
2005).
Vascular endothelial
growth factor
(VEGF)/VEGF
receptor
VEGF signalling activates mTOR (Kim et al., 2008).
Table 1.3 Recent progress on neurotransmitters and receptors that engage
rapamycin-sensitive pathways.
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Signalling molecule Evidence
PI3K PI3K activation engages rapamycin-sensitive pathways
that are implicated in neuronal development and
plasticity (Takei et al., 2001; Schratt et al., 2004;
Horwood et al., 2006; Hu et al., 2006; Chenal and
Pellerin, 2007; Hu et al., 2007; Kelly et al., 2007;
Tsokas et al., 2007).
PKC PKC activation engages rapamycin-sensitive pathways
that are implicated in neuronal plasticity (Khan et
al., 2001; Kelly et al., 2007).
Extracellular signal
regulated kinase (ERK)
ERK activation engages rapamycin-sensitive pathways
that are implicated in neuronal plasticity (Gelinas et
al., 2007; Kelly et al., 2007; Tsokas et al., 2007).
Ca2+/calmodulin-dependent
protein kinase II (CaMKII)
CaMKII activation engages rapamycin-sensitive
pathways that are implicated in neuronal
development and plasticity (Schratt et al., 2004;
Kelly et al., 2007).
Table 1.4 Recent progress on neuronal intracellular signalling molecules that
engage rapamycin-sensitive pathways.
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1.10.1 Multi-signalling convergence upon mTOR
The information in tables 1.3 and 1.4 gives the impression that there are group of
specific neurotransmitters, receptors and intracellular signalling pathways that
engage rapamycin-sensitive pathways. However, given what is already known about
the complexity and diversity of intracellular signalling pathways, this is not the
case. For example, whereas ERK-dependent pathways and PI3K-dependent
pathways will both activate mTOR, at the receptor level, they can both be
indirectly regulated by the same transmitters/receptors and can converge before
they reach mTOR (Tsokas et al., 2007; Swiech et al., 2008). Essentially, there are a
number of cellular processes that act to enhance or inhibit neuronal excitability
that converge on mTOR. The information in tables 1.3 and 1.4 merely represents
recent progress on some of the most characterised intracellular signalling
molecules relevant to neuronal excitability.
Relevant to pain, many of the neurotransmitters, receptors and signalling
molecules that engage mTOR pathways, have been shown to have key roles in
nociception and persistent pain-like states. CaMKII and ERK have been shown to
play important roles in mediating behavioural hypersensitivity to formalin-induced
inflammation or nerve injury (Zhuang et al., 2005; Choi et al., 2006). BDNF has
been shown to be important in mediating formalin-induced inflammation (Kerr et
al., 1999) as well as nerve injury-induced behavioural hypersensitivity (Yajima et
al., 2005). Likewise, there are numerous reports on the importance of the action of
glutamate on NMDARs and mGluRs in mediating the neuronal changes and
behavioural hypersensitivity associated with persistent pain-like states (Haley et
al., 1990; Chaplan et al., 1997; Dogrul et al., 2000; Suzuki et al., 2001; Varty et
al., 2005)
Importantly, rapamycin-sensitive pathways exert significant effects on neuronal
excitability that can be modulated by neurotransmitters, receptors and signalling
molecules that are known to play crucial roles in persistent pain-like states.
However, there have been few studies that have specifically investigated the
importance of these pathways in nociception and persistent pain-like sates.
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1.11 Rapamycin-sensitive pathways and neuronal excitability
Key studies on Aplysia and hippocampal-induced LTP have revealed important
aspects of rapamycin-sensitive pathways and neuronal excitability. Neurones from
Aplysia have been used to test the hypothesis that axonal injury (crush) or the
focal depolarisation that accompanies axonal injury (using a high extracellular K+
treatment) can trigger a local decrease in action potential threshold and result in
long-term hyperexcitability (LTH) (Weragoda et al., 2004). In this study,
nociceptive tail sensory and motor nerve axons exhibited LTH lasting at least 24 hr
after crushing or an elevated extracellular K+ treatment. Furthermore, exposure of
the nerve axons to the global protein translation inhibitor anisomycin and
rapamycin resulted in prevention of the LTH induced by both treatments. This
dependence on protein synthesis was found to be state specific because thresholds
of axons in uninjured or untreated nerves were unaffected by the inhibitors
The crush-induced LTH was later found to be mediated by 5-HT (Weragoda and
Walters, 2007) because application of the 5-HT receptor antagonist methiothepin
to nerve segments inhibited this crush-induced LTH. In addition, the 5-HT-induced
LTH was also inhibited by rapamycin. These studies are of particular interest
because of the involvement of 5-HT as a nociceptive signal within the peripheral
and central nervous systems. Further substantiating the link between 5-HT and
rapamycin-sensitive pathways is the finding that 5-HT application decreases the
phosphorylation of the elongation factor downstream of mTOR, eEF2 thus enabling
subsequent protein translation (Carroll et al., 2004).
The importance of rapamycin-sensitive pathways in neuronal plasticity has been
well demonstrated by in vitro studies involving hippocampal LTP. Disruption of
mTOR signalling by rapamycin has been shown to reduce LLTP, whilst not affecting
the early phase. In addition, these effects were mediated at the postsynapse
because immunoreactivity for the presynaptic marker synapsin-I opposes and
slightly overlaps immunoreactivity for rapamycin-sensitive pathways.
Immunoreactivity for rapamycin-sensitive pathways showed that these pathways
were present in both cell body (stratum pyramidale) and dendritic (stratum
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radiatum) structures of the CA1 hippocampal region (Tang et al., 2002).  Following
on from these studies, Cammalleri et al. determined exactly when during LLTP that
rapamycin-sensitive pathways are important. In their studies, they showed that
rapamycin prevents LLTP only when applied during induction. Specifically, when
rapamycin was applied transiently to hippocampal slices for 40 min during LLTP
induction, there was a significant decrease in LLTP. However, a transient
rapamycin application 5 min after the induction of LLTP or 2 hr after the
completion of LLTP had no effect. In addition, it was found that p70S6K
phosphorylation was dependent on NMDARs and PI3K. Also of interest was the
discovery that immunoreactivity for the phosphorylated form of p70S6K was very
low in the dendrites of CA1 hippocampal neurones until there was a delivery of the
LLTP-inducing stimulus, after which immunoreactivity for phosphorylated p70S6K
increased in the dendrites but not the cell bodies of the neurones (Cammalleri et
al., 2003).
LTP has also been shown to increase the expression of another elongation factor
downstream of mTOR, eEF1A. This is a process that is blocked by rapamycin
(Tsokas et al., 2005). As well as the link between mTOR and PI3K, LTP has also
been used to demonstrate the interaction between mTOR and ERK (Tsokas et al.,
2007). In this study, LTP-inducing stimuli resulted in an increase in mTOR signalling
that was blocked by inhibiting ERK signalling. The concept of ERK playing an
important part in regulating mTOR is not in line with the canonical mechanism
described earlier (see figure 1.4). However, it was found that ERK inhibition also
resulted in a decrease in phosphorylation of proteins involved in the canonical
PI3K-mTOR pathway. These proteins were PDK1 and Akt. This suggests that mTOR-
mediated protein synthesis in LTP requires mutually dependent and concomitant
activity of ERK and PI3K pathways.
In neurodegenerative disease, rapamycin-sensitive pathways have been studied in a
transgenic model of Alzheimer’s disease (Damjanac et al., 2008). In these studies,
mice that had a mutation of amyloid precursor protein (APP) and presenilin- two
proteins heavily implicated in Alzheimer’s disease, demonstrated a reduction in
activity of mTOR signalling at the level of p70S6K. These differences were specific
for phosphorylated p70S6K and activation of ERK1/2 and 4EBP1 were not modified.
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In addition, mTOR levels were not modified, yet there was a robust accumulation
of phosphorylated Akt, thus demonstrating a dissociation between Akt and mTOR
signalling markers such as p70S6K and confirming the complexity of subcellular
signalling involving mTOR.
1.11.1 Rapamycin-sensitive pathways and persistent pain
Relevant to pain, protein synthesis has been found to be an important component
of the behavioural hypersensitivity associated with formalin-induced inflammation
(Kim et al., 1998). In this study, the protein transcription inhibitor actinomycin and
the protein translation inhibitor anisomycin were found to attenuate formalin-
induced hypersensitivity when administered prior to the application of formalin to
the hind paw of mice. Rapamycin-sensitive pathways in particular have also been
implicated in formalin-induced hypersensitivity in mice lacking the fragile X mental
retardation gene (FMR1), another protein that influences protein translation in
neurones (Price et al., 2007). In these studies, it was found that FMR1 was
important for pain processing, since knock out (KO) mice displayed reduced
hypersensitivity to formalin-induced inflammation compared to their wild type
(WT) littermates. Furthermore, rapamycin was ineffective in reducing formalin-
induced behavioural hypersensitivity as well as thermal hyperalgesia as a result of
the spinal administration of the mGluR1/5 agonist (RS)-3,5-dihydroxyphenylglycine
(DHPG) in FMR1 KO mice compared to their WT littermates.
More recently, components of rapamycin-sensitive pathways have been identified
in myelinated nociceptive sensory fibres (fast conducting Aδ-fibres) at the level of
the hind paw in rat cutaneous tissue. In addition, electromyograhy (EMG) showed
that rapamycin inhibited the sensitivity of fast conducting Aδ-fibres since the
withdrawal threshold to noxious heat in anaesthetised rats was significantly
increased for the fast conducting Aδ-fibres rather than the slow conducting, but
nociceptive-specific C-fibres. Furthermore, behavioural studies showed that local
(hind paw) treatment with rapamycin, attenuated persistent capsaicin-induced
hypersensitivity akin to clinical secondary or referred hyperalgesia (Jimenez-Diaz
et al., 2008). Taken together, these studies implicate mTOR as a key player in pain
processing.
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1.12 Thesis aims
Presently, there are a wide range of drugs that are currently used to treat acute
and persistent pain syndromes such as NSAIDs, opioids and antidepressants. Yet
many of these drugs are only often partially effective and can often be
accompanied by unpleasant side effects or subject to abuse. In the past decade,
there has been an intensive drive to determine the molecular and genetic
signatures of persistent pain states with the hope of developing improved
therapies.
Although the pain studies investigating mTOR have identified a potential target
important in pain processing, there is still much to be discovered. The aims of this
thesis are as follows:
1. To use in vivo electrophysiology to characterise neuronal responses to
peripheral stimuli in naive rats and also rats where a persistent pain-like
state (based on clinical neuropathy and inflammation) has been induced.
The aim here is also to understand how spinal rapaymycin-sensitive
pathways influence these responses.
2. To use behavioural studies to characterise behavioural hypersensitivity in
rat persistent pain models and to understand how rapamycin-sensitive
pathways influence this behaviour.
3. To use immunohistochemistry to determine the distribution of rapamycin-
sensitive pathways at the spinal level and to determine how these pathways
are affected in rat models of persistent pain.
4. To use pharmacological agents to probe descending facilitatory pathways
from higher brain centres in persistent pain states and determine what
effect, if any these pathways have on rapamycin-sensitive pathways at the
spinal level.
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2 Methods
2.1 In vivo electrophysiology recordings from spinal cord
neurones
2.2 Animals
For all studies, male Sprague Dawley rats (250 – 280 g) were used. These were
supplied by the Biological Services Unit (BSU, University College London, UK). All
procedures described were approved by the Home Office (UK) and were in
agreement with the IASP guidelines (Zimmermann, 1983).
2.2.1 Set up
In vivo electrophysiology studies were carried out according to a well established
protocol (Urch and Dickenson, 2003). Rats were initially anaesthetised in an
induction box with 4 % isofluorane in a mixture of nitrous oxide (66 % v/v) and
oxygen (33 % v/v). Once the rats had lost consciousness and were completely
areflexic, the trachea was exposed and isolated and a tracheal cannula was
inserted into the trachea and fastened with 3-0 silk threads. This was used to
maintain anaesthesia throughout the recording period. At this stage, the
isofluorane was reduced to 2.5 % v/v (areflexia was maintained). Rats were then
secured in a stereotaxic frame and a rectal probe attached to a heating blanket
was used to maintain a core temperature of 37 °C.
An incision was made through the skin along the length of vertebrae and the skin
was then separated from the underlying muscle. Muscle, connective tissue and
vertebrae were specifically removed from lumbar vertebral segments L1 – L3 of the
spinal cord. Muscle and connective tissue from surrounding areas were kept intact
and this created a well in the exposed spinal cord area into which, drug solutions
could be added. Clamps were used to stabilise and straighten the cord.  The dura
mater was also removed to aid drug penetration. When the set up was complete,
the isofluorane was reduced to 1.8 % v/v, a level sufficient for anaesthesia, whilst
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maintaining areflexia. All drugs were applied directly onto the exposed spinal cord
in a volume of 50 µl.
2.2.2 Recording system
Recordings were obtained with an AC recording system (NeuroLog system,
Digitimer, UK). An electrode (parylene insulated tungsten microelectrode, 125 µm
diameter, 2 MΩ, A-M systems Inc., USA) inserted into a head stage attached to a 3-
axis manipulator was manually lowered into the exposed cord (L4 - L5) to a depth
of 500 – 1000 µM. This is an area occupied by WDR neurones, which were initially
characterised and located by tapping the receptive field of the ipsilateral hind paw
of the rat (varying from the foot pad of the rat to the toes). The recording system
was grounded via a lead connected to the stereotaxic frame and a second lead
connected to the rat. The signal from the rat was subtracted from the input form
the electrode using the Neurolog differential recording mode to reduce
interference. Neuronal activity was amplified, filtered, and then displayed on an
oscilloscope as well as being made audible via a speaker system. Quantification of
neuronal activity was achieved with a 1401 interface and Spike 4 software
(Cambridge Electronic Design or CED, UK) (see figures 2.1 and 2.2). Once a single
neurone had been isolated, based on a single amplitude series of action potentials,
a common shape and a good signal to noise ratio, a number of stimuli were then
applied to the receptive field.
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Figure 2.1 Overview of in vivo electrophysiology setup. (a) Laminectomy and
destination of electrode in the dorsal horn. (b) Close up of electrode in the dorsal
horn (recording from neurones in lamina V - VI). (c) Digital recording of neuronal
activity or spikes. (d) Example stimulus response profile comprising the different
components of the inputs that converge on the recorded neurone produced by
electrical stimulation (0.5 Hz) at three times the C-fibre threshold. A stimulus
response profile was also produced by a range of ‘natural’ stimuli including
mechanical (brush, pinprick and von Frey filaments) and thermal (water jet)
stimuli applied for 10 s each.
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Figure 2.2 Neurolog data capture system. The recording electrode is inserted into
the spinal cord (A) and a lead connected to the rat (B). A second lead is used to
ground the streotaxic frame. The signal is then fed into the NeuroLog data capture
system, differentiated as A-B, amplified and fed into an audio speaker and
oscilloscope. Action potentials above set amplitudes are discriminated and fed into
the computer system via the CED 1401 interface. Electrical stimuli can be
administered via the stimulating electrodes in the neuronal receptive field. The
frequency of stimulation, duration, amplitude of the current and number of pulses
are set with the period generator, digital width, pulse buffer and counter. The
number of action potentials evoked for a set time frame (90 - 800 ms), are
displayed on the latch counter and on the computer display. Natural stimuli are
applied with increasing intensity to the receptive field and the resulting action
potentials are displayed visually on a rate histogram and as numerical action
potentials per 10 s (adapted from Urch and Dickenson, 2003).
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2.2.3 Characterising and quantifying stimulus evoked responses
Punctate mechanical stimuli were delivered by applying graded von Frey filaments
or a pin, to the most sensitive part of the receptive field for 10 s (with the pinprick
stimuli, care was taken not to break the skin). This was also the case for dynamic
stimuli, where an artist’s brush was used and thermal stimuli, where increasing
heat was applied using a jet of water from a 60 ml syringe attached to a needle
(see figure 2.3 for typical neuronal responses). Previous studies have shown that in
naive rats, the 50 % behavioural mechanical withdrawal threshold varies from
around 11 g to 19 g (Chaplan et al., 1994; Baik et al., 2003). For thermally evoked
responses, the nociceptive threshold is approximately a 45 °C applied stimulus
(Hargreaves et al., 1988). Therefore for the purpose of these studies, all
mechanical stimuli > 15 g and thermal stimuli > 45 °C are classified as noxious
stimuli and all stimuli below these values are classified as innocuous stimuli.
Electrical stimuli were delivered by inserting two stimulating electrodes
intradermally into the most sensitive part of the receptive field. Firstly, Aβ- and C-
fibre thresholds were determined depending on their latencies to respond to
stimuli (Aβ-fibres = <20 ms post-stimulus; C-fibres = 90 - 300 ms post-stimulus).
The stimulator was then set to three times C-fibre threshold and a train of 16
stimuli (0.5 Hz, 2 ms pulse width) was delivered to the receptive field to determine
the number of action potentials attributable to Aβ-fibres (0 – 20 ms); Aδ-fibres (20
– 90 ms); C-fibres (90 – 300 ms) and post-discharge (300 – 800 ms) which is
attributable to the wind up elicited by repeated stimuli of nociceptive C-fibres.
The input (non-potentiated response) and the wind up (potentiated response) were
calculated as follows: C-fibre Input = action potentials (90 - 800 ms) evoked by the
first pulse at three times C-fibre threshold multiplied by the total number of pulses
(16). This then represents the theoretical baseline in the absence of wind up. Wind
up = total action potentials (90 – 800 ms) after the 16-train stimulus at three times
C-fibre threshold minus the input. This represents the excess activity above the
theoretical baseline due to wind up. Only stable cells where 3 consecutive stimulus
evoked responses were within 10 % of the previous result for the same test were
selected for further pharmacological study.
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At the end of all experiments, rats were overdosed on 5 % isofluorane and a
cervical dislocation of the neck was performed to ensure death
    
Figure 2.3 Example neuronal responses to natural stimuli. Stimulus histogram
showing neuronal responses to mechanical stimuli (brush, graded von Frey
filaments and pin prick) and graded thermal stimuli (water jets) applied for 10 s.
The ordinate shows the total number of spikes within a 1 s bin.
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2.3 Formalin-induced inflammation model
The formalin test was carried out based on a well established protocol (Dubuisson
and Dennis, 1977).
2.3.1 In vivo electrophysiology recordings from spinal cord
neurones
See 2.1. To monitor spontaneous neuronal activity as a result of formalin-induced
inflammation, a 5 % v/v formalin solution made from 40 % v/v formaldehyde
solution  (BDH Chemicals Ltd, UK) was intradermally injected into the hind paw (50
µl) ipsilateral to the WDR neurone, which had already been characterised using a
0.5 ml insulin syringe  (BD Micro-FineTM). A WDR neurone was selected on one side
of the cord for treatment with spinally administered  (intrathecal or i.t.) vehicle
prior to formalin injection into the corresponding hind paw. Only after a biphasic
control response was achieved was a neurone then selected on the opposite side
for treatment with the drug prior to formalin injection into the corresponding hind
paw.  Neuronal activity was separated into bins of 10 min.
2.3.2 Assessment of the effectiveness of drugs on pain-like
behaviour
Before each behavioural study, each rat was allowed to acclimatise for 30 min in
individual open top clear Plexiglass chambers (length, width, height = 25 x 25 x 25
cm). In order to determine the effect of drugs at the spinal level on pain-like
behaviour, rats were first lightly anaesthetised on 2 % v/v isofluorane in a mixture
of nitrous oxide (50 % v/v) and oxygen (50 % v/v) after which they were disinfected
and lightly shaved across their backs. A 0.5 ml insulin syringe  (BD Micro-FineTM)
was used to inject a 20 µl i.t. dose of drug solution through the skin, into the L5 –
L6 vertebral interspace, after which the rats were allowed to recover prior to
formalin injection into the hind paw. A 20 µl volume has been shown to produce
uniform coverage of the spinal cord which is restricted to the sacral and cauda
equina levels and extends up to thoracic T13 – lumbar L1 (Xu et al., 2006). After
the rats had recovered, they were restrained and 5% v/v formalin solution was then
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administered to the left hind paw. The rats were then placed back into their
chambers and observed for 1 hr. The following behaviours were measured: 1)
licking and biting and 2) lifting and flinching (Sufka et al., 1998). Behavioural data
were separated into bins of 5 min.  The drug regimen was blinded until the analysis
was complete. After all behavioural studies, rats were overdosed on a rising
concentration of CO2, after which, death was ensured by cervical dislocation of the
neck.
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2.4 Spinal nerve ligation model
2.4.1 Surgery
The spinal nerve ligation (SNL) model was produced by following a well established
protocol (Kim and Chung, 1992).  Rats (140 - 160 g) were initially anaesthetised in
an induction box with 4 % v/v isofluorane in a mixture of nitrous oxide (50 % v/v)
and oxygen (50 % v/v). After this, the isofluorane was reduced to 2.5 % (areflexia
was maintained). The rats were then cleaned with disinfectant and shaved across
their back. A heating blanket was placed underneath the rats (which were placed
in a prone position) that maintained a core temperature of approx 37 ºC.
An incision was made through the skin along the length of vertebrae and the skin
was then separated from the underlying muscle. The left paraspinal muscles were
separated from the spinous processes at the L4 - S2 levels. The L6 transverse
process was then partially removed with rongeurs to allow visual identification of
the L4, L5 and L6 spinal nerves. The left L5 and L6 spinal nerves were then isolated
and tightly ligated with 6-0 silk threads. The same procedure was performed in
sham animals, except for ligation of the spinal nerves. A complete homeostasis was
confirmed before the wound was then sutured (See figure 2.4).
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Figure 2.4 Schematic of spinal nerve ligation procedure. Spinal nerve ligation is
produced by the tight ligation (blue) of the spinal nerves distal to the dorsal root
ganglion at L5 and L6.
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2.4.2 Assessment of the progression of pain-like behaviour
Rats were tested on days 2, 7, 9 and 14 to assess the progression of pain-like
behaviour. Prior to testing, animals were allowed to acclimatise to the room in
their cages for at least 15 min. They were then transferred to a row of adjoining
plastic testing chambers (length, width, height = 10 cm x 12.5 x 25 cm) on a wire-
mesh platform where they were allowed to acclimatise for a further 15 min. The
rats were then tested with innocuous mechanical stimuli comprising 1, 6 and 8 g
von Frey filaments (Touch-testTM, North Coast Medical Inc., USA) and a cooling
stimulus comprising acetone in a modified syringe attached to plastic tubing (see
figure 2.5). The maximal force of each von Frey filament was applied to the
ipsilateral and contralateral hind paw a total of 10 times (to the most responsive
area of the receptive field determined with the 6 g von Frey filament). Acetone
was applied to the hind paw a total of 5 times by expelling 0.5 ml drop through a 1
ml syringe attached to a piece of tubing onto the hind paw, taking care not to
touch the paw with the tubing. Stimuli were applied for a total of 2 s and each set
was separated by at least 3 min. The testing sequence for each stimulation set was
as follows:
1. 1 x acetone to each hind paw.
2. 10 x von Frey 1 g to each hind paw.
3. 1 x acetone to each hind paw.
4. 10 x von Frey 6 g to each hind paw.
5. 1 x acetone to each hind paw.
6. 10 x von Frey 8 g to each hind paw.
7. 1 x acetone to each hind paw.
8. 1 x acetone to each hind paw.
Withdrawal responses were confirmed by full lifting of the foot from the stimuli.
Flinching and partial lifting were ignored. Difference scores were used to quantify
pain-like behaviour and were calculated as follows:  Difference score = number of
paw withdrawals from the injured (ipsilateral) paw minus noumber of paw
withdrawals from uninjured (contralateral) paw.
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Figure 2.5 Testing of pain-like behaviour. Von Frey filaments of varying forces
(left) and acetone (right) applied to hind paw.
In order to determine the effect of drugs at the spinal level on pain-like behaviour,
14 days post SNL, rats were first lightly anaesthetised on 2 % isofluorane in a
mixture of nitrous oxide (50 % v/v) and oxygen (50 % v/v), after which the were
disinfected and lightly shaved across their back. A 0.5 ml insulin syringe  (BD Micro-
FineTM) was used to inject 20 µl of drug solution through the skin, into the L5 – L6
vertebral interspace, after which the rats were allowed to recover. The drug
regimen was blinded until the analysis was complete. After all behavioural studies,
rats were overdosed on a rising concentration of CO2, after which, death was
ensured by cervical dislocation of the neck.
2.4.3 In vivo electrophysiology recordings from spinal cord
neurones
All neuronal recordings were taken from the side ipsilateral to the nerve ligations.
See 2.2.
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2.5 Carrageenan-induced inflammation model
This model is an adaptation on the formalin test, yet it presents with differing
features which have been well characterised (Kayser and Guilbaud, 1987; Stanfa et
al., 1992). With formalin-induced inflammation, behavioural hypersensitivity
presents as spontaneous licking, biting, lifting and flinching of the injected hind
paw, which peaks within 1 hr (Dubuisson and Dennis, 1977). Behavioural
hypersensitivity due to carrageenan-induced inflammation however is more
apparent when assessing withdrawal thresholds to noxious mechanical and thermal
stimuli i.e. the thresholds are lowered thus indicating mechanical and thermal
hyperalgesia. Behavioural hypersensitivity in this model peaks within 3 hr, yet
mechanical hypersensitivity is still present at 20 hr even though thermal
hypersensitivity has subsided (Hedo et al., 1999).
2.5.1 In vivo electrophysiology recordings from spinal cord
neurones
See 2.2. To monitor stimulus evoked neuronal activity as a result of carrageenan-
induced inflammation, a 2 % (w/v) solution made from carrageenan powder (Sigma
Aldrich, USA) was intradermally injected into the hind paw ipsilateral to the WDR
neurone being recorded, using a 0.5 ml insulin syringe  (BD Micro-FineTM). All WDR
neurones responded to both innocuous and noxious stimuli and all studies were
performed at t = 3 hr post carrageenan injection i.e. at the peak of behavioural
hypersensitivity.
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2.6 Immunohistochemistry (SNL rats)
2.6.1 Perfusion and tissue preparation
14 days post SNL, rats were terminally anaesthetised with 1 ml (200 mg)
pentobarbitone sodium intraperitoneally (i.p.) The thoracic cage was then opened
and the heart was exposed and freed from the pericardium. Animals were then
transcardially perfused with 200 ml saline (0.9 % w/v NaCl solution) with added
heparin solution (LEO laboratories UK, 1000 IU of heparin per l of saline. This was
followed by 300 ml per rat of 4 % w/v paraformaldehyde (VWR, UK) solution in 0.1
M phosphate buffer (PhB) mixed with 0.15 % picric acid (Sigma Aldrich, UK) to
‘strengthen’ the fix. A laminectomy was performed similar to that for in vivo
electrophysiology (see section 2.2.1), except much more vertebrae were removed,
starting from the sacral region, all the way up to the cervical region. DRG from L4,
L5 and L6 were removed from both the ipsilateral and contralateral side of the
ligations. The lumbar/sacral region (L3 – S2) of the spinal cord was also removed.
DRG were post-fixed for 2 hours and spinal cord overnight, before they were
transferred to a cryoprotectant solution containing 30 % w/v sucrose in 0.1 M PhB
and 0.01 % w/v sodium azide (Sigma Aldrich, UK) for a minimum of 24 hours. All
tissues were embedded in optimal cutting temperature (OCT) compound and
rapidly frozen on liquid nitrogen before being stored at –80 ºC prior to cutting.
Transverse sections were cut using a cryostat (20 µm) and mounted on Superfrost®
Plus slides. These slides were then stored at –20 ºC in a cryoprotectant solution
comprising 40 % v/v phosphate buffered saline (PBS), 30 % v/v ethylene glycerol
and 30 % v/v glycerol.
2.6.2 Standard staining
Slides containing tissue sections were washed in PBS six times for 5 min per wash to
remove the cryoprotectant solution. A mixture of 10 % v/v normal donkey serum in
PBS plus 0.2 % v/v triton X-100 (Sigma Aldrich, UK) and 0.1% w/v sodium azide was
applied to slides for 30 min to minimise non-specific binding. The donkey serum
was removed and primary antibodies in PBS plus 0.2 % v/v triton X-100 and 0.1 %
w/v sodium azide were added to the slides overnight. The following day, the slides
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were washed in PBS three times for 5 min per wash to remove excess primary
antibody. The secondary fluorescent antibody was then applied in the same way as
the primary antibody and left in the dark for 3 hr. The slides were then washed in
PBS 3 times for 5 min per wash to remove excess secondary antibody. A small
amount of Vectashield® solution was then placed onto each slide and a cover slip
was carefully positioned over the solution and tissue. Finally, the cover slip was
sealed onto the slide with nail varnish.
2.6.3 Tyramide signal amplification (for phospho p70S6K)
Slides containing tissue sections were immersed overnight in antigen unmasking
solution (Vector laboratories Inc, USA) 1:100 in PBS plus 0.2 % v/v triton X-100 and
0.1 % w/v sodium azide. The next day, the slides, still immersed in solution were
heated on high power (800 W) for 1 min 15 s. After a cooling period of 30 min, the
slides were washed in PBS three times for 5 min per wash to remove the unmasking
solution. A solution of 0.3 % v/v H2O2 was then applied to the slides for 20 min to
remove all endogenous peroxidase activity and therefore decrease the amount of
background signal due to the peroxidase-conjugated antibodies. It also helps to
activate the tyramide (Polak and Van Noorden, 2003).
The slides were then washed in PBS three times for 5 min per wash to remove H2O2.
A mixture of 10 % v/v normal donkey serum in PBS plus 0.2 % v/v triton X-100
(Sigma Aldrich, UK) and 0.1% w/v sodium azide was applied to slides for 30 min to
minimise non-specific binding. The donkey serum was removed and primary
antibody (rabbit phospho p70S6K Thr389, New England Biolabs, UK) at an optimal
concentration of 1:50 in PBS plus 0.2 % v/v triton X-100 and 0.1 % w/v sodium azide
was added to the slides overnight.
The following day, the slides were washed in PBS three times for 5 min per wash to
remove excess primary antibody. The secondary biotinylated antibody (goat anti-
rabbit biotin, Vector laboratories, USA) was then applied in the same way as the
primary antibody at a concentration of 1:400 for 1.5 hr. This biotinylated
secondary antibody recognises the primary rabbit antibody and is the first stage of
the amplification process. The slides were washed in PBS three times for 5 min per
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wash to remove excess biotinylated antibody. Next, slides were incubated with
avidin biotin labelled complex (ABC Elite, Vector Lab, USA) (1:250 PBS Vectastain
solution A plus 1:250 PBS Vectastain solution B) for 30 min followed by signal
amplification step with biotinylated tyramide solution (1:75 PBS for 10 min, Perkin
Elmer, USA). The avidin and biotin react together, forming large, highly labelled
complexes. The proportion of avidin to labelled biotin is such that some binding
sites on the avidin are left free to attach to the biotin on the secondary
biotinylated antibody (Polak and Van Noorden, 2003). The slides were washed in
PBS three times for 5 min per wash to remove the reaction components and a
fluorescent extra-avidin fluorescein isothiocyanate (FITC) was used to bind to the
biotin attached to the tyramide.
2.6.4 Analysis
Sections were viewed under an Axioplan 2 Imaging microscope (Imaging associates,
UK) fitted with 10 x, 20 x and a 40 x Plan-Neofluoro objectives (Zeiss, UK). Images
were taken using an Axioplan digital camera (Zeiss, UK) and AxioVision software
(Imaging Associates, UK). Image analysis was performed with the National Institutes
of Health (NIH) software Image J version 1.38 (USA). Post-acquisition processing
was performed with Adobe Photoshop version 7.0 (USA). For statistical analysis, a
minimum of 3 sections per group were chosen at random.
2.7 Statistical analysis
N.B. All statistical analyses were completed using GraphPad Prism version 4.0c
(USA). See individual chapters for specific details of tests employed.
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3 Rapamycin-sensitive pathways under physiological
conditions
3.1 Introduction
Apart from an important role in neuronal development, synaptic transmission and
plastic processes, mTOR and its associated pathways are important in a wide range
of physiological processes including cell growth, proliferation and animal size (Hay
and Sonenberg, 2004; Sarbassov dos et al., 2005; Jaworski and Sheng, 2006; Swiech
et al., 2008). In light of this, it was of great importance to understand what effects
if any, inhibiting neural pathways with rapamycin, would have on neuronal output
in naive animals over a full range of innocuous and noxious stimuli. Not only is this
a useful strategy in determining safe and effective doses of rapamycin, but it also
means predictions can be made about potential effects in a pathophysiological
state such as a persistent pain-like state.
3.1.1 Toxicity
A 2 d treatment with rapamycin (200 nM) has been found not to show any toxic
effects on cultured cells even with this direct contact with the cells. In contrast, 2
widely used protein synthesis inhibitors- anisomycin and cyclohexamide appear to
be toxic to nerve-muscle cultures when treated for the same amount of time (Je et
al., 2005). This dose of rapamycin used was effective in attenuating protein
synthesis induced by neurotrophin 3 (NT3). This coupled with the fact that the
immunosuppressant rapamycin, is still used as an immunosuppressant after kidney
transplant and is now used in clinical cancer research (Cohen, 2002; Faivre et al.,
2006) confirms that at the right dose, toxicity is not a major issue, although side
effects connected with suppression of the immune system still need to be taken
into account.
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3.1.2 Reversibility
Rapamycin-sensitive pathways have been shown to be important during the
induction phase of LLTP in hippocampal slices. However, when rapamycin (which
inhibits LLTP if administered during the induction phase) is transiently added to
hippocampal slices for 40 min and the LLTP-inducing tetanisation paradigm is
delivered after washing out the inhibitor, LLTP can still be elicited (Cammalleri et
al., 2003). This supports the notion that the action of rapamycin is indeed
reversible.
3.1.3 Activity-dependency
In many cases, the effects that rapamycin exerts are only apparent when there is a
sufficient stimulus that engages the appropriate pathways. For example, treating
synaptosomes for 10 min with 5-HT has been shown to induce a decrease in the
phosphorylation (and therefore inactivation) of the elongation factor eEF2. In the
presence of rapamycin, 5-HT no longer induced this decrease. However, rapamycin
in the absence of 5-HT had no such effect on eEF2 (Carroll et al., 2004).
Furthermore, whilst rapamycin will successfully attenuate the amount of LLTP
achieved with the required tetanisation stimulus, rapamycin alone, in the absence
of a tetanus, will have no effect on basal synaptic transmission suggesting that
rapamycin-sensitive pathways are much more important in longer lasting forms of
plasticity (Tang et al., 2002; Cammalleri et al., 2003; Cracco et al., 2005). Also,
when nerve-muscle cocultures are incubated with the growth factor NT3 and
rapamycin together for 2 d, the long-term effects of NT3 on synapses (new protein
synthesis) are abolished. However, the effect of chronic NT3 on potentiating acute
spontaneous synaptic transmission is unchanged by rapamycin (Je et al., 2005).
In vivo behavioural studies have shown that whilst local rapamycin injections are
successful in reducing the amount of secondary or referred mechanical
hyperalgesia induced by capsaicin as well as mechanical hypersensitivity in a rat
model of nerve injury-induced chronic pain, they are ineffective in attenuating
acute nociceptive thresholds (Jimenez-Diaz et al., 2008). Thus, rapamycin-sensitive
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pathways can potentially be continually upregulated and are dependent upon
specific types of stimuli. The aim of these studies was to identify how true this was
using in vivo electrophysiology to study neuronal responses to rapamycin and the
ester form of rapamycin, cell cycle inhibitor (CCI)-779 (Temsirolimus, USA)
administration.
3.2 Methods
3.2.1 Rapamycin compounds
Two different forms of rapamycin have been used throughout these studies:
rapamycin (sirolimus, LC laboratories, USA) which was initially dissolved in 100 %
dimethyl sulphoxide (DMSO) and CCI-779, which was dissolved in saline with the aid
of a sonicator. Once rapamycin was dissolved in DMSO, the mixture was then
dissolved in saline to obtain the appropriate concentrations. The maximum
concentration of DMSO never exceeded 25 % v/v. There was a strong preference
towards using CCI-779, due to the fact that it has a much more improved solubility
in water compared with the non-ester form of rapamycin and therefore making it
more ideal for in vivo studies (Lee et al., 2006). In addition, 100 % DMSO has been
shown to cause short-term (2 min) scratching behaviour when injected i.t. into
mice (Welch et al., 1995) and DMSO concentrations as low as 9 % v/v have been
shown to block C-fibre responses in the cat when directly applied to the nerves
(Evans et al., 1993). The non-ester form of rapamycin was obtained before
obtaining CCI-779 and, due to constraints on time it was not possible to use CCI-779
throughout these studies. Therefore some studies involved the non-ester form of
rapamycin, which is referred to as rapamycin, and others have involved CCI-779.
3.2.2 In vivo electrophysiology setup
See 2.2. After obtaining a stable baseline, dose-response data was generated using
rapamycin. The maximal vehicle concentration- 25 % v/v DMSO was applied and the
effects followed before administering 25 nM (1.14 ng in 50 µl saline/DMSO), 125 nM
(5.72 ng in 50 µ l saline/DMSO) and 250 nM (11.43 ng in 50 µl saline/DMSO)
rapamycin in a cumulative fashion i.t. to the exposed spinal cord. Electrical stimuli
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and ‘natural’ stimuli were applied every 20 min, for 1 hr, before the next dose of
drug was added. For CCI-779, only the top dose of 250 nM (12.88 ng in 50 µl saline)
was used and this was followed for 2 hr. This was compared with an effective 4.7
mM (62.35 µg in 50 µl saline/DMSO) dose of anisomycin (Sigma Aldrich, UK)
(Jimenez-Diaz et al., 2008), a general translation inhibitor that acts by inhibiting
peptidyl transferase activity in eukaryoyte ribosomes. Anisomycin was first
dissolved in 100 % DMSO before diluting with saline to obtain a concentration of 4.7
mM with a DMSO content of 10 % v/v.
3.2.3 Statistical analysis
Electrophysiological raw data are presented as mean number of spikes + SEM. When
comparing baseline neuronal responses to maximum change (positive or negative)
neuronal responses after administration of DMSO, student’s t-tests were used to
compare differences in Aβ-, Aδ- and C-fibre firing, post-discharge, input, wind up
and brush. Two way analysis of variance (two way ANOVA) of maximum change
data with repeated measures and Bonferroni’s post-tests were used to determine
significance between groups for natural stimuli i.e. graded mechanical and thermal
stimuli. For rapamycin, CCI-779 and anisomycin, one way ANOVA of maximum
change data with repeated measures Dunnett’s post-test comparisons to control
were used to determine significant changes for electrical stimuli as well as brush
and pin (control = 0 min for CCI-779 and anisomycin and 25 % DMSO for rapamycin).
Two way ANOVA of maximum change data with repeated measures and
Bonferroni’s post-tests were used to determine significant changes for graded
natural stimuli i.e. graded mechanical and thermal stimuli (*P<0.05; **P<0.01
***P<0.001).
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3.3 Results
3.3.1  DMSO has no significant effect on baseline neuronal
responses
    
Figure 3.1 Effects of 25 % DMSO on neuronal responses. (a) There were no
significant effects of DMSO on pre-drug control responses for electrically evoked
Aβ, Aδ and C-fibre-mediated transmission as well as post-discharge (PD); (b)
electrically induced input and wind up (number of spikes after a train of 16 pulses);
(c) brush (number of spikes during a 10 s stimulus); as well as (d) graded
mechanically evoked (number of spikes during a 10 s stimulus);  and (e) graded
thermally evoked responses (number of spikes during a 10 s stimulus, see 2.2 and
3.2.2 for methods). For all data sets, pre-drug control n = 10, DMSO n = 8.
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3.3.2 Rapamycin inhibits electrically evoked neuronal responses
     
Figure 3.2 Effects of rapamycin on electrically evoked neuronal responses. (a)
C-fibre-mediated transmission onto WDR neurones was significantly inhibited by
125 and 250 nM rapamycin (Rap) compared to 25 % DMSO from 312 + 33 to 203 + 32
and 161 + 30 spikes respectively. Aβ- and Aδ-fibre mediated transmission were
unaffected as was WDR neurone post-discharge (PD). (b) Input was also
significantly reduced with 250 nM rapamycin compared to 25 % DMSO from 373 + 72
to 139 + 40 spikes. (c) Wind up however was unaffected by rapamycin (see figure
3.2.2 for methods) For all data sets, spikes = number of spikes after a train of 16
pulses; n = 10 except 250 nM Rap where n = 9 (*P<0.05; **P<0.01).
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3.3.3 Rapamycin inhibits mechanically evoked neuronal responses
     
Figure 3.3 Effects of rapamycin on mechanically evoked neuronal responses. (a)
Rapamycin (Rap) inhibited dynamic brush responses at 250 nM compared to 25 %
DMSO (black) from 261 + 40 to 114 + 25 spikes. (b) 25 nM Rap (green) significantly
inhibited responses to 26 and 60 g compared to 25 % DMSO (black) from 487 + 86 to
309 + 58 and 594 + 71 to 450 + 83 spikes respectively. (c) 125 nM Rap (blue)
significantly inhibited responses to 8 and 60 g compared to 25 % DMSO (black) from
234 + 63 to 97 + 23 and 594 + 71 to 395 + 61 spikes respectively. (d) 250 nM Rap
(red) significantly inhibited responses to 8, 15, 26 and 60 g compared to 25 % DMSO
(black) from 234 + 63 to 64 + 14; 328 + 47 to 149 + 52; 487 + 85 to 257 + 50 and 594
+ 71 to 383 + 74 spikes respectively. For all data sets, spikes = number of spikes
during a 10 s stimulus; n = 10 except 250 nM Rap, where n = 9 (*P<0.05; **P<0.01;
***P<0.001).
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3.3.4 Rapamycin inhibits graded thermally evoked neuronal
responses
                                      
Figure 3.4 Effects of rapamycin on graded thermally evoked neuronal
responses. 250 nM rapamycin (Rap) was only effective in attenuating responses
evoked by 35 °C from 183 + 66 (25 % DMSO) to 47 + 15 spikes. For all data sets,
spikes = number of spikes during a 10 s stimulus; n = 10 except 250 nM rapamycin,
where n = 9. (*P<0.05).
The data so far suggests that rapamycin has dose-dependent effects on stimulus
evoked responses of WDR neurones. Specifically, rapamycin dose-dependently
inhibited C-fibre mediated transmission to WDR neurones, non-potentiated input,
dynamic mechanical stimuli (bush) and punctate mechanical stimuli including
innocuous (< 8 g) and noxious (> 15 g) von Frey filaments. However, the effects on
thermally evoked responses were minimal and only the top dose inhibited
responses to the lowest innocuous stimulus (35 °C). It was decided that this dose
would also be studied using CCI-779. The effects of this drug were followed for a
longer time period of 2 hr, with all comparisons being made to pre-drug control
responses (at 0 min). The effects of the global translation inhibitor anisomycin
were also studied in the same manner and was used as a positive control to confirm
that effects of rapamycin were due to inhibition of translation (Jimenez-Diaz et
al., 2008).
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3.3.5 CCI-779 has no effect on electrically evoked neuronal
responses
     
Figure 3.5 Effects of  CCI-779 on electrically evoked neuronal responses from
naive rats over 2 hr. (a) 250 nM CCI-779 was ineffective on Aβ-, Aδ-, and C-fibre
mediated transmission as well as post-discharge (PD) of WDR neurones.  (b) Input
as well as (c) wind up were also unaffected by CCI-779. For all data sets, spikes =
number of spikes after a train of 16 pulses; n = 9, except wind up where n = 8.
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3.3.6 CCI-779 has no effect on brush and pinprick evoked
neuronal responses
 
Figure 3.6 Effects of CCI-779 on brush and pinprick evoked neuronal responses
from naive rats over 2 hr. 250 nM CCI-779 was ineffective on (a) innocuous,
dynamic brush evoked stimuli (n = 9) and (b) noxious punctate pinprick evoked
stimuli (n = 5). For all data sets, spikes = number of spikes during a 10 s stimulus.
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3.3.7 CCI-779 has selective effects on graded mechanically and
thermally evoked neuronal responses
   
Figure 3.7 Effects of CCI-779 on graded mechanically and thermally evoked
neuronal responses from naive rats over 2 hr. (a) CCI-779 has no effects on
innocuous mechanically evoked responses. (b) At 80, 100 and 120 min, CCI-779
significantly inhibited innocuous thermally evoked responses to 40 °C from 356 + 51
(at 0 min) to 202 + 35; 184 + 34 and 186 + 37 spikes respectively. (c) At 80, 100 and
120 min, CCI-779 significantly inhibited noxious mechanically evoked responses to
26 g from 580 + 69 (at 0 min) to 440 + 71; 419 + 55 and 428 + 57 spikes
respectively. Also at 100 min, CCI-779 significantly inhibited noxious mechanically
evoked responses to 60 g from 777 + 73 (at 0 min) to 602 + 72 spikes. (d) At 100
min, CCI-779 significantly inhibited noxious thermally evoked responses to 45, 48
and 50 °C from 606 + 78  (at 0 min) to 356 + 44; 829 + 80 (at 0 min) to 600 + 53 and
999 + 82 (at 0 min) to 838 + 74 spikes respectively. At 120 min, CCI-779
significantly inhibited noxious thermally evoked responses to 45 and 48 °C from 606
+ 78 at (at 0 min) to 444 + 49 and 829 + 80 (at 0 min) to 671 + 65 spikes
respectively. For all data sets, spikes = number of spikes during a 10 s stimulus; n =
9 (*P<0.05; **P<0.01; ***P<0.001).
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3.3.8 Anisomycin has no effect on electrically evoked neuronal
responses
      
Figure 3.8 Effects of anisomycin on electrically evoked neuronal responses from
naive rats over 2 hr. (a) Anisomycin was ineffective on Aβ-, Aδ-, and C-fibre
mediated transmission and post-discharge (PD) of WDR neurones.  (b) Input as well
as (c) wind up were also unaffected by anisomycin. For all data sets, spikes =
number of spikes after a train of 16 pulses; n = 12.
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3.3.9 Anisomycin has no effect on brush and pinprick evoked
neuronal responses
 
Figure 3.9 Effects of anisomycin on brush and pinprick evoked neuronal
responses from naive rats over 2 hr. Anisomycin was ineffective on (a) innocuous,
dynamic brush evoked stimuli and (b) noxious punctate pinprick evoked stimuli. For
all data sets, spikes = number of spikes during a 10 s stimulus; n = 12.
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3.3.10 Anisomycin has no effect on graded mechanically or
thermally evoked neuronal responses
     
Figure 3.10 Effects of anisomycin on graded mechanically and thermally evoked
neuronal responses from naive rats over 2 hr. Anisomycin was ineffective against
innocuous graded mechanical and thermal stimuli (a and b respectively) as well as
graded noxious mechanical and thermal stimuli (c and d respectively). For all data
sets, spikes = number of spikes during a 10 s stimulus; n = 12.
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To summarise, 25 % DMSO had no effect on baseline responses at this concentration
(see figure 3.1), which is the maximum concentration achieved when administering
the highest dose of rapamycin. When compared to responses evoked after the
administration of different doses of rapamycin, it was found that rapamycin
inhibited responses to electrically, mechanically and thermally evoked responses
(see figures 3.2 - 3.4). These effects were found to be dose-dependent, with a
higher degree of significance occurring with the top dose.
CCI-779 also exerted inhibitory effects on stimulus evoked responses of WDR
neurones. However, unlike the non-ester form of rapamycin, there were no
inhibitory effects on electrically evoked responses (see figure 3.5). Instead,
inhibitory actions were restricted to responses evoked by 26 and 60 g von Frey
stimuli and 40, 45, 48 and 50 °C thermal stimuli (see figure 3.7). Furthermore,
unlike the non-ester form of rapamycin, these actions were exerted in the second
hr of testing. In contrast, the general translation inhibitor anisomycin was
ineffective against all measures under these conditions (figures 3.8 – 3.10).
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3.4 Discussion
The aim of these studies was to identify the importance of rapamycin-sensitive
pathways under physiological conditions. 2 different drugs were used in order to
achieve this. Firstly, the non-ester form of rapamycin (rapamycin) and secondly the
ester form of rapamycin (CCI-779). These are 2 drugs which differ in their water
solubility, with CCI-779 being much more soluble in water.
Dose-response studies were carried out using rapamycin. Dose-dependent inhibition
of nociceptive specific C-fibre-mediated transmission and presynaptic input
indicates that rapamycin-sensitive pathways are important in transmission from C-
fibres to the spinal cord. Presumably, this inhibition of C-fibre activity is
responsible for the accompanying inhibition of mechanically evoked responses. The
comparatively minimal effects on thermally evoked responses (250 nM only inhibits
responses to 35 °C) reveals a higher degree of selectivity of rapamycin for
mechanically evoked rather than thermally evoked responses.
Although establishing that rapamycin exerted maximal effects within the first hr of
administration, this was not the case for CCI-779. With CCI-779, there were no
effects on electrically evoked responses and all other effects on mechanically and
thermally evoked responses occurred after the first hr of drug administration. So
why does this happen?
Firstly, the studies with rapamycin involve the cumulative addition of 3 doses of
the drug: 25, 125 and 250 nM. Although all maximal drug effects were within the
first hr of administration, a 250 nM dose on top of previous 25 and 125 nM doses
would amount to a potential maximal final dose of 400 nM depending on clearance
rates and drug half-life. In support of this is the fact that rapamycin and it’s
associated analogues have a half life of >30 min (Wyeth Research, data
unpublished), suggesting that if it were not cleared within the 1 hr time frame that
was provided for each dose, then dose accumulation could easily occur. However,
it should be noted that mechanical von Frey stimulus evoked responses were
affected from the lowest dose of rapamycin (see figure 3.3).
90
Chapter 3
Secondly, although the solubility of CCI-779 in water is much better than that of
rapamycin, it may be less soluble in saline. Although this could be the case because
CCI-779 had to be sonicated in order to achieve solubilisation, the fact that
solubilisation was achieved should mean that this is not a factor. Nevertheless, it
may be that DMSO achieves slight but significantly improved solubilisation. This
may explain why inhibitory effects were not seen with electrically evoked
responses and why the effects were not seen until 1 hr after CCI-779
administration. Interestingly, the effects seen with rapamycin and CCI-779 do not
match the effects seen with anisomycin. However, this may be purely due to a
difference in potency i.e. a 250 nM dose of rapamycin or CCI-779 may be much
more efficacious than a 4.7 mM dose of anisomycin.
These studies demonstrate that rapamycin-sensitive pathways are at least partially
important under physiological conditions. This is not surprising due to the
involvement of mTOR in neuronal development and synaptic plasticity (Swiech et
al., 2008). It does however contradict the studies, which report that rapamycin has
no effect on basal synaptic activity (Tang et al., 2002; Cammalleri et al., 2003;
Cracco et al., 2005; Je et al., 2005). However, it is important to note that all these
previous studies were performed in vitro on isolated tissue where important
physiological processes are attenuated or completely absent, networks of neurones
are disrupted and afferent sensory evoked activity cannot be studied. In this
chapter, spinal neurones were activated in vivo by a range of innocuous and
noxious suprathreshold stimuli applied to peripheral sites.
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4 Rapamycin-sensitive pathways and pathophysiological
conditions: formalin-induced inflammation
4.1 Introduction
The formalin test was first presented by Dubuisson and Dennis in 1977 (Dubuisson
and Dennis, 1977). The test results in two key features: biphasic ongoing neuronal
hyperexcitability and behavioural hypersensitivity. The first phase occurs
immediately after formalin injection and lasts for 5 – 10 min. After a small pause in
activity (typically 5 - 10 min duration), a more prolonged and slowly developing
and longer lasting second phase occurs that typically lasts >30 min after its peak.
These features are now commonly used as markers of analgesic drug efficacy
(Tjolsen et al., 1992; Green et al., 2000).
4.1.1 Formalin-induced inflammation and upstream regulators of
mTOR
Although the importance of rapamycin-sensitive pathways in persistent pain-like
states has not been extensively studied, there have been reports focussing on the
importance of upstream regulators of mTOR in formalin-induced inflammation. The
role of phosphorylated CaMKII and ERK are two such regulators and these proteins
have been shown to either engage rapamycin-sensitive pathways or synergise with
them, leading to protein translation (Gelinas et al., 2007; Kelly et al., 2007; Tsokas
et al., 2007). The levels of these proteins in the spinal cord have been assessed by
choi et al. In their study, they found via a combination of Western Blots and
immunohistochemistry, that intraplantar injection of formalin solution caused an
increase in phosphorylated CaMKII and ERK that was restricted mainly to lamina I
and II of the spinal cord dorsal horn. Further support for the importance of these
regulators in formalin-induced inflammation was the fact that the ERK inhibitor
PD988059 and the CaMKII inhibitor KN-93 administered 20 min prior to formalin
administration inhibited the second phase of the formalin response (Choi et al.,
2006).
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Also upstream of mTOR is PI3K. A recent study by Pezet et al. has highlighted the
importance of PI3K in the establishment of central sensitisation. In this study, in
vivo electrophysiology was used to show that the PI3K inhibitor LY294002 dose-
dependently attenuated wind up. The significance of this effect was confirmed
behaviourally as it also attenuated the second phase of the formalin response when
administered i.t. 15 min prior to formalin injection into the hind paw.
Furthermore, immunohistochemical studies revealed that administration of
LY294002 i.t. prior to formalin injection resulted in a decrease in phosphorylation
of CaMKII and ERK, thereby suggesting that phosphorylation of both ERK and CaMKII
induced by peripheral inflammation are PI3K-dependent mechanisms (Pezet et al.,
2008). In addition, PI3K has also been shown to engage rapamycin-sensitive
pathways (Schratt et al., 2004; Takei et al., 2004; Horwood et al., 2006; Chenal
and Pellerin, 2007; Kelly et al., 2007; Tsokas et al., 2007).
Further upstream, at the receptor level, NMDA receptor activation has been
implicated in formalin-induced neuronal hyperexcitability (Haley et al., 1990) and
is also implicated in activation of rapamycin-sensitive pathways (Gong et al., 2006;
Gonzalez-Mejia et al., 2006). The electrophysiological studies by Haley et al., using
similar in vivo approaches to those used in this chapter, demonstrated that the
selective NMDA receptor antagonist D-2-amino-5-phosphonopentanoate (D-AP5) was
effective in reducing formalin-induced neuronal hyperexcitability of the second
phase when administered to the exposed spinal cord 40 min to prior to the
injection of formalin into the hind paw. These findings have also been confirmed
behaviourally, where spinal administration of various NMDA receptor antagonists-
D-AP5, memantine, MK801, dextrorphan and dextromethorphan via i.t. cannulae 15
min prior to the formalin injection were effective (to varying degrees) in
attenuating the second phase of formalin-induced flinching (Chaplan et al., 1997).
The metabotropic glutamate receptors mGluR1 and mGluR5 are two receptors that
are also of importance in formalin-induced behavioural hypersensitivity (Varty et
al., 2005) and these receptors are also implicated in activating rapamycin-sensitive
pathways (Page et al., 2006; Price et al., 2007). In their studies, Varty et al.
administered the mGluR5 antagonists- MPEP (2-methyl-6-(phenylehtynyl) pyridine)
and MTEP (3[2-methyl-1,3thiazol-4-yl)ethynyl]pyridine), as well as the mGluR1
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antagonist LY456236 i.p. and found that they reduced second phase (and even first
phase for top doses of MPEP and MTEP) formalin-induced licking and biting when
given prior to the injection of formalin into the hind paw.
At the transmitter level, BDNF has been shown to be important in formalin-induced
hypersensitivity (Kerr et al., 1999) and has also been shown to activate rapamycin-
sensitive pathways (Takei et al., 2001; Tang et al., 2002; Schratt et al., 2004;
Takei et al., 2004). In their studies, Kerr et al. administered NGF via the i.p. route
to rats. This is a method that is used to mimic peripheral inflammatory states and
increases BDNF levels in sensory neurones. The increase in BDNF can be countered
by TrkB-IgG, a BDNF binding protein. 30 min prior to formalin injection into the
hind paw, TrkB-IgG was administered via an i.t. cannula to rats that had been pre-
treated with NGF 24 hr earlier and this resulted in a significant reduction in the
behavioural score of second phase formalin-induced behavioural hypersensitivity
compared to rats that were administered saline after NGF pre-treatment.
4.1.2 Formalin-induced inflammation: global transcription and
translation
There is also direct evidence for the requirement of RNA and protein synthesis in
formalin-induced inflammation (Kim et al., 1998). In this behavioural study, mice
were injected i.t. with either actinomycin D, a general inhibitor of transcription  or
anisomycin, a general inhibitor of translation. Although responses to acute noxious
stimuli were unaffected, both drugs significantly decreased the second phase of
the formalin response when administered 30 min prior to the formalin injection.
4.1.3 Formalin-induced inflammation and mTOR
The importance of mTOR in formalin-induced inflammation has been studied in
mice lacking fragile X mental retardation protein (FMRP), another protein that
influences protein translation in neurones (Price et al., 2007).  This study
demonstrated decreased nociceptive sensitisation in Fmr1 KO mice. Due to the
similarities between FMRP and mTOR in terms of their importance in protein
translation, it was hypothesized that rapamycin would only inhibit nociceptive
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behaviours induced by formalin in WT and not KO mice. This was indeed the case
as it was shown that rapamycin dose-dependently attenuated the second phase of
the formalin test when administered spinally (i.t.) or peripherally (intradermally
into the hind paw) 15 min prior to formalin injection into the hind paw of WT mice.
The aim of this chapter was therefore to use in vivo electrophysiological and
behavioural studies in rats to confirm some of these findings, but also to add to
these findings by correlating an in vivo electrophysiological study with a
behavioural study.
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4.2 Methods
4.2.1 In vivo electrophysiology recordings from spinal cord
neurones
See 2.3.1. Once a WDR neurone had been found and characterised, a top dose of
rapamycin (250 nM or 11.43 ng), vehicle (25 % v/v DMSO) or anisomycin (4.7 mM or
62.35 µg) in 50 µl saline/DMSO was added directly to the exposed spinal cord. After
3 min, 50 µl of 5 % v/v formalin was injected intradermally into the hind paw into
the receptive field of the WDR neurone and ongoing neuronal activity as a result of
formalin was monitored for 1 hr, after which the experiment was terminated.
4.2.2 Assessment of the effects of rapamycin on pain-like
behaviour
See 2.3.2. A 250 µM dose of rapamycin (11.43 µg in 20µl saline/DMSO) or DMSO (25
% v/v) was administered i.t. under anaesthesia via a single lumbar injection either
5 or 20 min prior to formalin injection. This dose was chosen as it had been shown
to attenuate capsaicin- and nerve injury-induced behavioural hypersensitivity when
injected locally into the hind paw (Jimenez-Diaz et al., 2008).
4.2.3 Statistical analysis
All data are expressed as raw values + SEM. Unpaired t-tests were used when
comparing neuronal responses for specific characteristics of neurones between
drug and vehicle treatment groups except for graded thermally evoked responses
where two way ANOVA with Bonferroni’s post-tests were used. Unpaired t-tests
were also used to compare the area under the curve (AUC) of the two phases of the
formalin between the different groups. When specifically looking at the time
course of the formalin response, two way ANOVA with repeated measures and
Bonferroni’s post-tests were used to make comparisons between groups. For in vivo
electrophysiology data, first phase = 0 – 10 min and second phase = 20 – 60 min. For
behavioural data, first phase = 0 – 10 min and second phase = 15 – 60 min (*P<0.05;
**P<0.01; ***P<0.01)
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4.3 Results
4.3.1 Neurones selected for DMSO or rapamycin treatment were
not significantly different
DMSO (n = 11) Rapamycin (n = 9)
Depth (µM) 777 + 36 790 + 51
Aβ-fibre threshold (mA) 0.27 + 0.10 0.23 + 0.11
C-fibre threshold (mA) 0.78 + 0.17 0.55 + 0.13
Aβ-fibre spikes 104 + 9 104 + 16
Aδ-fibre spikes 92 + 18 93 + 19
C-fibre spikes 310 + 49 315 + 39
Post-discharge spikes 82 + 29 133 + 39
Input spikes 298 + 59 292 + 57
Wind up spikes 130 + 33 233 + 68
35 °C spikes 179 + 52 102 + 34
40 °C spikes 374 + 91 263 + 85
45 °C spikes 618 + 67 693 + 62
48 °C spikes 579 + 104 513 + 118
50 °C spikes 777 + 91 888 + 79
Table 4.1 Characterisation of WDR neurones selected for DMSO or rapamycin
treatment prior to formalin injection. Thresholds were determined using the
appropriate stimulus-response latency profiles. For electrically evoked responses, a
train of 16 pulses at three times C-fibre threshold (0.5 Hz, 2 ms pulse width) was
applied to the corresponding receptive field. For thermally evoked responses, a
small water jet was applied to the corresponding receptive field for 10 s. All data
are expressed as raw mean values + SEM. There was no significant difference
between cells that had the 25 % DMSO treatment prior to formalin injection or
those that were treated with rapamycin prior to formalin injection.
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4.3.2 Rapamycin attenuates the second phase of the formalin
response
                  
Figure 4.1 Example traces of ongoing neuronal activity due to formalin injection
into the hind paw. (a) When DMSO was added 3 min prior to 5 % v/v formalin
injection, a classic biphasic response was evoked. The first phase was measured
between 0 – 10 min and the second phase was measured between 20 – 60 min. (b)
In the presence of rapamycin however, the second phase was attenuated.
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Figure 4.2 Pooled data of responses from WDR neurones during the formalin
test. (a) When rapamycin (n = 9) was administered onto the exposed spinal cord 3
min prior to 5 % formalin injection into the hind paw, there was a significant
reduction in neuronal activity from 40 - 60 min when compared to DMSO (n = 11)
administration from 3,010 + 878 to 468 + 159; 3,209 + 919 to 533 + 183 and 3,489 +
1,306 to 343 + 131 spikes respectively. (b) AUC analysis revealed that overall,
rapamycin elicited a significant reduction in the second phase from 92,600 + 25,948
to 15,378 + 6,623 arbitrary units  (*P<0.05; **P<0.01). There were no effects of
rapamycin on the first phase of the formalin test.
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The formalin test was also repeated in the presence of the general translation
inhibitor anisomycin at its effective dose of 4.7 mM compared to 10 % DMSO
administered i.t. to the exposed spinal cord 3 min prior to formalin injection into
the hind paw.
4.3.3 Neurones selected for DMSO or anisomycin treatment were
not significantly different
DMSO (n = 7) Anisomycin (n = 6)
Depth (µM) 890 + 85 771 + 33
Aβ-fibre threshold (mA) 0.70 + 0.04 0.53 + 0.11
C-fibre threshold (mA) 1.73+ 0.24 1.64 + 0.16
Aβ-fibre spikes 224 + 40 176 + 29
Aδ-fibre spikes 189 + 24 145 + 26
C-fibre spikes 597 + 79 432 + 33
Post-discharge spikes 755 + 113 549 + 119
Input spikes 576 + 112 640 + 128
Wind up spikes 752 + 86 486 + 103
35 °C spikes 160 + 50 261 + 98
40 °C spikes 219 + 49 351 + 93
45 °C spikes 626 + 148 544 + 104
48 °C spikes 970 + 145 904 + 79
50 °C spikes 1409 + 103 1266 + 97
Table 4.2 Characterisation of WDR neurones selected for DMSO or anisomycin
treatment prior to formalin injection. Thresholds were determined using the
appropriate stimulus-response latency profiles. For electrically evoked responses, a
train of 16 pulses at three times C-fibre threshold (0.5 Hz, 2 ms pulse width) was
applied to the corresponding hind paw. For thermally evoked responses, a small
water jet was applied to the corresponding hind paw for 10 s. All data are
expressed as raw mean values + SEM. There were no significant differences
between cells that had the 10 % DMSO treatment prior to formalin injection or
those that had the anisomycin injection prior to formalin injection.
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4.3.4 Anisomycin attenuates the second phase of the formalin
response
                                    
Figure 4.3 Effects of anisomycin on the formalin test. (a) When anisomycin (n =
6) was administered onto the exposed spinal cord 3 min prior to 5 % v/v formalin
injection into the hind paw, there was strong trend for reduction in neuronal
activity from 10 - 30 min compared to DMSO (n = 7) administration, although there
was no significance. (b) AUC analysis however, revealed that overall, anisomycin
elicited a significant reduction in the second phase from 104,500 + 55,370 to
17,410 + 11,360 arbitrary units (*P<0.05). There was no significant effect of
anisomycin on the first phase of the formalin test.
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Rapamycin was then tested for its effects behaviourally. However, because the rats
were not fully conscious by 3 min after anaesthesia, this recovery period was
extended to 5 min.
4.3.5 Rapamycin is ineffective against formalin-induced
behavioural hypersensitivity when administered 5 min
before formalin
        
Figure 4.4 Effects of a lumbar injection of rapamycin on formalin-induced
behavioural hypersensitivity when applied 5 min prior to formalin injection. (a)
Total behaviour, (b) licking and biting and (c) lifting and flinching were all
unaffected when pre-treated with rapamycin (n = 7) compared to DMSO (n = 7).
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Although 5 min was adequate time for arousal from anaesthesia, it was likely that
the anaesthesia was still present in the system of the rat thus masking the effects
of rapamycin. Therefore, a longer recovery period of 20 min between rapamycin
injection and formalin injection into the hind paw was allowed.
4.3.6 Rapamycin attenuates total formalin-induced behavioural
hypersensitivity when administered 20 min before formalin
 
Figure 4.5  Effects of a lumbar injection of rapamycin on formalin-induced total
behavioural hyperexcitability when applied 20 min prior to formalin injection.
(a) When a lumbar dose of rapamycin (n = 6) was administered to rats 20 min prior
to formalin injection into the hind paw, there was a significant reduction in length
of total behaviour at 5, 20, 25 and 30 min when compared to DMSO (n =7) from 131
+ 11 to 89 + 7; 57 + 15 to 21 + 4; 85 + 15 to 46 + 4 and 89 + 12 to 49 + 8 s
respectively. AUC analysis revealed that overall, rapamycin elicited a significant
reduction in the first phase from 673 + 63 to 463 + 42 arbitrary units. Rapamycin
also elicited a significant reduction in the second phase from 2,248 + 151 to 1,330 +
166 arbitrary units.
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4.3.7 Rapamycin attenuates licking and biting pain-like behaviour
when administered 20 min before formalin
 
Figure 4.6 Effects of a lumbar injection of rapamycin on formalin-induced
licking and biting pain-like behaviour when applied 20 min prior to formalin
injection. (a) When a lumbar injection of rapamycin (n = 6) was administered to
rats 20 min prior to formalin injection into the hind paw, there was a significant
reduction in the length of licking and biting behaviour at 5 and 30 min when
compared to DMSO (n = 7) from 112 + 11 to 73 + 4 and 75 + 13 to 33 + 9 s
respectively. AUC analysis revealed that overall, rapamycin elicited a significant
reduction in the first phase from 569 + 61 to 364 + 26 arbitrary units. Rapamycin
also elicited a significant reduction in the second phase from 1,529 + 174 to 699 +
179 arbitrary units (*P<0.05; **P<0.01).
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4.3.8 Rapamycin is ineffective against lifting and flinching pain-
like behaviour when administered 20 min before formalin
  
Figure 4.7 Effects of a lumbar injection of rapamycin on formalin-induced lifting
and flinching pain-like behaviour when applied 20 min prior to formalin
injection. (a) There were no differences at any specific time points between DMSO
(n = 7) and rapamycin (n = 6) pre-treated rats. (b) Overall, there were no
differences for first and second phase responses between DMSO and rapamycin pre-
treated rats.
To summarise, rapamycin attenuated both neuronal hyperexcitability and
behavioural hypersensitivity when compared to DMSO. In vivo electrophysiology
studies revealed that rapamycin was effective if administered i.t. onto the exposed
spinal cord 3 min prior to formalin injection into the hind paw and its inhibitory
actions were specific for the second phase of the formalin test. These effects
correlated with the results seen with the general translation inhibitor anisomycin.
However, behaviourally, a single lumbar injection of rapamycin was ineffective in
attenuating formalin-induced behavioural hypersensitivity when given 5 min prior
to formalin injection into the hind paw, yet effective in attenuating both phases of
the formalin test when given 20 min prior to the formalin injection.
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4.4 Discussion
The results of these studies provide convincing evidence that rapamycin-sensitive
protein translation pathways are important in the induction of formalin-induced
neuronal excitability and also formalin-induced behavioural hypersensitivity and
therefore may also be important in the induction of more persistent and chronic
pain states.
It can be seen from the electrophysiology results that i.t. administration of
rapamycin (see figure 4.2) or anisomycin (see figure 4.3) 3 min prior to formalin
injection into the hind paw results in a significant attenuation in neuronal
hyperexcitability in the second phase of the formalin test. A time of 3 min
incubation with rapamycin was chosen due to the fact that direct evidence from
studies on the importance of rapamycin-sensitive pathways in hippocampal LLTP
points towards a time-restricted role for the involvement of rapamycin-sensitive
pathways (Cammalleri et al., 2003). In these studies, it was found that when
rapamycin (20 nM) was transiently (40 min) applied during LLTP induction of
hippocampal slices, there was a dramatic decay of field excitatory postsynaptic
potentials. However, a transient rapamycin application 5 min after the delivery of
the LLTP tetanisation paradigm or 2 hr after completion of the LLTP induction
paradigm did not alter LLTP.
Although rapamycin and anisomycin have very similar effects on the second phase
of neuronal hyperexcitability, their response profiles do appear to be markedly
different.  Specifically, it appears that the response profiles for DMSO (25 %) in the
rapamycin-formalin experiment (see figure 4.2) are lower in terms of neuronal
hyperexcitability than the response profile for DMSO (10%) in the anisomycin-
formalin experiment (see figure 4.3). Although DMSO was shown in chapter 3 not to
have an effect on electrical and natural stimulus evoked responses compared to
pre-drug controls, recent studies have highlighted the effects of DMSO on the
formalin test (Colucci et al., 2008). In these studies, it was found that 100 % DMSO
or DMSO:saline 1:3 (v/v) administered to mice either centrally via an
intracerebroventricular (i.c.v.) injection or orally (p.o.) was able to significantly
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inhibit the first and second phase via i.c.v. administration or only the second phase
via p.o. administration. Thus, although DMSO may not have a significant effect on
neuronal responses in naive animals, this may change in animals with an induced
pain-like state. Also, there was a greater degree of second phase inhibition
observed with rapamycin (see figure 4.3) compared with anisomycin (see figure
4.5). However, this may just be due to a difference in potency as well as differing
DMSO percentages. Importantly, the comparison with anisomycin indicates that
rapamycin does indeed act via inhibition of protein translation.
In an attempt to replicate these results behaviourally, pilot studies were carried
out whereby rats were first lightly anaesthetised before receiving a single lumbar
injection of rapamycin between the L5 - L6 vertebral interspace. The rats were
then allowed to recover for 3 min before administering formalin to the hind paw.
However, it was found that 3 min was not sufficient to allow the rats to fully regain
consciousness from the anaesthesia (data not shown). Therefore, a time of 5 min
was chosen, as all animals appeared to be fully conscious by this time. However, it
was found that a lumbar injection of rapamycin 5 min prior to formalin injection
did not replicate the results seen with in vivo electrophysiology (see figure 4.4).
This meant that either the dose was insufficient to alter behavioural
hypersensitivity; that the drug did not have enough time to exert its effects or that
the rats had still not fully recovered from the anaesthesia. In this case, the latter
was probably true. The behavioural study was repeated, but this time, the same
dose of rapamycin was injected 20 min prior to formalin injection into the hind
paw. On this occasion, there was a significant attenuation of the second phase of
behavioural hypersensitivity, which confirmed the in vivo electrophysiology results,
but there was also a significant inhibition of the first phase too (see figures 4.5 –
4.7). At first, this might appear to be due to a time related issue concerning drug
action behaviourally. However, closer observation of the two response profiles
presents a different view. When formalin was injected 5 min after a lumbar
injection of rapamycin, the first phase was markedly lower than when formalin was
injected 20 min after a lumbar injection of rapamycin. This is interesting because
it is the first phase, which is attributed to acute afferent activity in response to
direct activation of peripheral nociceptors that leads to onset of the second phase
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which involves longer-lasting changes in plasticity of spinal neurones as well as
descending controls from higher brain centres (Suzuki et al., 2004a). The fact that
there was such a contrast between the first phase responses depending upon the
length of recovery time prior to formalin injection indicates that although the rats
may have seemed fully conscious, there may have been residual systemic
anaesthetic isofluorane still present in high enough levels that were sufficient to
dampen down the response to formalin as well as mask the inhibitory effects of
rapamycin.
It is interesting that rapamycin-sensitive pathways are important in both phases of
the formalin test as this provides important information regarding the role of
rapamycin-sensitive pathways in both peripheral and central aspects of pain
processing. There is also strong electrophysiological evidence showing that
descending serotonergic controls from higher brain centres are also enhanced
during formalin-induced inflammation, acting via excitatory 5-HT3Rs in the dorsal
horn to maintain or even enhance the response of spinal neurones to formalin-
induced inflammation since the selective 5-HT3R antagonist ondansetron and SP-
SAP treatment (both i.t.) prior to formalin injection into the hind paw both
attenuate the neuronal hyperexcitability associated with formalin-induced
inflammation  (Green et al., 2000; Suzuki et al., 2002). In support of a spinal site
of action for rapamycin-sensitive pathways and their activation by descending
serotonergic pathways acting at spinal 5-HT3Rs, is a study whereby an i.t. dose of
the selective 5-HT3R antagonist ondansetron was shown to attenuate formalin-
induced behavioural hypersensitivity as well as the upstream regulator of mTOR,
ERK in the spinal cord (Svensson et al., 2006).
Also of interest is that fact that behaviourally, rapamycin is more effective in
reducing licking and biting as opposed to lifting and flinching. According to optimal
scoring strategies (Watson et al., 1997), licking and biting has a higher categorical
weight than lifting and flinching. One can imagine that lifting and flinching
behaviour comprises a significant proportion of reflex behaviour whereas licking
and biting may require much more conscious processing by the rat with the aim of
alleviating the behavioural hypersensitivity. Importantly, the behavioural data
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confirm that rapamycin-sensitive pathways are important in formalin-induced
behavioural hypersensitivity.
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5 Rapamycin-sensitive pathways and pathophysiological
conditions: spinal nerve ligation-induced neuropathy
5.1 Introduction
In 1994, neuropathic pain was defined as “pain initiated or caused by a primary
lesion or dysfunction of the nervous system” by the International Association for
the Study of Pain (IASP) taxonomy committee (Merskey and Boduk, 1994). However,
a report by Treede et al. has highlighted the need for this definition to be revised
and a new definition be created using the following wording “pain arising as a
direct consequence of a lesion or disease affecting the somatosensory system”.
With this definition, the term ‘dysfunction’, which is not well defined, is replaced
with the term ‘disease’, which refers to specific identifiable processes such as
inflammation, autoimmune conditions and channelopathies. The term nervous
system is replaced with the term somatosensory system because diseases and
lesions in other parts of the nervous system may cause other types of pain such as
that associated with spasticity and rigidity mediated by activation of muscle
nociceptive afferents that may be wrongly confused with neuropathic pain (Treede
et al., 2008).
5.1.1 The clinical situation
The more common peripheral and central neuropathic conditions associated with
neuropathic pain are shown in table 5.1. It is important to note that these
conditions will not always result in pain and the reasons behind this are not clear.
Neuropathic pain is thought to affect a small but significant percentage of the UK
population and although a precise number is not defined, there have been
numerous studies investigating incidence rates of particular neuropathic conditions
and their treatment. One such study carried out by Hall et al. determined the
incidence of four readily diagnosed pain syndromes: post-herpetic neuralgia (PHN),
trigeminal neuralgia, phantom limb pain (PLP) and painful diabetic neuropathy
(PDN) as managed in general practice (Hall et al., 2006). Over a 10 yr observational
period involving 39,731 patients for whom, a record of one or more of the four pain
syndromes had been identified, there were 12,386 incident cases of PHN
110
Chapter 5
(31 %), 8,268 cases of trigeminal neuralgia (21 %), 451 cases of PLP (5 %) and 4719
(12 %) cases of PDN. Hall et al. also studied treatment regimens and found that
many different drugs were prescribed as initial treatments, but the five most
commonly used were the same across all conditions: analgesics, tricyclic
antidepressants (TCAs), anticonvulsants, paracetamol and codeine. Data regarding
the number of changes from initial to stable therapy suggests that initial drug
choice is not perfect and that those patients whose initial drug treatment was with
conventional analgesics such as opioids and paracetamol were more likely to
change treatment than those whose initial drug was either an antidepressant such
as amytriptilline or an anticonvulsant such as carbemazepine (Hall et al., 2006).
In 2006, the European Federation of Neurological sciences (EFNS) panel on
neuropathic pain produced a set of guidelines based on the evaluation of existing
evidence about the pharmacological treatment of neuropathic pain.  They found
strong evidence for the efficacy of TCAs, the anticonvulsants GBP and pregabalin
and opioids for PHN and peripheral polyneuropathies (PPN) caused mainly by
diabetes. These drugs are recommended for first line treatment. Topical lidocaine,
the serotonin-noradrenaline reuptake inhibitors (SNRIs) such as venlafaxine and
duloxetine were found to have less established efficacy and are therefore
recommended for second line treatment. Opioids are suggested for second to third
line treatment in chronic non-cancer pain (Attal et al., 2006).  Despite these
guidelines and the large number of trials, neuropathic pain treatment remains
unsatisfactory for the many patients that endure a trial and error process before
obtaining some kind of satisfactory regimen that may often combine more that one
drug treatment.
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Peripheral trauma Central trauma
Traumatic (including iatrogenic) nerve
injury
Stroke (infarct or haemorrhage)
Ischaemic neuropathy Multiple sclerosis
Nerve compression/entrapment Spinal cord injury
Polyneuropathy (hereditary, metabolic,
toxic, inflammatory, infectious,
paraneoplastic, nutritional, or in
amyloids or vasculitis)
Syringomyelia/syringobulbia
Plexus injury
Root compression
Stump and phantom pain after
amputation
PHN
Cancer-related neuropathy (i.e. due to
neural invasion of the tumour, surgical
nerve damage, radiation-induced nerve
damage, or chemotherapy-induced
neuropathy)
Scar pain
Table 5.1 Some common conditions in which neuropathic/neurogenic pain may
appear (adapted from Hansson, 2008).
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5.1.2 Animal models of neuropathic pain
In light of the fact that neuropathic pain treatment for many patients is
unsatisfactory, basic studies using animal models have been used to provide clues
into the mechanism of action of many drugs as well as improve current drug
treatment regimes. So far, the most intensively studied animal models for
neuropathic pain are those involving a mechanical trauma to peripheral nerves
(Zimmermann, 2001). The past 20 years have provided a multitude of rodent
neuropathic pain models that correspond with the various existing clinical
conditions. In terms of peripheral nerve injury, three commonly used
mononeuropathy models that simulate human neuropathic pain syndromes are the
chronic constriction injury (CCI) model, the partial sciatic nerve ligation (PSL)
model and the spinal nerve ligation (SNL) model.
The rat CCI model was created by Bennett and Xie in 1988 and involves loosely
tying the left or right sciatic nerve with four chromic gut ligatures at the mid-thigh
level (Bennett and Xie, 1988). Then came the rat PSL model by Seltzer et al. in
1990. This model involves ligating the sciatic nerve at the high thigh level, ensuring
that a third to half the thickness of the sciatic nerve is ligated (Seltzer et al.,
1990). In 1992, Kim and Chung reported on their rat model of neuropathic pain.  In
this model, both the L5 and L6 spinal nerves on one side of the rat are tightly
ligated at a site distal to the DRG (Kim and Chung, 1992). Kim and Chung also
described a commonly used modification of this model that involves tight ligation
of the L5 spinal nerve only, a model which also exhibits long-lasting
hypersensitivity (Kim and Chung, 1992).
All three models of neuropathic pain show behavioural signs of both mechanical
and cold hypersensitivity as well as spontaneous pain, although in terms of the
magnitude of responses, there is some variation between the different models. In a
study comparing these particular models, it was found that responses to
mechanical stimuli were the highest in the SNL model and lowest in the CCI model.
The responses to cold stimuli were similar in magnitude in all three models.
However, there was much more variability between animals in the CCI model (Kim
et al., 1997).  Taking this information into consideration, the studies presented
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here will involve the SNL model (ligation of L5 and L6 spinal nerves) due to the
large and stable magnitude of stimulus evoked behavioural hypersensitivity. In
addition to behavioural hypersensitivity, electrophysiological studies of neuronal
activity have shown that SNL alters neuronal plasticity and particularly enhances
ongoing neuronal activity such that pharmacological agents that inhibit neuronal
activity- some of which are used clinically, are more efficacious in this pain-like
state compared to sham or naive animals (Suzuki et al., 1999; Suzuki et al., 2000;
Suzuki et al., 2001; Suzuki et al., 2004b; Suzuki et al., 2005).  Furthermore, there
is little variability between individual rats of this model (Kim and Chung, 1992)
which is presumably due to the fact that single ligatures are being placed on a
single spinal nerve as opposed to a number of ligatures covering a comparatively
larger area of sciatic nerve (as is the case with CCI), or a ligature of a variable
section (third to half) of the sciatic nerve (as is the case with PSL).
5.1.3 Animal models of neuropathic pain and upstream modulators
of mTOR
Much like formalin-induced inflammation, there is also little information on the
importance of rapamycin-sensitive pathways in neuropathy, although more is
known regarding animal models of neuropathic pain and upstream regulators of
mTOR. ERK activation has been shown to be important in engaging or synergising
with rapamycin-sensitive pathways (Gelinas et al., 2007; Kelly et al., 2007; Tsokas
et al., 2007). As well as being important in inflammatory pain-like conditions, ERK
activation has also been shown to be important in mediating pain-like
hypersensitivity induced by nerve injury (Zhuang et al., 2005). In this particular
study, Zhuang et al. found that an L5 spinal nerve ligation of rats induced
activation of ERK via phosphorylation in the superficial neurones of the dorsal horn
of the spinal cord as well as astrocytes and microglia. Furthermore, i.t.
administration of the inhibitor of ERK kinase (which is upstream to ERK)- PD98059
to these rats caused significant reductions in mechanically evoked hypersensitivity.
PI3K is also upstream of mTOR and its role in activating rapamycin-sensitive
pathways has been well documented (Schratt et al., 2004; Takei et al., 2004;
Horwood et al., 2006; Chenal and Pellerin, 2007; Kelly et al., 2007; Tsokas et al.,
2007). Little is known about the role of PI3K in nerve injury-induced behavioural
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hypersensitivity although a recent study addressed this by exploring the role of
PI3K signalling in mechanical and thermal hypersensitivity after ligation of the L5
spinal nerve. By measuring downstream Akt phosphorylation levels, it was found
that there was an increase in PI3K activity in the dorsal horn and DRG ipsilateral to
the injury. To further substantiate this, the PI3K inhibitors wortmanin or LY294002
were shown to attenuate mechanical and thermal behavioural hypersensitivity (Xu
et al., 2007).
At the receptor level, NMDA receptors are implicated in activating rapamycin-
sensitive pathways (Gong et al., 2006; Gonzalez-Mejia et al., 2006) and have also
been studied for their role in nerve-injury induced behavioural hypersensitivity. In
a study examining the efficacy of specific NMDA receptor antagonists on the L5 and
L6 SNL model, it was found that the antagonists memantine, D-AP5, dextrophan,
dextromethorphan, MK801 and ketamine were effective (to varying degrees) in
attenuating SNL-induced mechanical behavioural hypersensitivity (Chaplan et al.,
1997). In accordance with these results, electrophysiological data studies on the
same models have demonstrated that systemic administration of the NMDA
antagonists memantine, ketamine and MK801 are effective (again to varying
degrees) in reducing post-discharge, wind up as well as thermally and mechanically
evoked responses from SNL rats compared to sham controls (Suzuki et al., 2001).
Much like formalin-induced inflammation, the metabotropic glutamate receptors
mGluR1 and mGluR5 have also been shown to be important in SNL-induced
behavioural hypersensitivity (Dogrul et al., 2000; Varty et al., 2005) and they are
known to be important in engaging rapamycin-sensitive pathways (Page et al.,
2006; Price et al., 2007). In 2000, Dogrul et al. showed that the selective mGlur5
antagonist SIB-1757 was effective in fully reversing SNL-induced thermal
behavioural hypersensitivity when administered via an i.t. lumbar spinal injection
or locally to the hypersensitive hind paw (Dogrul et al., 2000). Later in 2005, it was
shown that the mGluR5 antagonists MPEP, MTEP and the mGluR1 antagonist
LY456236 were all effective in attenuating SNL-induced mechanical hypersensitivity
when administered i.p. (Varty et al., 2005).
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At the transmitter level, BDNF has been shown to be important in engaging
rapamycin-sensitive pathways (Takei et al., 2001; Tang et al., 2002; Schratt et al.,
2004; Takei et al., 2004) as well as modulating the effects of nerve injury-induced
behavioural hypersensitivity. In a study by Yajima et al., it was found that PSL-
induced behavioural thermal hypersensitivity and mechanical hypersensitivity could
be suppressed by repeated i.t. injections of the BDNF sequestering protein
TrkB/Fc. In addition, heterozygous BDNF KO mice presented with a significantly
lower degree of PSL-induced thermal and mechanical hypersensitivity compared to
WT mice (Yajima et al., 2005).
5.1.4 Direct nerve injury and rapamycin-sensitive pathways
It is widely accepted that nerve damage experienced by neuropathic pain patients
leads to various changes in the excitability of these nerves which contributes to the
symptoms commonly associated with neuropathic pain i.e. allodynia, hyperalgesia
dysasthesia and even loss of sensation. Although the importance of rapamycin-
sensitive pathways in neuropathy has not been extensively studied, much can be
learned from the first demonstration of the importance of rapamycin-sensitive
pathways in nerve-injury induced hyperexcitability (Weragoda et al., 2004).  In this
study involving easily identifiable neurons from Aplysia californica (Californian sea
slug), intracellular recordings from the somata of sensory and secretomotor
neurones were found to exhibit stimulus evoked hyperexcitability (LTH) lasting at
least 24 hr when they were either crushed or briefly exposed (2 min) to elevated
extracellular [K+]. This hyperexcitability was prevented when the nerve segments
were incubated for 3 hr prior to the treatment with rapamycin. Subsequently, in
2005, it was also reported that this crush-induced LTH could be prevented by
incubating the nerve segments with the 5-HTR antagonist methiothepin, providing
evidence for the mediation of this response by 5-HT (Weragoda and Walters, 2007),
as well as an interesting correlation with animal models of pain where descending
serotonergic influences have been to shown to play a significant role in maintaining
persistent and chronic pain-like states (Suzuki et al., 2004a).
More recently, rapamycin-sensitive pathways have been shown to be important in
the rat spared nerve injury (SNI) model, whereby mechanical hypersensitivity
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occurs as a result of ligation and then removal of the peroneal and tibial nerve
stumps that branch off the sciatic nerve (Jimenez-Diaz et al., 2008). In this study,
it was found that this injury resulted in an enhanced response to pinprick
stimulation in the hind paw as determined by the amount of time holding the paw.
When rapamycin was injected into the intraplantar region of the hind paw, there
was a significant decrease in time holding the paw 4 to 24 hr post-injection. To
date, there have been no studies investigating the importance of rapamycin-
sensitive pathways at the spinal level in rodent models of neuropathy and this was
the aim here. The studies presented in this chapter utilise in vivo electrophysiology
and behavioural studies techniques to investigate this further using the rapamycin
ester CCI-779.
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5.2 Methods
5.2.1 SNL surgery
Surgery was performed as described in 2.4.1.
5.2.2 Behavioural studies: confirmation of pain-like behaviour and
assessment of CCI-779 efficacy
See 2.4.2. When assessing the efficacy of CCI-779, 12.88 µg in 20 µl saline (250 µM)
was injected into the lumbar region of lightly anaesthetised rats, which were then
allowed to recover (20 min) before testing began. This dose was chosen as it had
been shown to attenuate capsaicin- and nerve injury-induced behavioural
hypersensitivity when injected locally into the hind paw (Jimenez-Diaz et al.,
2008). The total testing period was 2 hr.
5.2.3 In vivo electrophysiology setup
See 2.2. After obtaining a stable baseline, 12.88 ng of CCI-779 in 50 µl of saline was
applied to the exposed spinal cord and electrically and naturally evoked stimuli
were obtained every 20 min for 2 hr.
5.2.4 Statistical analysis
To confirm pain-like behaviour, comparisons were made between sham and SNL
difference scores using the Kruskal-Wallis test with  Bonferroni’s post-tests. When
determining the maximal effects of CCI-779 compared to saline within the first hr
of administration to SNL animals, AUC response profiles were constructed for all
difference scores within the first hr and CCI-779 AUC data was compared to saline
AUC data using Mann-Whitney tests. Electrophysiological raw data are presented as
mean + SEM response. Student’s unpaired t-tests were used to compare sham and
SNL pre-drug baseline control neuronal responses with each other, except for
graded thermally and mechanically evoked responses where two way ANOVA with
Bonferroni post-tests were used. For time course data, responses at a given time
point were compared to t = 0, when CCI-779 was added to the cord. One way
ANOVA with repeated measures and Dunnett’s post-test comparisons to control (at
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0 min) were used to determine significance between groups for electrical stimuli as
well as brush and pin. Two way ANOVA with repeated measures and Bonferroni’s
post-test comparisons to control (at 0 min) were used to determine significance
between groups for graded natural stimuli i.e. graded mechanical and thermal
stimuli. In addition, maximal stimulus evoked responses (positive or negative) to
drug administration were analysed. For drug-induced maximal response changes to
electrical, brush and pinprick stimuli, one way ANOVA with Bonferroni multiple
comparisons post-tests were used. For maximal graded mechanical and thermal
stimuli evoked responses, two way ANOVA with Bonferroni multiple comparisons
post-tests were used (*P<0.05; **P<0.01 ***P<0.001).
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5.3 Results
5.3.1 SNL induces persistent pain-like behaviour post-surgery
          
Figure 5.1 Effects of SNL on stimulus evoked behavioural withdrawal responses.
(a) When a 1 g von Frey stimulus was applied 10 times to each hind paw, there was
an increase in behavioural hypersensitivity in SNL rats (n = 22) compared to sham
rats (n = 24) as demonstrated by the increase in difference score. This increase was
significant at post-surgery days 9 and 14, where the difference score increased
from 0.19 + 0.14 and 0 + 0.12 to 1.04 + 0.24 and 1.38 + 0.26 respectively. (b) When
6 g was applied, there was a significant increase in difference score at 2, 7, 9 and
14 days from –0.45 + 0.25 to 2.75 + 0.41; -0.09 + 0.29 to 2.38 + 0.43; -0.27 + 0.30
to 2.67 + 0.48 and –0.50 + 0.27 to 2.63 + 0.5 respectively. (c) When 8 g was
applied, there was a significant increase in difference score at 2, 7, 9 and 14 days
from –0.50 + 0.30 to 2.75 + 0.47; -0.64 + 0.24 to 3.67 + 0.47; -0.82 + 0.27 to 3.79 +
0.55 and –0.59 + 0.25 to 3.92 + 0.48 respectively. (d) When acetone was applied,
there was a significant increase in difference score at 2, 7, 9 and 14 days from
–0.05 + 0.10 to 2.33 + 0.25; 0.05 + 0.19 to 2.50 + 0.33; 0.05 + 0.01 to 2.21 + 0.32
and –0.14 + 0.17 to 2.29 + 0.31 respectively. Difference score (see 2.4.2.) = number
of paw withdrawals from injured side minus noumber of paw withdrawals from
uninjured side (*P<0.05, **P<0.01, ***P<0.001).
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5.3.2 CCI-779 is not effective against electrically evoked neuronal
responses from SNL rats
   
Figure 5.2 Effects of 250 nM CCI-779 on electrically evoked neuronal responses
from SNL rats over 2 hr. (a) Only Aδ-fibre activity was significantly inhibited at 80
min from 136 + 15 (at 0 min) to 95 + 12 spikes. There were trends for inhibition
within the first hr for: (a) Aβ-, Aδ-, C-fibre-mediated activity and post discharge
(PD); (b) input and (c) wind up, particularly at 40 min.  For all data sets, spikes =
number of spikes after a train of 16 pulses; n = 12, except wind up, where n = 11
(*P<0.05).
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5.3.3 CCI-779 is not effective on electrically evoked neuronal
responses from sham rats
   
Figure 5.3 Effects of 250 nM CCI-779 on electrically evoked neuronal responses
from sham rats over 2 hr. Much like SNL rats, electrically evoked responses were
on the whole unchanged for (a) Aβ-, Aδ-, C-fibre-mediated activity, post discharge
(PD) and (b) input. However, there were trends for facilitation rather than
inhibition seen with SNL rats, particularly at 40 min. This was more apparent with
(c) windup where there was an increase at 40 min from 457 + 46 (at 0 min) to 610 +
64 spikes. For all data sets, spikes = number of spikes after a train of 16 pulses; n =
10 (**P<0.01).
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5.3.4 CCI-779 has small effects on brush but not pinprick evoked
neuronal responses from SNL rats
 
Figure 5.4 Effects of 250 nM CCI-779 on brush and pinprick evoked neuronal
responses from SNL rats over 2 hr. (a) When CCI-779 was administered to the
spinal cord, there was a reduction in brush evoked activity from 449 + 51 (at t = 0)
to 308 + 41; 265 + 32; 324 + 56 and 312 + 51 at 20, 80, 100 and 120 min
respectively. (b) There was no effect on pinprick evoked stimuli. For both data
sets, spikes = number of spiked during a 10 s stimulus; n = 12 (*P<0.05; **P<0.01).
123
Chapter 5
5.3.5 Inhibitory effects of CCI-779 on brush evoked neuronal
responses are absent from sham rats
 
Figure 5.5 Effects of 250 nM CCI-779 on brush and pinprick evoked neuronal
responses from sham rats over 2 hr. When CCI-779 was administered to the spinal
cord, there were no effects on (a) brush evoked responses or (b) pinprick evoked
responses. For both data sets, spikes = number of spikes during a 10 s stimulus; n =
10.
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5.3.6 CCI-779 has selective effects on graded mechanically and
thermally evoked neuronal responses from SNL rats
    
Figure 5.6 Effects of CCI-779 on graded mechanically and thermally evoked
neuronal responses from SNL rats over 2 hr. (a) At 20 min, 250 nM CCI-779
specifically inhibited responses to 8 g from 237 + 65 (at t = 0) to 117 + 29 spikes.
(b) CCI-779 had no effect on innocuous thermally evoked stimuli. (c) At 20 min,
CCI-779 inhibited responses to 15, 26 and 60 g from 364 + 84, 479 + 102 and 637 +
100 spikes (at 0 min) to 223 + 61, 316 + 62 and 506 + 77 spikes respectively. At 40
min, CCI-779 inhibited responses to 15, 26 and 60 g from 364 + 84, 479 + 102 and
637 + 100 spikes (at 0 min) to 225 + 48, 309 + 66 and 435 + 65 spikes respectively.
At 60 min, CCI-779 inhibited responses to 15, 26 and 60 g from 364 + 84, 479 + 102,
637 + 100 spikes (at 0 min) to 241 + 52, 328 + 72 and 472 + 78 spikes respectively.
At 80 min, CCI-779 inhibited responses to 60 g from 364 + 84 spikes (at 0 min) to
294 + 68 spikes. At 120 min, CCI-779 inhibited responses to 15, 26 and 60 g from
364 + 84, 479 + 102 and 637 + 100 spikes (at 0 min) to 244 + 51, 358 + 70 and 499 +
82 spikes respectively. (d) At 100 min, CCI-779 inhibited responses to 50 °C from
754 + 112 spikes (at  0 min) to 543 + 132 spikes. At 120 min, CCI-779 inhibited
responses to 45 and 50 °C from 359 + 99 and 754 + 112  spikes (at 0 min) to 174 +
27 and 510 + 91 spikes respectively. For all data sets, spikes = number of spikes
during a 10 s stimulus; n = 12 (*P<0.05; **P<0.01).
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5.3.7 CCI-779 is less effective in attenuating graded mechanically
and thermally evoked responses from sham rats
    
Figure 5.7 Effects of CCI-779 on graded mechanically and thermally evoked
neuronal responses from sham rats over 2 hr. Although there were trends for
inhibition within the first hr of testing,  (a) 250 nM CCI-779 had no effect on
responses to innocuous mechanically evoked responses and (b) innocuous thermally
evoked responses. (c) Although CCI-779 did not inhibit responses to noxious
mechanically evoked responses, there was a facilitation at 80 min to a stimulus of
15 g from 437 + 83 spikes (at 0 min) to 591 + 116 spikes. (d) At 120 min, CCI-779
inhibited responses to 48 and 50 °C and from 718 + 203 and 1028 + 214 spikes (at 0
min) to 406 + 105 and 700 + 142 spikes respectively. For all data sets, spikes =
number of spikes during a 10 s stimulus; n = 10 (*P<0.05).
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The electrophysiological results so far reveal that unlike naive rats (see chapter 3)
and sham rats, there is a greater degree of inhibition of evoked responses taking
place within the first hr in SNL rats and where these changes are not significant,
there is certainly a strong trend for inhibition. It was therefore decided to look at
the maximal changes (positive or negative) occurring for all responses evoked
within the first hr of testing. The following electrophysiological data compares 3
groups: pre-drug baseline controls comprising pooled mean sham and SNL baseline
responses; sham and SNL responses to CCI-779 within the first hr post-
administration. Pre-drug control means were pooled into one group for sham and
SNL pre-drug baseline responses called ‘control’ as it was found that pre-drug
responses between the two groups were not significantly different.
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5.3.8 Sham and SNL pre-drug baseline control neuronal responses
were not significantly different
Sham (n = 10) SNL (n = 12)
Aβ-fibre spikes 87 + 16 111 + 16
Aδ-fibre spikes 112 + 19 136 + 15
C-fibre spikes 461 + 55 531 + 57
Post-discharge spikes 293 + 33 245 + 49
Input spikes 480 + 64 464 + 64
Wind up spikes 467 + 46 344 + 82
Brush spikes 572 + 89 445 + 52
Pin spikes 400 + 75 311 + 59
1 g spikes 31 + 17 21 + 10
6 g spikes 195 + 46 125 + 44
8 g spikes 300 + 60 237 + 65
15 g spikes 437 + 83 364 + 84
26 g spikes 570 + 101 479 + 102
60 g spikes 782 + 118 637 + 100
35 °C spikes 342 + 104 192 + 47
40 °C spikes 427 + 143 234 + 61
45 °C spikes 444 + 167 359 + 99
48 °C spikes 610 + 204 509 + 278
50 °C spikes 975 + 208 754 + 118
Table 5.2 Pre-drug control responses of WDR neurones from sham and SNL rats.
For electrically evoked responses, a train of 16 pulses at three times C-fibre
threshold (0.5 Hz, 2 ms pulse width) was applied to the corresponding hind paw.
For mechanically evoked responses, von Frey filaments of ascending force were
applied to the corresponding receptive field for 10 s. For thermally evoked
responses, a small water jet was applied to the corresponding receptive field for 10
s. All data are expressed as raw mean values + SEM. There were no significant
differences between WDR neurone responses from sham or SNL rats prior to CCI-
779 administration.
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5.3.9 CCI-779 inhibits electrically evoked neuronal responses from
SNL rats
 
Figure 5.8 Effects of CCI-779 on electrically evoked neuronal responses from
SNL and sham rats over 1 hr. (a) 250 nM CCI-779 inhibited C-fibre mediated
transmission onto WDR neurones from 493 + 39  (pre-drug controls) and 530 + 64
(sham rats) to 340 + 46 spikes in SNL rats. CCI-779 also inhibited post discharge of
WDR neurones from 382 + 44 (sham rats) to 176 + 52 spikes in SNL rats. (b) CCI-779
inhibited wind up of WDR neurones from 601 + 74 spikes (sham rats) to 172 + 65
spikes (SNL rats). For all data sets, spikes = number of spikes after a train of 16
pulses; pre-drug sham and SNL controls n = 22; sham n = 10 and SNL n = 12
(*P<0.05; **P<0.01; ***P<0.001).
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5.3.10  CCI-779 has no effects on brush and pinprick evoked
neuronal responses from SNL rats
                                   
Figure 5.9 Effects of CCI-779 on brush and pinprick evoked neuronal responses
from SNL and sham rats over 1 hr. Although there were trends for inhibition
within the first hr in SNL rats compared with sham rats and pre-drug controls,
brush evoked responses were unaltered by 250 nM CCI-779, as were pinprick evoked
responses. For both data sets, spikes = number of spikes during a 10 s stimulus;
pre-drug sham and SNL controls n = 22; sham n = 10 and SNL n = 12.
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5.3.11  CCI-779 selectively inhibits graded mechanically
evoked neuronal responses from SNL rats
Figure 5.10 Effects of CCI-779 on graded mechanically and thermally evoked
neuronal responses from SNL and sham rats over 1 hr. (a) When compared to
pre-drug control responses, 250 nM CCI-779 was effective in attenuating responses
to 15, 26 and 60 g from 397 + 59, 520 + 71 and 703 + 76 spikes to 168 + 41, 265 + 65
and 422 + 70 spikes respectively. This was also true for sham responses where, CCI-
779 attenuated responses to 8 g from 388 + 68 spikes to 116 + 25 spikes in addition
to significant inhibition of SNL responses to 15, 26 and 60 g from 467 + 73, 575 + 71
and 819 + 83 spikes to 115 + 25, 265 + 65 and 422 + 70 spikes respectively. (b) CCI-
779 was ineffective against thermally evoked responses in SNL or sham rats
compared to pre-drug control responses. For all data sets, spikes = number of
spikes during a 10 s stimulus; pre-drug sham and SNL controls n = 22; sham n = 10
and SNL n = 12.
The efficacy of CCI-779 was also tested behaviourally, by administering a single
injection of CCI-779 under light anaesthesia to the lumbar region of the spinal cord
(L5 - L6 vertebral interspace) of SNL rats at day 14 post-surgery. After recovery,
the rats were allowed to recover for 20 min and then tests involving the application
of graded von Frey filaments (10 applications per paw) or acetone (5 applications
per paw), were carried out every 20 min for 2 hr.
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5.3.12  CCI-779 inhibits mechanical behavioural
hypersensitivity from SNL rats
    
Figure 5.11 Effects of CCI-779 on behavioural hypersensitivity over 2 hr. (a)
Trends for inhibition of withdrawal response difference scores by 250 µM CCI-779 (n
= 8) compared to saline (n = 7) were seen as early as 20 min, with recovery to pre-
drug baseline (B) levels. (b) CCI-779 inhibited withdrawal response difference
scores to 6 g. Significance was achieved at 20 min where the difference score for
saline treatment was 5.29 + 1.37 and the difference score for CCI-779 treatment
was 0.89 + 0.97. (c) CCI-779 inhibited withdrawal response difference scores to 8 g.
Significance was achieved at 20 min where the difference score for saline
treatment was 8.00 + 0.57 and the difference score for CCI-779 treatment was 0.75
+ 0.67. (d) CCI-779 inhibited withdrawal response difference scores to acetone
application at 40, 60 and 100 min where the difference scores for saline treatment
were 1.86 + 0.29; 2.00 + 0.19 and 2.29 + 0.70 respectively. The difference scores
for CCI-779 treatment were 0.00 + 0.00; 0.38 + 0.26 and 0.00 + 0.36 respectively
(*P<0.05; **P<0.01, ***P<0.001).
132
Chapter 5
Much like the electrophysiological data, the behavioural data reveals that there is
a greater degree of inhibition by CCI-779 taking place within the first hr in SNL rats
and where these changes are not significant, there is a strong trend for inhibition.
It was therefore decided to analyse AUC data for the first hr of testing. Statistically
significant differences between saline and CCI-779 treatment groups were
determined by applying the Mann-Whitney test.
5.3.13  CCI-779 inhibits cold and mechanical behavioural
hypersensitivity from SNL rats
                                 
Figure 5.12 Effects of CCI-779 on behavioural hypersensitivity over 1 hr. Saline
AUC of the difference scores for acetone, 1 g, 6 g and 8 g were 76 + 4; 76 + 43; 217
+ 41 and 268 + 37 arbitrary units respectively. 250 µM CCI-779 AUC of the
difference scores for acetone, 1 g, 6 g and 8 g were 10 + 5; 3 + 3; 33 + 10 and 89 +
41 arbitrary units respectively. For all data sets, saline treatment n = 7; 250 µM
CCI-779 treatment n = 8 (*P<0.05; **P<0.01; ***P<0.001).
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To summarise, the rapamycin analogue CCI-779 was effective in attenuating
neuronal responses to electrical, mechanical and thermal stimuli. Like the naive
rats in chapter 3, neuronal responses of SNL rats were attenuated in the second hr
of testing. However, unlike naive rats, this attenuation was in fact greater in the
first hr of testing, particularly for mechanical stimuli. When cross-comparing
neuronal responses to CCI-779 within the first hr, it was apparent that this degree
of inhibition was specific to SNL rats and not their sham counterparts. Also of
interest was the fact that mechanically evoked responses and not thermally evoked
responses from SNL rats were inhibited compared to shams and pre-drug controls.
In addition, behavioural studies of SNL rats that had received CCI-779 revealed that
the drug was also effective in inhibiting behavioural hypersensitivity to cold and
mechanical stimuli as a result of SNL. Much like the electrophysiological data, it
was found that the majority of the maximal inhibitory effects occurred within the
first hr of administration of the drug. In addition, evoked responses after the
maximal inhibitory effects of CCI-779 returned to pre-drug baseline values
confirming the reversible nature of the drug (see figure 5.11).
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5.4 Discussion
Chapter 4 examined the importance of rapamycin-sensitive pathways in the
induction of formalin-induced inflammation in terms of neuronal hyperexcitability
and behavioural hypersensitivity.  In this chapter, the importance of rapamycin-
sensitive pathways in a more persistent pain state- SNL-induced neuropathy was
used to assess other aspects of this protein translation pathway. The neuropathic
state induced by SNL is a much longer-lasting pain-like state and the long-lasting
behavioural hypersensitivity to innocuous stimuli is in many ways similar to the
allodynia presented by patients. Furthermore, whilst the formalin test was used to
test the importance of rapamycin-sensitive pathways in the induction of a pain-like
state, the SNL model was used to test the importance of rapamycin-sensitive
pathways in maintaining pain-like states, by administering the rapamycin ester CCI-
779 (in electrophysiological or behavioural studies) after the full establishment of
the persistent pain-like state.
These studies show that the SNL model produces robust hypersensitivity to
innocuous and cold stimuli of the innervated hind paw from as early as early as day
2 post-surgery and this is maintained for at least 2 weeks (see figure 5.1). In fact,
this procedure has been found to produce long-lasting hypersensitivity to noxious
heat for at least 5 weeks post-surgery and mechanical hypersensitivity at least 10
weeks post-surgery (Kim and Chung, 1992) perhaps mimicking chronic pain
conditions in patients. The electrophysiological results clearly show that CCI-779
exerts a mixture of inhibitory effects in SNL rats when administered to the spinal
cord. There appeared to be trends for a greater degree of inhibition by CCI-779
after the first test at 20 min or within the first hr of testing. This was particularly
true for mechanically evoked responses to brush and 8  - 60 g von Frey filaments
(see figures 5.2, 5.4 and 5.6). There were also significant inhibitions at later time
points, but these changes were similar to those seen in Chapter 3 with naive
animals, where many of the inhibitions exerted by CCI-779 occurred within the
second hr of testing. This was particularly true for mechanical and thermal stimuli
(see figure 3.7). Of interest here is that while the results in chapter 3 clearly show
that there is an important role for rapamycin-sensitive pathways under
physiological conditions, these pathways are also important for pathological
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conditions such as persistent pain-like states. However, it appears that the changes
that underlie persistent pain-like states may also change the activity of rapamycin-
sensitive pathways to the extent where they are now more readily inhibited due to
an increase in activity of these pathways.
CCI-779 was also tested electrophysiologically in sham rats. These rats had their
nerves exposed but not ligated and therefore would be expected to produce a state
similar to those of the naive rats in chapter 3. Although to some extent, this is
true, it can be seen that the inhibitions seen during the second hr of testing in
naive animals (see figure 3.7) are absent here, except for inhibitions by CCI-779 to
48 °C and 50 °C stimuli at 120 min (see figure 5.7). Furthermore, there are in fact
facilitations of wind up responses at 40 min and also responses to 15 g at 80 min
(see figures 5.3 and 5.5). Whilst these results clearly indicate that rapamycin-
sensitive pathways are specifically altered in SNL rats, they also suggest that they
are also altered in sham rats too. This is to be expected as sham surgery still
involves disruption of tissue and stimulating the nerves albeit in a less physically
damaging way than SNL surgery.
Due to the fact that CCI-779 appeared to have a more significant effect within the
first hr of administration in SNL rats compared to sham and naive rats, the effects
of CCI-779 on stimulus evoked neuronal activity was further investigated by
analysing the maximal changes (positive or negative) within the first hr after CCI-
779 administration. This reanalysis revealed just how much inhibitory action CCI-
779 was exerting in SNL rats compared to sham rats and pre-drug control
responses. The pre-drug control responses for both sham and SNL neuronal
responses were pooled into one group in order to make comparisons with sham and
SNL rats treated with CCI-779. Although it might be expected that the pre-drug
baseline neuronal response levels would differ between the two groups, this was
not the case here. This may be due to the fact that although neuronal excitability
would be expected increase in SNL rats, there is also a reduction of peripheral
input to the spinal cord due to the ligation procedure (see chapter 6) so that
neuronal changes are only apparent due to differential responses to drug
treatment.
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When compared to sham rats, C-fibre mediated transmission onto WDR neurones
was significantly inhibited, as was post discharge and wind up of WDR neurones.
There was also significant inhibition of punctate mechanically evoked responses to
von Frey filaments 8 – 60 g. However, this inhibitory action was not extended to
thermally evoked stimuli (see figures 5.8 – 5.10) suggesting that rapamycin-
sensitive pathways are more important for transmission mediated by particular
sensory modalities.
The effects of CCI-779 were also examined behaviourally in SNL rats at day 14.
Here, the rapid effects on withdrawal responses to mechanical and cold stimuli
were even more apparent than the effects of the drug seen in the
electrophysiological studies. In most cases, maximal inhibition of difference scores
occurred at 20 min when compared to saline administration, except for acetone,
where inhibition was significant at 40 min. Also, in most cases, inhibition returned
to baseline levels, except for acetone, where there was a more sustained level of
inhibition (see figure 5.11). Again, reanalysis of withdrawal responses in the first hr
of CCI-779 administration by looking at the AUC for the results produced in the first
hr revealed the large extent of rapid inhibition of withdrawal responses to
innocuous cold and mechanical stimuli. It should be noted that this was not a
sedative effect as all tests were performed on fully conscious and alert rats.
Furthermore, there have been no reports of this dose of rapamycin or rapamycin
analogues administered via the i.t. route having any sedative effects.
These results together with the results in chapter 4 show that rapamycin-sensitive
pathways are not only important in the induction of persistent pain-like states, but
also in the maintenance of persistent pain-like states too. Of particular interest is
the fact that rapamycin-sensitive pathways are specifically altered after nerve
injury which results in an enhancement in the efficacy time course of CCI-779.
These results bear some similarities to those obtained in a study investigating the
effectiveness of the anti-neuropathy drug GBP in attenuating neuronal responses of
SNL rats (Suzuki et al., 2005). In this study, GBP was found to have no effect on
neuronal responses in the absence of nerve injury so that in sham operated
animals, GBP had no effect after administration on any neuronal responses to
electrical, mechanical or thermal stimuli. However, after nerve injury, systemic
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administration of GBP attenuated spontaneous spinal neuronal activity as well as
neuronal responses to mechanical and thermal stimuli. Since GBP binds to a unique
site on the α2δ subunit (Gee et al., 1996), this suggests an enhanced functional
role of calcium channels and/or α2δ subunits after nerve injury, much like a
proposed enhanced functional role of rapamycin-sensitive pathways and/or mTOR.
Suzuki et al., also demonstrated the importance of descending serotonergic
facilitation from higher brain centres acting at spinal 5-HT3Rs in the induction and
maintenance of neuropathy and this has also been confirmed in other studies
(Suzuki et al., 2004b; Suzuki et al., 2005; Rahman et al., 2006). The results form
Suzuki et al., whereby ondansetron is administered i.t. to neuropathic rats bears
striking similarity to that seen in this chapter. Suzuki et al., showed that
ondansetron produced robust inhibitions of the mechanically evoked responses in
SNL rats compared to sham rats or pre-drug controls, suggesting an enhancement in
the effectiveness of the drug after peripheral nerve injury (Suzuki et al., 2004b).
However, although neuronal responses to thermal stimuli were attenuated by
ondansetron, the drug’s effects on this modality did not differ between SNL and
sham rats. This similarity in results demonstrates that much like descending
facilitatory action at spinal 5-HT3Rs, rapamycin-sensitive pathways are also
enhanced after peripheral nerve injury and are particularly important for
mechanically evoked responses. In accordance with this is the study carried out by
Svensson et al. whereby ondansetron administered i.t. attenuated formalin-
induced behavioural hypersensitivity in a manner not dissimilar to rapamycin
(Svensson et al., 2006).  The possibility exists therefore of an interaction between
spinal 5-HT3Rs and intracellular rapamycin-sensitive pathways that act to induce
and maintain persistent pain-like states.
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6 Visualising rapamycin-sensitive pathways at the spinal
level
6.1 Introduction
The results so far have shown that rapamycin-sensitive pathways at the spinal level
are important in the induction and maintenance of neuronal hyperexcitability and
behavioural hypersensitivity, which arise as a result of direct nerve injury or tissue
damage. Immunohistochemistry is the only technique which can identify an antigen
in its tissue or cellular location (Polak and Van Noorden, 2003). It was therefore
decided that immunohistochemistry would be used to determine exactly where
rapamycin-sensitive pathways are active and therefore where rapamycin exerts its
action on mTOR.
6.1.1  Location of rapamycin-sensitive pathways
In terms of neuronal excitability, most of the immunohistochemistry studies
investigating the cellular and subcellular distribution of rapamycin-sensitive
pathways have been carried out on primary neurones in culture or hippocampal
slices. In terms of the subcellular distribution of these factors in hippocampal
neurones, it has been found that various components of rapamycin-sensitive
pathways i.e. eIF4E and 4EBP are distributed in a punctate pattern. Furthermore,
some of the immunopositive puncta correspond to synaptic regions as revealed by
synapsin double labelling. Specifically, the immunoreactivity signals for rapamycin-
sensitive components oppose and slightly overlap with the signals for synapsin-I
which is a presynaptic protein as well as overlapping with postsynaptic domain
protein 95 (PSD 95), therefore suggesting their localisation at postsynaptic sites. In
addition, mTOR-positive regions have been found in the dendritic shaft in a diffuse
pattern that extends into synaptic regions (Tang et al., 2002; Schratt et al., 2004).
Interestingly, it appears that the distribution of these signals depends partly on
their level of activation such that phospho p70S6K immunoreactivity is very low in
dendrites of hippocampal neurones and is restricted mainly to the soma until an
LTP-inducing stimulus is applied (Cammalleri et al., 2003), when dendritic
immunoreactivity increases.
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At the tissue level in hippocampal slices, immunostaining for various components of
rapamycin-sensitive pathways including eIF4E, 4EBP, mTOR and phsopho p70S6K
has revealed rapamycin-sensitive pathways to be active in the cell bodies of the
CA1 region (stratum pyramidale) as well as the dendrites of the CA1 region
(stratum radiatum). Furthermore, in accordance with studies on primary neurones,
dendritic immunoreactivity was shown to increase after the application of LTP-
inducing stimuli (Tang et al., 2002; Cammalleri et al., 2003; Tsokas et al., 2005;
Tsokas et al., 2007).
Perhaps more relevant to my studies, immunohistochemical staining of skin
sections from glaborous and adjacent hairy skin of adult rat hind paw has revealed
that mTOR and phospho mTOR are extensively expressed in subsets of primary
afferent sensory fibres. Specifically, mTOR appears to be restricted to fibres that
do not cross the dermal-epidermal junction i.e. A-fibres. To further substantiate
this, it has been found that all mTOR and phospho mTOR immunoreactivity
overlaps with that of N52 (a marker for myelinated A-fibres).  Furthermore,
intraplantar injections of rapamycin were found to reduce the immunoreactivity of
phosphorylated phospho p70S6K as well as reduce capsaicin-induced secondary
mechanical hypersensitivity and mechanical hypersensitivity to pinprick stimuli in
the SNI model, both features thought to be mediated by capsaicin-insensitive A-
fibres (Jimenez-Diaz et al., 2008).
Although rapamycin-sensitive pathways have been well characterised in the
peripheral nervous system at the level of the hind paw, there have been no studies
to date that have investigated the location of rapamycin-sensitive pathways at the
spinal level. In this chapter, immunohistochemistry techniques were used to study
rapamycin-sensitive pathways in DRG and the spinal cord of rats that had
undergone SNL.
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6.2 Methods
6.2.1 Spinal nerve ligation
Surgery, electrophysiological and behavioural studies were performed as described
in 2.4.
6.2.2 Immunohistochemistry
Standard immunohistochemistry and tyramide signal amplification were performed
as described in 2.6.
Details of primary antibodies and relevant secondary antibodies are given in table
6.1. All concentrations were based on suggestions from colleagues who had
previously used the antibodies, or by the suppliers themselves. In the case of
phospho p70S6K, a dilution of 1:50 in PBS plus 0.2 % v/v triton X-100 and 0.1 % w/v
sodium azide was used based on a study which probed for this protein in brain
slices (Damjanac et al., 2008). This concentration was tested firstly on brain
sections that were prepared in exactly the same way as the spinal cord and DRG
sections in an attempt to replicate the results using a modified protocol before
testing it on spinal cord slices. In order to confirm neuropathy in the sections being
analysed, the markers glial fibrillary protein (GFAP) and CGRP were used to label
glial cells and nociceptive primary afferent terminals containing CGRP respectively
in the superficial dorsal horn as these components have been shown to be altered
as a result of spinal nerve ligation (Zhuang et al., 2006; Kaku et al., 2007; Zheng et
al., 2008). Other markers of interest that were also stained for included N52 (200
kDa neurofilament or NF200), a marker of A-fibres (Ma, 2001) and PKCγ, a marker
of a subset of interneurones in the superficial dorsal horn (Polgar et al., 1999).
Specific lumbar regions were identified using a low power microscope and
comparing the structural morphology of the sections to a rat spinal cord atlas.
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Primary antibody Secondary antibody
Rabbit anti-phospho p70S6K Thr 389
(plus antigen unmasking and tyramide
signal amplification steps- see 2.6.3),
1:50, Cell signalling, USA
Bioy iny lated goat  ant i - rabbi t
Immunoglobulin G; 1:400; Vector
laboratories Inc, USA
Rabbit anti-CGRP, 1:200, Sigma Aldrich,
UK
Goat anti-rabbit Cyanine 3 (Cy3), 1:400,
Stratech, UK
Rabbit anti-GFAP, 1:5000, Dako, USA Goat anti-rabbit Cyanine 3 (Cy3), 1:400,
Stratech, UK
Mouse anti-NF200 (anti-N52); 1:500,
Sigma Aldrich, UK
Goat anti-mouse Cy3 1:400, Stratech,
UK
Rabbit anti-PKCγ, 1:500, Santa Cruz,
USA 
Goat anti-rabbit Cy3, 1:400m, Stratech,
UK
Table 6.1 Primary and secondary antibodies used to localise proteins of
interest.
6.2.3 Statistical analysis
For quantification of spinal cord immunohistochemistry, regions of interest
templates were set (one set of templates for the ipsilateral side and one set of
templates for the contralateral side) and maintained for all sections throughout the
analysis. Fluorescence levels were determined by calculating the mean grey value
using Image J 1.38x (USA) and corrected for background levels. All values were
then normalised to the side contralateral to the injury. For normalisation, all mean
grey values were normalised to the highest mean grey value of the contralateral
side for that region (total, medial or lateral). A Wilcoxon matched paired test was
then used to compare the normalised ipsilateral mean grey values to the
normalised contralateral mean grey values (*P<0.05; **P<0.01 ***P<0.001).
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6.3 Results
6.3.1 SNL results in loss of input to the spinal cord at L5
  
Figure 6.1 Effects of SNL on CGRP immunoreactivity in the spinal cord at L5.
Immunostaining for CGRP in (a) the dorsal horn ipsilateral (ipsi) to the injury
compared to (b) the dorsal horn contralateral (contra) to the injury was
significantly lower when normalised to the contralateral side for the total region of
interest. (c) CGRP fluorescence was found to be 17 + 11 % in the ipsilateral side
compared to 54 + 10 % in the contralateral side. (d, e, f) There were trends for a
reduction in input from the ipsilateral side compared to the contralateral side in
the medial region of interest of the dorsal horn, which is at the dorsal root entry
zone. (g, h, i) There were no significant differences between ipsilateral and
contralateral immunoreactivity in the lateral region of interest of the dorsal horn.
Scale bars = 100 µm. For all data sets, n = 12 sections from 3 rats (*P<0.05).
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6.3.2 SNL has no effect on input to the spinal cord at L4
  
Figure 6.2 Effects of SNL on CGRP immunoreactivity in the spinal cord at L4. (a,
b, c). There were no significant differences in immunoreactivity of the total region
of interest between the dorsal horn ipsilateral (ipsi) and contralateral (contra) to
the nerve injury. (d, e, f) Although there were trends for increases in
immunoreactivity of the ipsilateral medial region of interest, these did not prove
to be significant. (g, h, i) There were no significant differences in
immunoreactivity between the ipsilateral and contralateral sites at the lateral
region of interest. Scale bars = 100 µm. For all data sets, n = 9 sections from 3 rats.
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6.3.3 SNL has no effect on input to the spinal cord at L3
   
Figure 6.3 Effects of SNL on CGRP immunoreactivity in the spinal cord at L3. (a,
b, c) There were no significant differences in immunoreactivity of the total region
of interest, (d, e, f) the medial region of interest as well as (g, h, I) the lateral
region of interest between ipsilateral (ipsi) and contralateral (contra) sites to the
nerve injury. Scale bars = 100 µm. For all data sets, n = 9 sections from 3 rats.
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6.3.4 SNL induces astrogliosis in the spinal cord
Figure 6.4 Effects of SNL GFAP immunoreactivity in the spinal cord at L5.
Staining with anti-GFAP to probe for astroglia shows a marked increase in
immunoreactivity in the ipsilateral (ipsi) side compared to the contralateral
(contra) side, which is a well established sign of nerve injury. Scale bars = 100 µm.
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6.3.5 Establishing conditions for detecting phospho p70S6K
 
Figure 6.5 Phospho p70S6K immunoreactivity in cortical neurones and the CA1
of the hippocammpus. Since most immunohistochemistry studies probing for
phospho p70S6K have involved using brain sections, here brain sections were used
to validate the chosen protocol. Rabbit anti-phospho p70S6K  was used to probe for
phospho p70S6K  using antigen unmasking and tyramide signal amplification steps.
(a) Cortical neurones showing staining of the cell bodies as well as neuronal
processes. (b) Hippocampal CA1 region showing some staining of the cell bodies
(stratum pyramidale), but mainly staining of the dendrites (stratum radiatum) of
the CA1 region.  Scale bars = 50 µm.
147
Chapter 6
6.3.6 SNL results in a reduction in phospho p70S6K activity at L5
  
Figure 6.6 Effects of SNL on phospho p70S6K immunoreactivity in the spinal
cord at L5. Immunostaining for phospho p70S6K in (a) the dorsal horn ipsilateral
(ipsi) to the injury compared to (b) the dorsal horn contralateral (contra) to the
injury was found to be significantly lower when normalised to the contralateral
side for the total region of interest. (c) phospho p70S6K fluorescence was found to
be 23 + 10 % in the ipsilateral side compared to 56 + 8 % in the contralateral side.
(d, e, f) For the medial regions of interest, phospho p70S6K fluorescence was found
to be 30 + 11 % in the ipsilateral side compared to 61 + 8 % in the contralateral
side. (g, h, i) There were no significant differences between ipsilateral and
contralateral immunoreactivity in the lateral regions of the dorsal horn. Scale bars
= 100 µm. For all data sets, n = 11 sections from 3 rats (*P<0.05).
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6.3.7 SNL has no effect on phospho p70S6K activity at L4
  
Figure 6.7 Effects of SNL on phospho p70S6K immunoreactivity in the spinal
cord at L4. (a, b, c) There were no significant differences in immunoreactivity of
the total region of interest, (d, e, f) the medial region of interest as well as (g, h,
i) the lateral region of interest between ipsilateral (ipsi) and contralateral (contra)
sites to the nerve injury. Scale bars = 100 µm. For all data sets, n = 12 sections
from 3 rats.
149
Chapter 6
6.3.8 SNL has no effect on phospho p70S6K activity at L3
  
Figure 6.8 Effects of SNL on phospho p70S6K immunoreactivity in the spinal
cord at L3. (a, b, c) There were no significant differences in immunoreactivity of
the total region of interest, (d, e, f) the medial region of interest as well as (g, h,
i) the lateral region of interest between the dorsal horn at ipsilateral (ipsi) and
contralateral (contra) sites to the nerve injury. For all data sets, n = 11 sections
from 3 rats. Scale bars = 100 µm.
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In order to confirm specificity of the antibody against phospho p70S6K, control
experiments were carried out whereby the primary antibody (anti-phospho p70S6K)
was omitted from the protocol.
6.3.9 Anti-phospho p70S6K is antigen-specific
 
Figure 6.9 Effects of the omission of the primary antibody on phospho p70S6K
immunoreactivity. These sections were taken from L5 and the immunostaining
protocol for phospho p70S6K was followed in exactly the same way as that used to
obtain the previous results, except that the primary antibody was omitted from the
protocol. This resulted in a complete loss of immunoreactive signal for phospho
p70S6K in both the ipsilateral (ipsi) and contralateral (contra) sections. Scale bars
= 100 µm.
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Interestingly, immunoreactivity for phospho p70S6K was found to be restricted to a
specific region of the dorsal horn of the spinal cord i.e. the inner layer of lamina II.
This region is also known to contain a specialised group of small interneurones that
stain positive for PKCγ and have been shown to be important in nociception and
pain maintenance (Polgar et al., 1999). It was therefore decided to investigate
whether neurones expressing phospho p70S6K were also positive for PKCγ.
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6.3.10  Rapamycin-sensitive pathways are present in PKCγ-
expressing neurones
                    
Figure 6.10 Ipsilateral dorsal horn inner lamina II neuronal immunoreactivity for
phospho p70S6K and PKCγ. (a) Immunoractivity for phospho p70S6K shown in
green. (b) Immunoreactivity for PKCγ shown in red. (c) Merged images show
colocalisation of the two signals in orange. Scale bars = 50 µm.
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Spinal cord sections at L5 were also stained solely for PKCγ to see if the
immunoreactivity for this protein followed a similar pattern to the decrease in
immunoreactivity for phospho p70S6K.
6.3.11  Immunoreactivity for PKCγ is unaltered at L5
 
Figure 6.11 Dorsal horn immunoreactivity of PKCγ. Immunoreactivity of PKCγ
unlike phospho p70S6K, is unaltered at L5 at dorsal horn sites ipsilateral (ipsi) or
contralateral (contra) to the site of injury. Scale bars = 100 µm.
The role of rapamycin-sensitive pathways in the periphery at the level of the hind
paw has been covered elsewhere (Jimenez-Diaz et al., 2008). However, what was
not known was whether these pathways were also important in the periphery at
the level of primary afferent terminals that are located within the spinal cord. In
order to investigate this, DRG were sectioned and stained for phospho p70S6K in
order to determine which fibre types and therefore which primary afferent
terminals have the capacity for rapid protein translation.
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6.3.12  Immunoreactivity for phospho p70S6K is present in
DRG neurones
  
Figure 6.12 Phospho p70S6K immunoreactivity of C-fibres and A-fibres from
DRG ipsilateral to nerve injury. (a) Immunoreactivity for phospho p70S6K shown in
green. (b) Immunoreactivity for CGRP, a marker for small, unmyelinated C-fibres
shown in red. (c) Merged images show colocalisation of phospho p70S6K and CGRP
in C-fibres  (in orange). It was not possible to determine colocalisation of phospho
p70S6K and the marker for A-fibres (N52) using the protocol described in 2.6 (d, e,
f). Similar immunoreactivity patterns were also seen in contralateral DRG (data not
shown). Scale bars = 100 µm.
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To summarise, SNL results in a loss of primary afferent input to the ipsilateral
region of the spinal cord (L5) as shown by staining spinal cord sections with anti-
CGRP. At L4 and L3, where the spinal nerves were uninjured, this change in
immunoreactivity did not occur. SNL also results in astrogliosis in the same areas as
shown by staining spinal cord sections with anti-GFAP. After validating the
immunostaining protocol for phospho p70S6K in brain sections, immunostaining
with anti-phospho p70S6K antibody in spinal cord sections ipsilateral to the nerve
injury at L5 revealed that there was a decrease in immunoreactivity for phospho
p70S6K. Again, this change in immunoreactivity was not seen at L3 and L4 where
the spinal nerves were uninjured. Interestingly, immunoreactivity for phospho
p70S6K was found to be restricted to the inner layer of lamina II of the dorsal horn
and this is an area that is occupied by small interneurones that are immunopositive
for PKCγ. Double labelling spinal cord sections with anti-phospho p70S6K and anti-
PKCγ revealed that neurones positive for phospho-p70S6K appear to form part of a
larger population of neurones that are PKCγ-positive. However, unlike the decrease
in immunoreactivity for phospho p70S6K at dorsal horn sites ipsilateral to nerve
injury, PKCγ immunoreactivity was unaltered. Finally, immunoreactivity for
phospho p70S6K was examined in DRG as an indicator for possible activity in
primary afferent terminals at the level of the spinal cord. Double labelling for
phospho p70S6K with CGRP for small unmyelinated C-fibres revealed that
rapamycin-sensitive pathways are present in many of these fibres, at least at the
level of the DRG.
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6.4 Discussion
The previous results chapters up to this point have clearly identified a role for
rapamycin-sensitive pathways at the spinal level in the induction and maintenance
of persistent pain-like states. However what was not known was where these
pathways were active. This chapter set out to answer that question with the aid of
immunohistochemistry techniques on spinal cord and DRG sections.
In this study, it was found that SNL resulted in a decrease in immunoreactivity in
CGRP in superficial dorsal horn spinal cord regions ipsilateral to the site of injury
(see figures 6.1 – 6.3). This finding is in accordance with that by Zheng et al. who
found that following SNL, CGRP expression is not only reduced in the spinal cord,
but it is also reduced in DRG for at least 28 days (Zheng et al., 2008). CGRP is
therefore an excellent marker for confirming a neuropathic state at a purely
cellular level. It is important to note however that a reduction in immunoreactivity
is specific for SNL and other neuropathic models such as sciatic nerve crush and
spinal nerve transection will actually cause an increase in immunoreactivity for
CGRP in the spinal cord (Zheng et al., 2008). However, of importance here is that
CGRP can be reliably used as a marker for neuropathy and its role as a
multifunctional neuropeptide also means that these changes must at least in part
contribute to the behavioural phenotype associated with neuropathic pain.
SNL also induces marked astrogliosis as shown by immunostaining for GFAP (see
figure 6.4). This is an accordance with findings by Zhuang et al. who found that
astrogliosis is present at 3 weeks post-SNL. This therefore not only implicates
spinal astrocytes as having a potential role in maintaining persistent neuropathic
pain, but also highlights the usefulness of GFAP as a marker for neuropathy (Zhuang
et al., 2006).
Much like CGRP immunostaining, it was found that there was a decrease in
immunoreactivity for phospho p70S6K in superficial dorsal horn spinal cord regions
ipsilateral to the site of injury (see figures 6.6 – 6.8). This finding is of particular
interest because perhaps intuitively, based on previous studies particularly
concerning neuronal activity in the brain, a condition like neuropathy would be
157
Chapter 6
expected to result in an increase in p70S6K immunoreactivity. For example, in
hippocampal slices receiving high frequency stimulation in order to induce LTP,
there is an increase in dendritic phospho p70S6K immunoreactivity (Cammalleri et
al., 2003; Tsokas et al., 2005). In synaptosomes, phospho p70S6K immunoreactivity
was shown to increase after treatment with BDNF (Takei et al., 2004).
Furthermore, phospho p70S6K immunoreactivity has been shown to increase after
learning in a fear conditioning paradigm (Parsons et al., 2006). Although, in a
transgenic mouse model of Alzheimer’s disease, immunoblotting for phospho
p70S6K has revealed that there is less activity in these transgenic mutants
compared to their WT littermates (Damjanac et al., 2008).
In terms of the results seen in this chapter, a decrease in immunoreactivity may
mean that rapamycin and CCI-779, which are less active in naive animals now exert
much more of an inhibitory action because there is less ‘signal’ to inhibit. This
reduction in immunoreactivity presumably arises from a reduction of input to the
spinal cord from primary afferent fibres, some of which are CGRP containing
neurones, so it would be interesting to see how this result would vary depending on
the neuropathic pain model that is studied. However, although it is clear that there
is a reduction in immunoreactivity of phospho p70S6K, what is not clear is what
role these rapamycin-sensitive pathways are playing in the neurones in which the
activity remains. Is there an increase in turnover in pathway activity that
contributes to neuropathy? Are these neurones inhibitory interneurones such that
any decrease in activity in these neurones leads to disinhibition of a sensitised
system and thus the pathophysiological changes associated with neuropathy? In
addition, phospho p70S6K has also been identified in astrocytes albeit to a lesser
extent than neurones (Damjanac et al., 2008). The focus of this study has been on
neuronal activity, however, the contribution of non-neuronal cells to the various
features of neuropathy have been well documented (see section 1.8)
The restricted localisation of phospho p70S6K is of particular interest in this study
because these neurones are restricted mainly to the inner layer of lamina II and
this is where neurones that show immunoreactivity for PKCγ also reside. Double
labelling of sections for both PKCγ and phospho p70S6K revealed extensive overlap
therefore confirming that phospho p70S6K-positive neurones also express PKCγ (see
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figure 6.10). PKCγ is important because it has been shown that mice that lack the
PKCγ isoenzyme fail to develop neuropathic pain-like syndromes and the
neurochemical changes that occur in the spinal cord after nerve injury (Malmberg
et al., 1997).
Besides being located in inner lamina II, PKCγ interneurones have also been shown
to be present in lamina III, with some weak immunoreactivity in lamina I and the
outer layer of lamina II. Most PKCγ-positive neurones are not GABA or µ-opioid
receptor-immunoreactive (Polgar et al., 1999), therefore substantiating their roles
as excitatory interneurones that have roles in the induction and maintenance of
persistent pain-like states. It is important to note that expression of PKCγ, unlike
phospho p70S6K did not appear to decrease (see figure 6.11). This suggests that
PKCγ-positive neurones rely on input from primary afferent fibres in order to
engage intracellular rapamycin-sensitive pathways.
Interestingly, each spinal segment receives nociceptive fibre inputs from several
segmental dorsal roots.  And it has recently been found that one third of lamina II
interneurones receive simultaneous monosynaptic inputs from two to four different
segmental roots. For lamina II interneurones, the major synaptic input has been
found to be from the L4 - L6 roots, whereas for those located in L3, the input was
from the L2 - L5 roots. Thus a new model is proposed whereby several C- or Aδ-
fibres innervating one cutaneous region (peripheral convergence) and ascending
together in a common peripheral nerve may first diverge at the level of the spinal
nerves and enter the spinal cord through different segmental dorsal roots, but
finally reconverge monosynaptically onto a single lamina II interneurone (Pinto et
al., 2008). This model of organisation suggests that there will be changes seen in
lamina II interneurones in L4 as a result of the loss of primary afferent input after
SNL that is due to loss of inputs form L5 and L6. Yet, my results show that the
reduction seen in denervated L5 and L6 in p70S6K are not replicated in L4,
suggesting some upregulation in this signal in this segment (see figures 6.1 - 6.3
and 6.6 - 6.8), thus contributing to an increase in dorsal horn excitability and
central sensitisation.
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Initially, it was widely accepted that PKCγ interneurones in the spinal cord receive
their input from unmyelinated, non-peptidergic, IB4-positive nociceptors (Snider
and McMahon, 1998). However, there is now recent evidence to dispute this
(Neumann et al., 2008). In their study, Neumann et al. showed that the terminal
field of IB4-positive neurones in fact lies dorsal to that of PKCγ interneurones. In
contrast, medium diameter and large diameter myelinated afferents that are
generally associated with innocuous signal transmission and express the vesicular
glutamate transporter VGluT1, were found to extensively overlap with PKCγ
interneurones. Furthermore, PKCγ interneurones were specifically activated by
innocuous input generated by rotarod-induced locomotion. These studies suggest
that A-fibre mediated transmission should be affected by rapamycin and CCI-779,
however, when observing the data in chapter 3 (see figure 3.2) and chapter 5 (see
figure 5.8), this was not the case, as C-fibre mediated transmission was affected by
these drugs to a greater extent than Aβ- or Aδ-fibre mediated transmission. This
may be due to the fact that all fibres are stimulated at three times the C-fibre
threshold during an electrical stimulus train. Whilst this means that nociceptive
specific C-fibre wind up can be studied, it may also be the case that this stimulus is
excessively suprathreshold for A-fibres and therefore that all A-fibre mediated
changes are masked. However, even in SNL rats, where CCI-779 had a greater
inhibitory effect on mechanically evoked responses, dynamic innocuous brush
evoked responses and low mechanical stimuli below 8 g, which we can assume to
be mainly mediated by A-fibres, were not affected by CCI-779 (see figures 5.9 –
5.10). My studies therefore suggest that the net effect of rapamycin and CCI-779 is
an inhibitory effect on C-fibre mediated transmission onto WDR neurones and
therefore noxious stimulus evoked responses.
Interestingly, CGRP nociceptors were found to be immunoreactive for phsopho
p70S6K in DRG (see figure 6.12). This finding is at odds with the findings by
Jimenez-Diaz et al., who found that in the periphery, at the level of the hind paw,
all phospho mTOR and mTOR staining was found to co-exist with N52
immunoreactivity in A-fibres that do not penetrate the dermal-epidermal junction,
indicating that mTOR is largely restricted to myelinated A-fibres (Jimenez-Diaz et
al., 2008).  This apparent contradiction may be due to a mismatch between
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immunoreactivity in DRG and immunoreactivity at afferent terminals even though
it is generally accepted that in most studied cases, the transport of molecules from
DRG is in both directions to the periphery and along the central processes that
terminate within the superficial dorsal horn. It is important to note however that
Jimenez-Diaz et al. did find that rapamycin affected thresholds of some C-fibres
confirming that rapamycin-sensitive pathways are also important in C-fibre
mediated transmission. Furthermore, the mTOR binding protein raptor was found
to be expressed in a small proportion of N52- negative fibres (Jimenez-Diaz et al.,
2008).
Taken together, these studies suggest a link between primary afferent fibres, PKCγ
and rapamycin-sensitive pathways. However, these are not the first studies to
report links between PKC and rapamycin-sensitive pathways. In studies examining
5HT-induced long-term facilitation, phosphorylation of p70S6K and the rapamycin-
sensitive increase in the synthesis and secretion of the sensory neurone
neuropeptide sensorin has been shown to be dependent on PKC (Khan et al., 2001;
Hu et al., 2007). Although PKC/PKCγ are clearly not the only upstream regulators
of mTOR,  these studies suggest a strong role for double labelled PKCγ-phospho
p70S6K interneurones as well as primary afferent fibre terminals in the induction
and maintenance of persistent pain states.
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7 Rapamycin-sensitive pathways and upstream
regulation by 5-HT
7.1 Introduction
Although the focus to this point has been on spinal mechanisms of pain
maintenance, it is important to note that in these intact in vivo preparations, there
will be an active component of descending modulation from the brain stem and
higher centres in the brain that act on spinal neurones and peripheral afferent
terminals, which also play an important role in pain maintenance. One major
contributor to descending modulation of spinal neurones and primary afferent
terminals is 5-HT. Relevant to pain processing, the predominant supraspinal source
of 5-HT is the RVM, which can either enhance or dampen down incoming
nociceptive signals from primary afferent fibres depending on the receptors that
are activated (Millan, 2002).
7.1.1 5-HT-dependent neuronal hyperexcitability and behavioural
hypersensitivity
With more than 15 receptor subtypes that are not solely confined to pain
pathways, it is not surprising that 5-HT can exert a diverse range of physiological
and pathological effects which are all dependent to some extent on serotonergic
neurotransmission (Suzuki et al., 2004a).  This diversity partly explains the
conflicting views on the action of 5-HT at specific receptors as either a pro-
nociceptive or anti-nociceptive transmitter. Serotonergic modulation of
nociceptive processing in the spinal cord is mediated via the action of 5-HT on
peripheral afferent fibres that terminate on neuronal cells, acting to either inhibit
or facilitate neurotransmitter release onto spinal neurones; or by directly acting on
serotonergic receptors on dorsal horn neurones themselves (Millan, 2002). Despite
the diversity of serotonergic receptors and the opposing effects that the
neurotransmitter may impart, dissecting out the serotonergic system in pain
pathways has become a point of focus in understanding chronic pain conditions and
more recently, there has been a greater emphasis on understanding the role of
descending facilitation mediated by 5-HT.
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5-HT is delivered to the spinal cord via the brain stem and higher centres in the
brain (Millan, 2002). The obvious involvement of descending 5-HT pathways has, in
recent times lead researchers to alter the activity of endogenous pathways in an
attempt to further clarify the importance of 5-HT in maintaining persistent pain
states. One research group has investigated this by administering the selective
serotonergic neurotoxin 5,7 dihidroxytryptamine (5,7 DHT) i.t. to rats in order to
deplete endogenous spinal 5-HT (Rahman et al., 2006). The effect of this
procedure was examined in naive rats as well as rats that had undergone SNL.
Electrophysiological studies of naive rats that had been given 5,7 DHT showed
reductions in mechanically and thermally evoked responses of WDR neurones
compared to rats given saline, suggesting that at the spinal level, 5-HT exerts a
mainly facilitatory effect under physiological conditions. This effect was also seen
behaviourally in rats that had undergone SNL after 5,7 DHT administration, i.e. SNL
rats displayed attenuated responses to innocuous mechanical and cold stimuli
compared to SNL rats that had received saline. These 5-HT associated changes
were also independent of other spinal changes such as upregulation of NK1
receptors and microgliosis.
The studies by Rahman et al. suggest that supraspinal influences mediated by 5-HT
are facilitatory and are responsible at last in part for the neuronal and behavioural
changes associated with nerve injury-induced pain-like syndromes. Taking these
studies a step further, another group have studied the pain-like behaviour of a
conditional KO mouse (Lmx1bf/f/p) which completely lacks 5-HT neurones in the CNS
(Zhao et al., 2007). These mice were found to exhibit normal basal thermal
sensitivity and visceral pain-like responses, although mechanical sensitivity was
reduced compared to WT littermates. In the capsaicin-induced inflammatory pain-
like model, there was an increase in the duration of mechanical behavioural
hypersensitivity in these KO mice, which was reduced when these mice were
administered 5-HT i.t. Furthermore, the analgesic effects of the antidepressants
such as fluoxetine and amytriptilline were not as effective in the KO mice
compared to the effects in WT mice, confirming a requirement of 5-HT for
antidepressants to exert their pain-relieving effects These studies suggest that
although the main role of the central 5-HT-mediated transmission in inflammatory
hypersensitivity is inhibitory, its role in acute mechanical nociception is
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facilitatory. This apparent contradiction in findings is not surprising and it is
evident that different approaches that study different pain-like models or employ
different methods and/or tools of altering the serotonergic system as well as
studying it, will lead to different conclusions. What is undoubtedly true is that 5-
HT is crucial to the modulation of nociception and persistent pain-like states.
Although the role of 5-HT in the induction and maintenance of persistent pain
states is not clear-cut, recent studies have focussed on the role of the 5-HT3R,
which, unlike all the other 5-HTRs, is the only ligand gated ion channel (Barnes and
Sharp, 1999; Millan, 2002). 5-HT3Rs are located on the terminals of glutamate
releasing myelinated primary afferent fibres as well as excitatory interneurones
and some NK1 projection neurones in lamina I/III (Conte et al., 2005). As previously
mentioned, 5-HT3Rs can be inhibited by the selective antagonist ondansetron. In
the formalin test, pre-treatment with a single i.t. dose of ondansetron
administered directly to the exposed spinal cord has been shown to attenuate
neuronal hyperexcitability in both phases of the test, therefore highlighting the
peripheral and central effects of 5-HT3R activation in neuronal hyperexcitability in
a pain-like state (Green et al., 2000; Suzuki et al., 2002). In accordance with these
studies is a study showing that ondansetron attenuates second phase formalin-
induced behavioural hypersensitivity when administered 15 min prior to formalin
injection (Svensson et al., 2006).  Also, in SNL rats, a low dose of ondansetron
which has no effects on neuronal responses from WDR neurones of sham rats, is
effective in attenuating responses evoked by mechanical stimuli (Suzuki et al.,
2004b). Furthermore, in a rat model of cancer-induced bone pain, the inhibitory
effects of ondansetron i.t. on mechanically and thermally evoked responses are
significantly greater compared to sham rats (Donovan-Rodriguez et al., 2006).
Substantiating the role of 5-HT3Rs in pain maintenance further, KO mice lacking
the A subunit of the 5-HT3R, which is required for functionality of the receptor,
have been shown to display normal acute pain-like responses, but ongoing
hypersensitivity produced by formalin-induced inflammation is attenuated (second
phase only) (Zeitz et al., 2002). Taken together, these results show that 5-HT
facilitates persistent pain-like states via activation of 5-HT3Rs most likely due to
an increased descending serotonergic drive from the brain and in particular, the
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RVM (Suzuki et al., 2004a). In accordance with these findings, in a small
randomised double-blind study, a single intravenous bolus of ondansetron has been
shown to alleviate the overall pain experienced by neuropathic pain patients
(McCleane et al., 2003).
Interestingly, not all pain models involve altered serotonergic activity at 5-HT3Rs.
Carrageenan-induced inflammation has been shown to produce mechanical and
behavioural hypersensitivity as well as significant neuronal plasticity (Kayser and
Guilbaud, 1987; Stanfa et al., 1992). However, electrophysiological approaches
have shown that when ondansetron is administered i.t. to rats with carrageenan-
induced inflammation, stimulus evoked neuronal responses are inhibited to the
same degree in both naive and carrageenan-injected rats (Rahman et al., 2004).
Therefore, in this model, the spinal plasticity and the behavioural hypersensitivity
are mediated by different mechanisms.
7.1.2 5-HT-dependent neuronal hyperexcitability and rapamycin-
sensitive pathways
Studies on Aplysia have demonstrated that endogenous 5-HT is important for basic
reflexes (Glanzman et al., 1989). In these studies Aplysia were treated with 5,7
DHT to deplete endogenous 5-HT which resulted in a reduction in the
dishabituation (enhancement of responses after habituation) of the withdrawal
reflex produced by tail shock as well as reduced plasticity of the siphon sensory
neurones and corresponding motor neurones. These studies therefore indicate that
5-HT plays important roles in mediating dishabituation and sensitisation of the
Aplysia withdrawal reflexes. In accordance with these findings, exogenous 5-HT has
been shown to induce LTH of Aplysia neurones that can be blocked by prior
treatment with rapamycin. Furthermore, localised 5-HT application to nerve
segments will induce local axonal (and not somal) LTH that is inhibited by the 5-HT
antagonist methiothepin (Casadio et al., 1999; Weragoda and Walters, 2007).
In an attempt to dissect out the components of the rapamycin-sensitive pathways
that are important in contributing to 5-HT-induced LTH, Khan et al., examined the
effect of rapamycin on the phosphorylation of p70S6K and found that p70S6K
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phosphorylation was attenuated by rapamycin as well as an inhibitor of PKA
(KT5720) and PKC (chelerythrine) (Khan et al., 2001). These results demonstrate
that 5-HT can engage rapamycin-sensitive pathways and involves PKA and PKC. 5-
HT has also been shown to decrease eEF2 phosphorylation, another downstream
effector of mTOR that is inactivated by phosphorylation (Carroll et al., 2004).
The results from the previous chapters clearly demonstrate a link between
persistent pain-like states and rapamycin-sensitive pathways. In addition, these
persistent pain-like states are known to involve descending facilitatory
serotonergic pathways mediated at least in part by 5-HT3Rs. The aim of this
chapter was to investigate a possible link between 5-HT3Rs and rapamycin-
sensitive pathways in rats using electrophysiological techniques. Specifically, the
selective 5-HT3R antagonist ondansetron was used to block 5-HT3Rs and the
selective 5-HT3R agonist 2-methyl-5-HT was used to activate these receptors. In
addition, the carrageenan-induced inflammation model where descending
serotonergic facilitation at 5-HT3Rs is not altered was also studied.
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7.2 Methods
7.2.1 In vivo electrophysiology
See 2.2. All drugs were added i.t. to the exposed spinal cord in a volume of 50 µl.
Tests were carried out every 20 min for 1 hr. In the studies using ondansetron to
study the interactions between 5-HT3Rs and rapamycin-sensitive pathways, WDR
neurones were first pre-treated with ondansetron (100 µg in 50 µl saline) or saline
10 min prior to rapamycin (250 nM or 11.43 ng in 50 µl saline/DMSO) which was also
on the cord for 10 min prior to the first set of tests. In separate experiments, CCI-
779 (250 nM or 12.88 ng in 50 µl saline) or a low dose of ondansetron (10 µg in 50 µl
saline) was administered to the exposed spinal cords of rats with 2 % w/v
carrageenan-induced inflammation (see 2.5) to determine if rapamycin-sensitive
pathways are involved in this model of persistent hypersensitivity and also if
serotonergic pathways which are affected by low dose ondansetron in neuropathic
animals (Suzuki et al., 2004b) are also affected by low dose ondansetron in this
model. Finally, to investigate the rapid mode of action of CCI-779, a facilitatory
dose of the selective 5-HT3R agonist 2-methyl 5-HT (0.1 µg in 50 µl saline) was
administered i.t. to rats after CCI-779 had been administered 2 hr earlier. For all
these experiments, maximal changes in neuronal responses (positive or negative)
over 1 hr were analysed.
7.2.2 Statistical analysis
Electrophysiological raw data are presented as mean + SEM response (no. of spikes
evoked by a given stimulus). When determining significant differences between
neuronal responses for which there were only two groups, student’s t-tests were
used to compare differences in Aβ-, Aδ-and C-fibre firing, post discharge, input,
wind up, brush and pin (unpaired for 7.3.2; paired for 7.3.4, 7.3.5 and 7.3.6). Two
way ANOVA with repeated measures and Bonferroni post-tests were used to
determine significance between groups for natural graded stimuli i.e. graded
mechanical and thermal stimuli (*P<0.05; **P<0.01 ***P<0.001).
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7.3 Results
7.3.1 Neurones selected for saline or ondansetron pre-treatment
prior to rapamycin were not significantly different
Saline (n = 7) Ondansetron (n = 6)
Depth (µM) 620 + 30 636 + 27
Aβ-fibre threshold (mA) 0.87 + 0.06 0.66 + 0.11
C-fibre threshold (mA) 1.60 + 0.18 1.23 + 0.19
Aβ-fibre spikes 102 + 25 154 + 10
Aδ-fibre spikes 55 + 15 70 + 20
C-fibre spikes 235 + 28 215 + 38
Post-discharge spikes 140 + 26 194 + 64
Input spikes 304 + 48 320 + 64
Wind up spikes 158 + 48 235 + 84
Brush Spikes 336 + 109 542 + 77
1 g Spikes 46 + 24 27 + 18
6 g Spikes 256 + 74 210 + 48
8 g Spikes 360 + 115 314 + 49
15 g Spikes 457 + 125 506 + 75
26 g Spikes 593 + 142 669 + 70
60 g Spikes 707 + 151 945 + 95
35 °C spikes 248 + 79 333 + 93
40 °C spikes 313 + 103 430 + 94
45 °C spikes 547 + 141 802 + 95
48 °C spikes 724 + 144 987 + 122
50 °C spikes 858 + 128 1120 + 133
Table 7.1 Characterisation of WDR neurones selected for ondansetron or saline
pre-treatment prior to rapamycin. For electrically evoked responses, a train of 16
pulses at three times C-fibre threshold (0.5 Hz, 2 ms pulse width) was applied to
the corresponding hind paw. For naturally evoked responses, von Frey filaments or
a small water jet was applied to the corresponding hind paw for 10 s. All data are
expressed as raw mean values + SEM.
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7.3.2 Electrically and brush evoked neuronal responses show no
link between spinal 5-HT3R activation and rapamycin-
sensitive pathways
       
Figure 7.1 Effects of rapamycin on electrically and brush evoked neuronal
responses after ondansetron and saline pre-treatment. (a) Aβ-, Aδ-, C-fibre
mediated transmission as well as post-discharge  (PD), (b) input and wind up
(spikes after a train of 16 pulses) and (c) brush evoked activity (spikes during a 10 s
stimulus) were not significantly different when the spinal cord was pre-treated
with a high dose of ondansetron 10 min prior to rapamycin  (Ond-Rap, n = 6)
compared to when the spinal cord was pre-treated with saline 10 min prior to
rapamycin (Sal-Rap, n = 7).
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7.3.3 Spinal 5-HT3R activation due to noxious mechanically and
thermally evoked neuronal responses engages rapamycin-
sensitive pathways
 
Figure 7.2  Effects of rapamycin on graded mechanically and thermally evoked
neuronal  responses after ondansetron and saline pre-treatment.  (a) When the
spinal cord was pre-treated with ondansetron 10 min prior to rapamycin, there was
significantly less inhibition of noxious mechanically evoked responses compared to
saline pre-treatment. Responses for ondansetron pre-treatment  (Ond-Rap, n = 7)
were 550 + 60 and 744 + 138 spikes for 26 and 60 g respectively. Responses for
saline pre-treatment  (Sal-Rap, n = 6) were 262 + 60 and 430 + 67 spikes for 26 and
60 g respectively. (b) When the spinal cord was pre-treated with ondansetron 10
min prior to rapamycin, there was significantly less inhibition of noxious thermally
evoked stimuli compared to saline pre-treatment.  Responses for ondansetron pre-
treatment (Ond-Rap, n = 7) were 818 + 176 and 1026 + 228 spikes for 48 and 50 °C
respectively. Responses for saline pre-treatment   (Sal-Rap, n = 6) were 377 + 60
and 416 + 62 spikes for 48 and 50 °C respectively. Spikes = number of spikes during
a 10 s stimulus (*P<0.05; **P<0.01).
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These results seem to suggest that there is an interaction between 5-HT acting at
5-HT3Rs and rapamycin-sensitive pathways. In order to probe this interaction
further, in vivo electrophysiology was used to study the effects of CCI-779 on
inflammation induced by carrageenan, a model whereby at 3 hr, descending
serotonergic pathways acting at 5-HT3Rs are unaltered (Rahman et al., 2004).  In
addition to these studies, the effects of a low dose of ondansetron that has been
shown to be effective in pain-like states where descending serotonergic pathways
acting at excitatory 5-HT3 pathways are active (Suzuki et al., 2004b) was studied in
the carrageenan-induced inflammation model. Finally, the duration of suppression
of rapamycin-sensitive pathways by CCI-779 was also tested by activating spinal 5-
HT3Rs with the agonist 2-methyl 5-HT, which normally produces modest
facilitations (Suzuki et al., 2005), after 2 hr of CCI-779 pre-treatment to confirm
the long-lasting effects suggested in chapter 3.
171
Chapter 7
7.3.4 CCI-779 has no effect on neuronal responses from rats with
carrageenan-induced inflammation
    
Figure 7.3 Effects of CCI-779 on neuronal responses from rats with
carrageenan-induced inflammation.  (a) There were no significant effects of CCI-
779 on pre-drug control responses after carrageenan-imduced inflammation was
established for electrically evoked Aβ, Aδ, C-fibre mediated transmission as well as
post discharge (PD); (b) input and wind up (spikes after a train of 16 pulses); (c)
brush and pinprick evoked responses as well as (d) graded mechanically and (e)
graded thermally evoked responses (spikes during a 10 s stimulus). For all data
sets, n = 10.
172
Chapter 7
7.3.5 Serotonergic activity at spinal 5-HT3Rs is unaltered by
carrageenan-induced inflammation.
    
Figure 7.4 Effects of ondansetron on neuronal responses from rats with
carrageenan-induced inflammation. (a) There were no significant effects of
ondansetron on pre-drug control responses after carrageenan-induced inflammation
was established for electrically evoked Aβ-, Aδ-, C-fibre mediated transmission as
well as post discharge (PD); (b) input and wind up (spikes after a train of 16
pulses); (c) brush and pinprick evoked responses as well as (d) graded mechanically
(e) graded thermally evoked responses (spikes during a 10 s stimulus). For all data
sets, n = 9.
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7.3.6 CCI-779 is still inhibitory at 2 hr post-administration
     
Figure 7.5 Effects of 2-methyl 5-HT administration on neuronal responses after
2 hr CCI-779 pre-treatment. (a) There were no significant effects of excitatory 2-
methyl 5-HT on stimulus evoked responses after 2 hr CCI-779 pre-treatment for
electrically evoked Aβ, Aδ, C-fibre mediated transmission as well as post discharge
(PD). (b) Input was also unnaffected but wind up was significantly inhibited  from
271 + 19 to 153 + 40 spikes (spikes after a train of 16 pulses). (d) Graded
mechanically (e) graded thermally evoked responses were unaffected by excitatory
2-methyl 5-HT after 2 hr CCI-779 pre-treatment (spikes during a 10 s stimulus). For
all data sets, n = 9.
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To summarise, the inhibitory effects of rapamycin, were significantly reduced for
graded mechanically and thermally evoked neuronal responses when the spinal
cord was pre-treated with the selective 5-HT3R antagonist ondansetron. These
results imply that descending serotonergic facilitation acting at 5-HT3Rs engage
rapamycin-sensitive pathways. This was further substantiated in experiments
examining rapamycin-sensitive pathways in a persistent pain-like state where
descending serotonergic activity at 5-HT3Rs is unaltered i.e. carrageenan-induced
inflammation. In these experiments, CCI-779 was ineffective in attenuating
stimulus evoked neuronal responses. This was also the case with a dose of
ondansetron that is known to have effects on stimulus evoked neuronal responses
in SNL rats (Suzuki et al., 2004b). Finally, the time course of CCI-779 action was
investigated by pre-treating the cord with CCI-779 for 2 hr prior to the addition of
the facilitatory drug 2-methyl 5-HT. In these studies, CCI-779 was effective in
attenuating wind up even 2hr after initial treatment with CCI-779.
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7.4 Discussion
The results preceding this chapter showed that rapamycin-sensitive pathways were
activated in persistent pain-like states that are known to involve activated
descending serotonergic transmission that is facilitatory at spinal 5-HTRs.  The aim
of this chapter was to use pharmacological approaches to confirm that this was in
fact true.
The selective 5-HT3R antagonist ondansetron has been shown to have inhibitory
effects on stimulus-induced neuronal activity when administered i.t. in
electrophysiological studies of persistent pain-like states (Green et al., 2000;
Suzuki et al., 2002; Suzuki et al., 2004b; Suzuki et al., 2005). Interestingly, by pre-
blocking 5-HT3R activation in naive animals, the inhibitory effects of rapamycin
were reduced significantly for graded mechanically and thermally evoked stimuli,
therefore suggesting that 5-HT3R activation engages rapamycin-sensitive pathways
and also that descending facilitatory action of serotonergic pathways at 5-HT3Rs is
permissive for the inhibitory action of rapamycin (see figures 7.1 and 7.2).
The permissive action by descending serotonergic activity at 5-HT3 receptors for
the inhibitory action of rapamycin was further confirmed by two in vivo
electrophysiology experiments utilising the carrageenan-induced inflammation
model. Although this model has been shown to present behavioural hypersensitivity
at 3 hr post carrageenan injection (Hedo et al., 1999) that is partly due to an
increase in spinal inflammatory mediators such as prostaglandins (Yang et al.,
1996), in vivo electrophysiology has revealed that in this pain-like state at this time
point, descending serotonergic activity at  5-HT3Rs is unaltered (Rahman et al.,
2004). The results from this chapter revealed that the rapamycin analogue CCI-779
had no significant effects on any stimulus evoked neuronal responses in rats where
inflammation had been induced by carrageenan injection into the hind paw (see
figure 7.3). This was also the case for a low dose of ondansetron (10 µg in 50 µl
saline) which has been shown to be effective in attenuating stimulus evoked
neuronal activity from rats with SNL (Suzuki et al., 2004b). Taken together, these
results confirm that rapamycin-sensitive pathways are dependant at least in part
upon descending serotonergic facilitation at 5-HT3Rs. It is important to note that
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rapamycin-sensitive pathways could in theory, be activated by descending
modulation at other excitatory or inhibitory receptors. However, persistent pain-
like states involve shifts in neuronal thresholds and neuronal excitability to
comparatively more excitatory states.  Given what is already known about the
importance of 5-HT3Rs in this process, excitatory 5-HT3R activation at the spinal
level appears to be an important prerequisite for the activation of rapamycin-
sensitive pathways.
Interestingly, although descending activation of spinal 5-HT3Rs is not altered at 3
hr, it may well be altered at a later time point. Indirect evidence of this comes
from the study by Hedo et al. who showed that maximal behavioural
hypersensitivity occurred at 3 hr post carrageenan injection. However, at 20 hr
post carrageenan injection when thermal hypersensitivity fades and mechanical
hypersensitivity remains, in an in vitro preparation using isolated spinal cord to
measure spinal reflexes, it was found that there were significant increases in the
responses to both single high intensity stimuli and to trains of stimuli, as well as a
novel form of wind up that was induced by low intensity stimuli (Hedo et al.,
1999). In addition, NMDA function is increased following 20 hr of carrageenan-
induced inflammation (Rygh et al., 2001).
Mechanistically, although 5-HT has been shown to be important in engaging
rapamycin-sensitive pathways (Casadio et al., 1999; Khan et al., 2001; Carroll et
al., 2004; Weragoda and Walters, 2007), this the first study using these approaches
to show specifically, that 5-HT3Rs are important upstream modulators of
rapamycin-sensitive pathways. 5-HT3Rs are located on primary unmyelinated
glutamatergic afferent terminals, excitatory interneurones as well as lamina I/III
projection neurones (Zeitz et al., 2002; Conte et al., 2005). The results from
chapter 6 show that rapamycin-sensitive pathways are present in spinal neurones
and DRG and therefore likely to be present in afferent terminals, which has already
been shown at the level of the hind paw (Jimenez-Diaz et al., 2008). Therefore,
rapamycin-sensitive pathways may have different effects at different sites. At
afferent terminals in the spinal cord, 5-HT3R activation would lead to an influx of
Ca2+, which could lead to activation of rapamycin-sensitive pathways via a Ca2+
dependent mechanism similar to NMDA mediated activation. These rapamycin-
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sensitive pathways may contribute to glutamate release from nociceptive afferents
into the spinal cord. Glutamatergic release into the dorsal horn of the spinal cord
could then further activate and facilitate spinal neurones including excitatory
interneurones. Activation of these excitatory interneurones via mGluRs and/or
NMDARs engages rapamycin-sensitive pathways in spinal neurones that enhance
dorsal horn neuronal excitability and these pathways may be more prominent
particularly in persistent pain-like states.
The results in chapter 3 showed that in naive rats, CCI-779 has most significant
inhibitory effects on stimulus evoked neuronal responses at >1 hr post i.t.
administration (see figure 3.7). However, when rats had undergone SNL, the most
significant inhibitory effects of CCI-779 were shifted to <1 hr. In this chapter, the
selective 5-HT3R agonist 2-methyl 5-HT was used to mimic injury-induced
activation of descending serotonergic activity at 5-HT3R (Suzuki et al., 2005). 2-
methyl 5-HT was administered 2 hr after CCI-779 pre-treatment to investigate the
probable time course of drug efficacy. Normally, 2-methyl 5-HT would be expected
to cause modest facilitations of neuronal stimulus evoked responses. However, at 2
hr post rapamycin pre-treatment, these facilitations were absent and in the case of
wind up, there was a significant inhibition when compared to pre-2-methyl 5-HT
responses. These effects were likely due to the inhibitory action of CCI-779,
confirming that CCI-779 can inhibit rapamycin-sensitive pathways for more than 1
hr even though the maximal effects are within the first hr of administration.
However, determining if the immediate (<1 hr) actions of CCI-779 involve the same
mechanisms as the later effects (>2 hr) would need further investigation.
Importantly, these studies provide a link between peripheral activity, spinal cord
excitability, descending serotonergic activity and rapamycin-sensitive pathways,
providing new insights into the importance of protein translation mechanisms and
persistent pain states.
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8 Final discussion
Protein translation and therefore protein synthesis are physiological processes that
are important to all living cells. Using rapamycin and the rapamycin ester CCI-779-
two inhibitors of mTOR activity, I have shown that at the spinal level, protein
translation that utilises mTOR is required for nociception and pain maintenance
and can be engaged by descending pathways from higher brain centres.
8.1 Rapamycin-sensitive pathways are upregulated in persistent
pain-like models
In vivo electrophysiology studies showed that in naive rats, rapamycin administered
i.t. produced a dose-dependent inhibition of C-fibre mediated transmission to the
spinal cord (see figure 3.2), as well as inhibition of mechanically evoked responses
(see figure 3.3), although thermally evoked neuronal responses remained largely
unaltered (see figure 3.4). Consequentially, in the formalin-induced inflammation
model, when rapamycin was administered i.t. 3 min prior to formalin injected into
the hind paw, there was a significant attenuation of the second phase of the
formalin test. This was confirmed in behavioural studies where rapamycin was
injected i.t. into lightly anaesthetised rats after which, they were allowed to
recover before injecting dilute formalin solution into the hind paw. In these
studies, rapamycin also inhibited behavioural hypersensitivity in both phases of the
formalin test, therefore confirming a role for rapamycin-sensitive pathways in
persistent pain-like states.
It would be logical to assume that if anaesthesia during the lumbar i.t. injection
were not a factor, then the effects of rapamycin, like that in the
electrophysiological studies would be seen as early as 3 min. However, the only
feasible way to achieve this, whilst satisfying Home Office guidelines would be to
implant a small polyethylene catheter through the atlanto-occipital membrane and
down to the lumbar enlargement of the spinal cord. This procedure could be
performed e.g. a week in advance of behavioural studies in order to allow for
recovery from the procedure and would remove the need for anaesthesia during
the administration of rapamycin to the spinal cord. However, whilst this is a useful
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approach for studying the effects of repeated i.t. dosing over time, there are
disadvantages associated with this technique. Specifically, this technique is
associated with post-surgical mortality as well as neurological morbidity and the
procedure can affect the overall functional state of the animal (Xu et al., 2006).
Whereas rapamycin was dissolved in 100 % DMSO before diluting with saline to
achieve the appropriate concentrations, CCI-779 was dissolved in saline with the
aid of a sonicator due to its improved solubility profile.  It was however surprising
that CCI-779 displayed a different response profile to that produced by rapamycin.
Specifically, whereas rapamycin dose-dependently inhibited neuronal responses to
electrical and mechanical stimuli in naive rats within the 1 hr time period allotted
to each dose (see figures 3.2 and 3.3), as well as neuronal hyperexcitability and
behavioural hypersensitivity due to formalin-induced inflammation (see figures 4.1
– 4.2 and 4.5 – 4.6), the effects of CCI-779 on neuronal responses from naive rats
were delayed.
In electrophysiological studies, when a dose of CCI-779 equivalent to the top dose
of rapamycin (i.e. 250 nM) was administered i.t. there were no inhibitions of C-
fibre mediated transmission to the spinal cord (see figure 3.5). Furthermore,
although mechanically and thermally evoked neuronal responses were attenuated,
these effects were not present until the second hr of testing (see figure 3.7).
Perhaps surprising however, was the finding that when CCI-779 was administered to
nerve-injured rats, there was now a shift in the effectiveness of CCI-779 such that
it was attenuating stimulus evoked neuronal activity within the first hr of testing,
(see figures 5.6 and 5.8 – 5.10). However, changes in thermally evoked neuronal
responses were still restricted to the second hr of testing. These results produced
using electrophysiology techniques were substantiated by behavioural studies
whereby CCI-779 injected i.t. into the lumbar region of the spinal cord attenuated
nerve-injury induced behavioural hypersensitivity within the first hr of
administration (see figures 5.11 – 5.12).
Taken together, these results suggest that whilst protein translation via mTOR is
important under physiological conditions for sensory processing at the spinal level,
protein translation via mTOR becomes more important under pathophysiological
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conditions. This bears similarities yet also differences with previous studies
investigating the importance of rapamycin-sensitive pathways in neuronal
excitability. Previous studies demonstrated that whilst rapamycin was effective in
attenuating hippocampal LTP, there were no effects on basal synaptic transmission
(Tang et al., 2002; Cammalleri et al., 2003; Cracco et al., 2005). In my studies, I
have shown that as well as attenuating altered synaptic transmission in persistent
pain-like states, rapamycin also inhibits sensory transmission at the spinal level in
naive rats. It is important to note however that my experiments are conducted in
whole animals rather than tissue slices and also that the mechanisms that mediate
central sensitisation such as that observed in persistent pain-like states like
formalin-induced inflammation and SNL are not necessarily identical to the
mechanisms that mediate hippocampal LTP. In broad terms, central sensitisation
and hippocampal LTP share two mechanisms- phosphorylation of synaptic receptors
and insertion of new AMPA receptors into the postsynaptic membrane.  However,
whilst hippocampal LTP reflects only synaptic strengthening, central sensitisation
also reflects other cellular mechanisms such as changes in intrinsic membrane
properties and/or neuronal networks (e.g. disinhibition) (Ji et al., 2003).
8.1.1 Protein translation is rapidly inhibited by rapamycin and
CCI-779
The results from chapter 4 show that rapamycin can attenuate formalin-induced
neuronal hyperexcitability when injected i.t. as soon as 3 min prior to formalin
being injected into the hind paw. Furthermore, in chapters 4 and 5 respectively,
behavioural hypersensitivity due to formalin-induced inflammation and SNL is
attenuated within 1 hr of rapamycin/CCI-779 administration. In the SNL studies,
the attenuation of stimulus evoked neuronal responses as well as behavioural
hypersensitivity was only temporarily inhibited after administration of CCI-779.
This rapid yet temporary maximal effect of rapamycin and CCI-779 on neuronal
responses and behavioural hypersensitivity indicates that rapamycin sensitive
pathways are continuously active and that their continuous activation rapidly
regulates neuronal activity. Such rapid signalling which has a direct effect on
neuronal function is not a novel concept. It has been shown that NGF, which is
implicated in peripheral sensitisation, can rapidly (< 10 min) lead to sensitisation of
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TRPV1 receptors. This sensitisation involves PI3K-dependent mechanisms,
phosphorylation of TRPV1 and increased insertion of TRPV1 channels into the
surface membrane (Zhang et al., 2005). In addition and perhaps more relevant, the
LTP-associated increase in the elongation factor eEF1A, which is downstream of
mTOR, increases within 5 min after stimulation in a translation-dependent manner
i.e. the increase is attenuated with the addition of rapamycin (Tsokas et al., 2005).
8.1.2 Rapid modulation of neuronal responses by rapamycin-
sensitive pathways is not a feature of thermally evoked
responses
It is clear that in persistent pain-like states, rapamycin-sensitive pathways are
more important in mediating neuronal responses to electrical and mechanical
stimuli rather than thermal stimuli. Figure 3.4 shows that inhibition of thermally
evoked responses only occurs with the top dose of rapamycin and only at the
lowest temperature tested (35 °C). Whilst rapamycin-sensitive pathways are
important in mediating neuronal responses to thermal stimuli (see figure 3.7), the
shift in response profile to CCI-779 observed with mechanically evoked neuronal
responses after SNL was not apparent with thermally evoked responses (see figure
5.10).
This apparent selectivity may in part, be due to the classical ‘heat sensor’ TRPV1,
which is known to play an important roles in pain processing and is activated by the
chilli extract capsaicin. In a study examining the role of central and peripheral
TRPV1 in pain processing, the antinociceptive effects of TRPV1 antagonists were
compared in persistent pain-like states via different routes of administration (Cui
et al., 2006). These drugs were known to have comparable in vitro potency, but
differed in CNS penetration. When administered orally, both compounds effectively
attenuated capsaicin-induced spontaneous hypersensitivity and CFA-induced
thermal hypersensitivity. In addition, intraplantar or i.t. administration of the
compound with good CNS penetration also attenuated CFA-induced thermal
hypersensitivity, suggesting that both peripheral and central TRPV1 plays a role in
inflammatory thermal hypersensitivity. When assessing markers of central
sensitisation i.e. capsaicin- and CFA-induced mechanical hypersensitivity and
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osteoarthritis-induced hypersensitivity, i.t. administration of the two compounds
attenuated behavioural hypersensitivity to the same degree. However, when
administered orally, the compound with good CNS penetration was much more
potent, demonstrating that TRPV1 in the CNS plays a role in pain mediated by
central sensitisation. Furthermore, referred or secondary mechanical
hypersensitivity like that seen in the above persistent pain-like states is believed to
be mediated by central sensitisation, whereas thermal hypersensitivity appears to
be caused by peripheral sensitisation because it is restricted to the immediate area
of injection (LaMotte et al., 1992). Thus, rapamycin-sensitive pathways may be less
important in mediating thermally-evoked neuronal responses in persistent pain-like
states because they are less important in peripheral sensitisation whereas they
have a larger effect on mechanically-evoked responses in persistent pain-like states
like SNL because they are more important in central sensitisation and may also be
engaged by activation of TRPV1.
It is clear that there are many receptors that are at least to varying degrees,
modality specific, yet many nociceptive fibres are polymodal (Julius and Basbaum,
2001). Despite this, there have been attempts to identify specific neurones and
receptor subtypes that convey essential information sufficient to activate central
pathways and elicit neuronal and behavioural responses relevant to pain. This is
the case in a recent study whereby a thoroughly characterised Nav1.8 Cre
recombinase-expressing mouse that shows normal pain behaviour was used to
excise a floxed stop codon upstream of the globally expressed diphtheria toxin A
(DTA)-subunit gene. Crossing the heterozygous Nav1.8 Cre mice with the
homozygous DTA-expressing floxed mice resulted in control and DTA-expressing
floxed mice in which all Nav1.8-expressing neurones (nociceptors) were killed.
These mice showed attenuation of C-fibre-mediated activity, threshold and wind
up; a loss of neuronal responses to mechanical stimuli but not thermal stimuli as
well as behavioural hypersensitivity due to formalin-induced inflammation and
CFA-induced inflammation and reduced sensitivity to cold. However, this genetic
manipulation did not affect the mechanical and thermal hypersensitivity observed
in nerve-injured mice.  Taken together, the results demonstrate that Nav1.8-
expressing neurones are essential for mechanical, cold and inflammatory sensation
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but not neuropathic pain-like indications or heat sensing (Abrahamsen et al.,
2008).
Although, parallels can be drawn between the response profile of Nav1.8-
expressing neurones and rapamycin-sensitive pathways, it is clear from my
research that unlike Nav1.8, rapamycin-sensitive pathways are important in
neuronal and behavioural responses from nerve-injured rats (see chapter 5).
However, the studies by Abrahamsen et al. suggest that there are perhaps specific
pathways in the peripheral and central nervous systems that act to transmit
modality and pain specific signals that may differentially engage rapamycin-
sensitive pathways.
8.1.3 Rapamycin-sensitive pathways are engaged by descending
facilitation acting at spinal 5-HT3Rs
A key feature of many persistent pain-like states and therefore central
sensitisation is an enhanced drive from higher brain centres which converge on the
RVM before projecting down to the spinal cord where they act mainly on 5-HT3Rs
located on primary afferent terminals (Green et al., 2000; Suzuki et al., 2002;
McCleane et al., 2003; Suzuki et al., 2004b; Conte et al., 2005; Suzuki et al., 2005;
Donovan-Rodriguez et al., 2006). My studies have shown that rapamycin-sensitive
pathways are important in mediating neuronal excitability and behavioural
hypersensitivity in the formalin test (see chapter 4) as well as neuronal responses
and behavioural hypersensitivity displayed by SNL rats (see chapter 5)- both models
that are mediated by descending facilitation acting at spinal 5-HT3Rs. I have shown
that rapamycin-sensitive pathways at the spinal level in the whole animal require
descending facilitation for full activation. Specifically, noxious mechanically and
thermally evoked responses that were inhibited by rapamycin, showed less
inhibition when spinal 5-HT3Rs were pre-blocked with the selective blocker
ondansetron (see figure 7.2). However, rapamycin-sensitive pathways were not
affected in persistent pain-like states where descending facilitation acting at spinal
5-HT3Rs was unaltered i.e. carrageenan-induced inflammation, since the effects of
CCI-779 were comparable to pre-drug control responses (see figure 7.3). A
continuous serotonergic drive from the brainstem perhaps explains the continuous
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nature of rapamycin-sensitive pathways as well as the rapid yet temporary action
of CCI-779 with the studies focussing on SNL (chapter 4). I propose that with
persistent pain-like states and particularly SNL, peripheral and central sensitisation
result in a continuous drive from higher brain centres (particularly 5-HT from the
RVM) which project down to the spinal cord. This continuous drive from higher
centres sets in a motion an ongoing cycle of signalling involving mTOR, which acts
to mediate neuronal and behavioural responses relevant to pain. These responses
can be attenuated in the presence of rapamycin due to its inhibitory action on
mTOR. Thus, when rapamycin or CCI-779 are diluted away from the site of action
with the cerebrospinal fluid, the continuous drive from the RVM reengages
rapamycin-sensitive pathways, which then continue to drive the neuronal responses
and behavioural hypersensitivity associated with pain.
In the case of CCI-779, which shows minimal effects on neuronal activity from
naive rats (see chapter 3), it is apparent that in order for the inhibitory actions of
the drug to be revealed at the dose given, it must be administered to rats with an
induced pain-like state that involves an increased serotonergic drive from
supraspinal sites acting at spinal 5-HT3Rs. This state-dependency is similar to that
seen in a study investigating mechanisms of action of the analgesic drug GBP
(Suzuki et al., 2005). In this electrophysiological study, it was found that the
usually powerful actions of GBP after SNL were blocked by either the ablation of
NK1-expresssing neurones with i.t. SP-SAP, or the administration of i.t.
ondansetron. However, activating spinal 5-HT3Rs with the selective agonist 2-
methyl 5-HT, provided the state-dependency required for GBP to inhibit neuronal
responses in uninjured rats. GBP binds to the α2δ subunit of VDCCs (Gee et al.,
1996) so it is apparent that both 5-HT3R activation and α2δ subunit binding are
prerequisites for GBP efficacy. Likewise 5-HT3R activation is a prerequisite for
rapamycin/CCI-779 efficacy, yet it is extremely likely that there are other factors
too due to what is known about the complexities of mTOR signalling (Hay and
Sonenberg, 2004; Jaworski and Sheng, 2006; Swiech et al., 2008).
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8.1.4 Rapamycin-sensitive pathways are present in nociceptors
and spinal neurones
Using immunohistochemistry, I have shown that rapamycin-sensitive pathways are
present in nociceptors at least at the level of the DRG and neurones of the spinal
cord. A previous study has already demonstrated the presence of rapamycin-
sensitive pathways in peripheral afferents at the level of the hind paw (Jimenez-
Diaz et al., 2008).  Specifically, components of rapamycin-sensitive pathways were
present in fibres that terminate in the dermis and not the epidermis, a feature of
myelinated A-fibres. The lack of C-fibre staining does not correlate with my results
as I found that DRG staining revealed colocalisation between rapamycin-sensitive
pathways and CGRP- a common marker of small unmyelinated fibres. I was not able
to determine the presence of rapamycin-sensitive pathways in myelinated A-fibres
that are associated with innocuous stimuli (see figure 6.12). Nevertheless,
rapamycin-sensitive pathways may be present in all sensory fibres, at least in the
DRG. Interestingly, Jimenez-Diaz et al. found that analysis of the mechanical
thresholds of a small population of C-fibres revealed that they were actually
influenced by rapamycin. Furthermore, the expression of the mTOR binding partner
raptor was expressed in N52-negative fibres, thus substantiating my findings. It is
possible that in the periphery, at the dermis/epidermis, whilst rapamycin-sensitive
pathways are readily active in A-fibres, they are only activated in C-fibres after
nerve injury/inflammation. It is important to note that the immunohistochemistry
studies carried out by Jiminez-Diaz et al. were on naive rats and not rats in which a
persistent pain-like state had been induced. There is also no reason why peripheral
and central terminals should behave in exactly the same manner and there may be
differential trafficking of proteins from the cell body.
To date, there have been no studies that have investigated the distribution of
rapamycin-sensitive pathways in the spinal cord. Given what is known about the
wide distribution of rapamycin-sensitive pathways and the wide range of processes
that they mediate- not just limited to neuronal function, it was surprising that
rapamycin-sensitive pathways in the spinal cord were largely restricted to a
specific region in the dorsal horn of the spinal cord (see figures 6.6 – 6.8).
Immunoreactivity for p70S6K appeared to be restricted to the inner layer of lamina
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II. This was confirmed by double labelling for PKCγ due to the fact that PKCγ-
expressing interneurones reside in this region of the dorsal horn (see figures 6.10
and 6.11). It had long been accepted that PKCγ interneurones in the spinal cord
receive their input from unmyelinated, non-peptidergic, IB4-positive nociceptors
(Snider and McMahon, 1998). However, in a recent study, it has been shown that in
the spinal cord, PKCγ immunoreactivity overlaps with large myelinated fibre
terminals that express VGluT1 and not IB4-binding nociceptor terminals. In
addition, PKCγ interneurones were shown to be activated by innocuous input
generated by rotarod walking (Neumann et al., 2008).
PKCγ interneurones have been shown to be important in pain processing since mice
that lack the PKCγ isoenzyme fail to develop nerve injury-induced hypersensitivity
(Malmberg et al., 1997). In addition, these interneurones are believed to be
excitatory interneurones since the majority of PKCγ interneurones lack GABA or µ-
opioid receptor immunoreactivity (Polgar et al., 1999). Taken together, it is
apparent that mTOR signalling at several sites within the spino-bulbo-spinal loop
mediates sensory transmission and therefore perception. I propose that rapamycin-
sensitive pathways present in all sensory fibres mediate transmission to spinal
neurones before the signals are then transmitted to higher brain centres. In the
spinal cord, rapamycin-sensitive pathways are restricted to spinal PKCγ
interneurones that receive input directly from myelinated A-fibres or indirectly
from C-fibres that terminate in superficial laminae. These neurones consequently
increase excitability of all dorsal horn neurones including the WDR neurones that
are recorded in the electrophysiology studies. During peripheral and consequent
central sensitisation, these pathways are upregulated, thus contributing to the
neuronal and behavioural responses associated with pain-like states.
Perhaps surprisingly, analysis of p70S6K immunoreactivity revealed that there was
a decrease in immunoreactivity on the injured side of the spinal cord compared
with the uninjured side, a change that was restricted to the spinal segments
innervated by the ligated nerves (see figures 6.6 – 6.8).  This decrease in
immunoreactivity was similar to that seen with primary afferent terminals that
release CGRP (see figures 6.1 – 6.3) and represents the loss of primary afferents
due to nerve damage. Interestingly, PKCγ immunoreactivity was unaffected by SNL
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(see figure 6.11). This implies that rapamycin-sensitive pathways in PKCγ
interneurones are activated by incoming signals from primary afferents. Therefore,
I propose that despite the downregulation in p70S6K in denervated spinal cord
segments, rapamycin-sensitive pathways must contribute to the abnormal evoked
responses seen after peripheral nerve injury, which are conveyed by the intact or
spared afferent fibres and are inhibited by both rapamycin and CCI-779.
8.1.5 mTOR: upstream neurotransmitters, downstream effectors
Taken together, my studies show that rapamycin-sensitive pathways are important
in mediating neuronal activity in primary afferents and spinal neurones. Given what
is already known about the spino-bulbo-spinal loop and neurotransmitters that
activate rapamycin-sensitive signalling, I have outlined below different mechanisms
of mTOR activation and its downstream effects.
5-HT
In Chapter 7, I described how the inhibitory effects of rapamycin were reduced in
the presence of ondansetron (see figure 7.2). In addition, formalin-induced
inflammation and SNL are pain-like states that are regulated by spinal 5-HT3Rs
(Green et al., 2000; Suzuki et al., 2002; McCleane et al., 2003; Suzuki et al.,
2004b; Conte et al., 2005; Suzuki et al., 2005; Donovan-Rodriguez et al., 2006;
Svensson et al., 2006). Virtually all spinal 5-HT originates from the brainstem
(Millan, 2002). I propose that central sensitisation is partly mediated by descending
serotonergic pathways acting at spinal 5-HT3Rs located on peripheral primary
afferent terminals of Aδ- and C-fibres, most of which lack SP (Kia et al., 1995;
Zeitz et al., 2002; Conte et al., 2005). In primary afferents, rapamycin-sensitive
pathways are activated via the Ca2+-dependent recruitment of the GTPase Ras and
canonical PI3K signalling pathways as well as other signalling pathways (see figure
1.4). These rapamycin sensitive pathways act to increase neurotransmitter release
into the dorsal horn of the spinal cord perhaps via modulation of key downstream
proteins and finally ion channel modulation.  It is important to note that despite
the conclusive evidence regarding 5-HT3Rs and their role in facilitating pain states,
that there are other 5-HTRs located on primary afferent terminals that act to
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modulate nociceptive signals at the spinal level and that can engage rapamycin-
sensitive pathways. Yet these are GPCRs and so the effects of their activation can
be just as antinociceptive as they are nociceptive and perhaps not as clear-cut as
the excitatory 5-HT3R, which is an excitatory ligand-gated ion channel (Millan,
2002). However, it is clear that the same principles that apply to spinal 5-HT3Rs
probably apply to other 5-HTRs that act to facilitate persistent pain states.
In support of my theory that descending serotonergic controls act to modulate
protein synthesis pathways at the spinal level is a recent study by Geranton et al
who found that that descending serotonergic controls regulate phosphorylation and
therefore activation of the nuclear transcription factor methyl-CpG-binding protein
2 (MeCP2), which is located in the dorsal horn and believed to be important in
persistent pain-like states. They found that specifically depleting the lumbar region
of the spinal cord of 5-HT with 5,7 DHT, not only reduced mechanical sensitivity
induced by injection of CFA into the rat hind paw, but also reduced MeCP2
activation (Geranton et al., 2008).
Glutamate
Glutamate is the main excitatory neurotransmitter in the central nervous system
and is released from descending pathways from higher brain centres acting on
spinal neurones as well as from primary afferent fibre terminals in the dorsal horn
of the spinal cord (Millan, 2002). At the receptor level, glutamate acting at
NMDARs has been shown to be important in mediating the neuronal and behavioural
responses that define persistent pain-like states (Haley et al., 1990; Chaplan et al.,
1997; Suzuki et al., 2001). Rapamycin-sensitive pathways are also engaged by
NMDAR activation (Gong et al., 2006; Gonzalez-Mejia et al., 2006). As well as
NMDARs, glutamate also acts at mGluRs. In particular, mGluR1 and mGluR5 are
thought to be important in mediating persistent pain-like states (Dogrul et al.,
2000; Varty et al., 2005) and these receptors are also known to engage rapamycin-
sensitive pathways (Page et al., 2006; Price et al., 2006). I propose that glutamate
released from descending pathways contributes to central sensitisation by acting
on NMDARs and mGluRs and thus sensitising primary afferent terminals, leading to
enhanced neurotransmitter release from primary afferent terminals. In addition,
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glutamate released from nociceptors terminating in the spinal cord will excite
spinal neurones, particularly those in the inner layer of lamina II. These are both
processes that are dependent on rapamycin-sensitive pathways.
BDNF
BDNF like glutamate, is synthesised in the DRG of nociceptors. However, unlike
glutamate which can be transmitted to the spinal cord via descending pathways,
primary afferents are believed to be the only source of spinal BDNF (Malcangio and
Lessmann, 2003). BDNF has been shown to be important in mediating the
behavioural hypersensitivity produced in persistent pain-like states (Kerr et al.,
1999; Yajima et al., 2005) and acts on spinal TrkB receptors within the dorsal horn,
contributing to sensitisation of dorsal horn neurones by facilitating NMDAR activity
and reducing GABA-mediated function (Malcangio and Lessmann, 2003). In
addition, BDNF has been shown to readily engage rapamycin-sensitive pathways
(Takei et al., 2001; Tang et al., 2002; Schratt et al., 2004; Takei et al., 2004). I
propose that BDNF released from nociceptors acts to sensitise spinal neurones,
particularly those situated in the inner layer of lamina II and that sensitisation of
these neurones is dependent upon rapamycin-sensitive pathways.
Protein kinase Mζ
Despite the progress made in delineating rapamycin-sensitive pathways and
upstream modulators, there has been less progress on identifying the downstream
effectors that act to modulate neuronal activity. The atypical protein kinase C
(PKMζ) has been shown to be critical during the maintenance of hippocampal LTP
that is required for the persistence of spatial memory storage in the hippocampus.
During LTP, PKMζ is rapidly synthesised from a PKMζ mRNA that encodes a protein
kinase Cζ catalytic domain without a regulatory domain so that second messengers
that activate full length PKC are not required to activate PKMζ. Using a panel of
antisera to phosphorylated and non phosphorylated sites on PKMζ, Kelly et al.
showed that mTOR as well as PI3K and CaMKII were all important for LTP induction,
optimal activation of pre-existing PKMζ and the synthesis of new PKMζ (Kelly et
al., 2007). I propose that nociceptor afferents and spinal neurones when sensitised
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or excited contribute to central sensitisation via rapamycin-sensitive pathways,
which contribute to the synthesis and optimal activation of PKMζ.
Potassium Channels (Kv1.1)
As well as upregulating protein-synthesis, rapamycin-sensitive pathways can also
act to inhibit or downregulate protein synthesis. Such is the case in hippocampal
neurones whereby rapamycin has been shown to increase the Kv1.1 voltage-gated
potassium channel protein in hippocampal neurones (Raab-Graham et al., 2006).
Specifically, rapamycin promoted Kv1.1 surface expression on dendrites during a
1 hr period without altering its axonal expression. This mechanism was localised to
dendrites since endogenous Kv1.1 mRNA was detected in dendrites. Furthermore,
using Kv1.1 fused to the photoconvertible fluorescence protein Kaede as a reporter
for local protein synthesis, it was found that rapamycin caused the synthesis of
Kv1.1 specifically in dendrites. This process was found to be NMDAR-dependent
since treatment of neurones with the NMDAR antagonist D-AP5 also resulted in
dendritic Kv1.1 synthesis.
Relevant to pain, altered K+ channel activity is associated with axonal dysfunction
from demyelination due to spinal cord injury (SCI). In order to clarify the molecular
basis of posttraumatic axonal pathophysiology after SCI, one group has sought to
specifically investigate changes in expression and distribution of Kv1.1 as well as
Kv1.2 in spinal cord white matter after SCI (Karimi-Abdolrezaee et al., 2004). In
this study, real-time polymerase chain reaction (PCR) revealed an increase in Kv1.1
and Kv1.2 mRNA levels as soon as 1 day after SCI that persisted for 6 weeks.  In
addition, confocal immunohistochemistry revealed a redistribution of these
channels from tight juxtaparanodal locations within the myelin sheath to a more
dispersed distribution along the injured axons from as early as 1 hr post injury. This
presumably results in aberrant neuronal activity and the neuronal and behavioural
responses associated with SCI.  Although SNL and SCI are two different models, I
propose that rapamycin-sensitive pathways in nociceptor afferents as well as spinal
neurones act to repress Kv1.1 synthesis under physiological conditions. Under
pathophysiological conditions such as SNL, which results in a decrease in mTOR
signalling (at L5 and L6), there is an increase in axonal Kv1.1, which alters neuronal
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excitability, therefore contributing to central sensitisation.  Figure 8.1 summarises
the proposed features of rapamycin-sensitive signalling at the spinal level.
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Figure 8.1 Proposed mechanisms of mTOR signalling that contribute to central
sensitisation. Intracellular rapamycin-sensitive pathways at the level of mTOR can
be activated by a variety of neurotransmitters that are released from neurones
descending from higher centres acting on nociceptor afferents and spinal neurones.
These pathways can also be activated in spinal neurones by neurotransmitters
released form nociceptor afferents. Signalling pathways upstream of mTOR have
been discussed in chapter 1 and involve PI3K, PKA/C ERK, and CaMKII. Activation of
mTOR results in the synthesis of PKMζ and the modulation of Kv1.1 and likely
facilitates receptor channels that facilitate central sensitisation. During central
sensitisation, the balance of these pathways is altered depending on the pain-like
state. The net result is a dysfunction of neuronal activity and behavioural
hypersensitivity.
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8.2 Future work
My studies have shown that rapamycin-sensitive pathways at the level of mTOR are
important in the induction and maintenance of persistent pain-like states and that
these pathways are engaged by descending controls from higher brain centres. It is
clear that multiple signalling pathways converge on mTOR, leading to its activation
and that these pathways are present in all peripheral sensory neurones, yet
restricted centrally to specific regions of the spinal cord. By administering
rapamycin directly to the lumbar region of the spinal cord, I have been able to
directly assess the roles of these pathways at the spinal level. It would however be
interesting to compare how this drug affects neuronal and behavioural responses in
persistent pain-like states when injected either intradermally into the hind paw or
systemically in order to determine where these pathways are more important since
it is clear that these pathways are present not just in the spinal cord, but sensory
afferent axons and terminals.
My studies have focussed on neuronal mechanisms of nociception and pain
maintenance, yet the recent surge in non-neuronal/glial research and their
importance in persistent pain-like states suggests that rapamycin-sensitive
pathways may also play important roles in mediating the roles these cells play in
persistent pain-like states. In support of this is the fact that rapamycin-sensitive
pathways are expressed in astrocyte nuclei in the CA1 region of the hippocampus as
well as the cortex of mouse brains (Damjanac et al., 2008).
Although I have focussed on rapamycin-sensitive pathways at the spinal level, the
importance of rapamycin-sensitive pathways in maintaining LTP (Tang et al., 2002;
Cammalleri et al., 2003; Cracco et al., 2005) suggests that there are rapamycin-
sensitive pathways in higher brain centres that may act to modulate output to the
spinal cord. This could easily be investigated by microinjecting rapamycin/CCI-779
into the specific brain regions involved in the spino-bulbo-spinal loop such as the
RVM. This is a technique that has already been successfully used to block RVM
activity with the anaesthetic lidocaine (Bee and Dickenson, 2007).
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When probing for rapamycin-sensitive pathways using immunohistochemistry
techniques, I focussed on p70S6K immunoreactivity as a read out of mTOR
reactivity since this protein kinase is directly downstream from mTOR. However, in
order to determine specific mechanisms of central sensitisation that utilise mTOR
activity, it would be of interest to probe for other proteins involved in mTOR
signalling such as mTOR’s binding protein raptor or downstream effectors of mTOR
such as the initiation factor eIF4E or its binding protein 4EBP using
immunohistochemistry. This could also be investigated with upstream regulators of
mTOR such as PI3K or ERK, for which there are also pharmacological inhibitors-
LY294002 and PD98059 respectively.
8.3 Closing remarks
Our knowledge of pain and its treatment has been greatly improved thanks to the
efforts of scientists and clinicians worldwide. Yet despite these improvements,
millions of people continue to suffer from chronic, debilitating pain that markedly
reduces their quality of life. By focussing on subcellular targets that are implicated
in pain, the hope is that we will be able to produce much more selective drug
treatments that are not only more effective, but that exert less side effects. My
thesis has focussed on rapamycin-sensitive pathways at the level of mTOR- a
protein that is regulated by multiple signalling pathways. This protein has been
shown to be important in modulating LTP in the hippocampus and LTH in injured
Aplysia neurones, suggesting it will have effects on other types of synaptic
plasticity. I have confirmed this with my studies by showing that this protein and
thus the signalling pathways that its involved in are important in nociception and
persistent pain-like states. The widespread distribution of these pathways as well
as their numerous cellular effects that include mediating the immune response
means that the therapeutic potential of rapamycin and its analogues remain in
question. However, these studies reveal that rapid, continuous protein translation
at the spinal level is an integral element of nociception and the induction and
maintenance of persistent pain-like states involving central sensitisation. These
studies provide new insights into pain processing that may ultimately lead to vastly
improved therapies.
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